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Abstract 
 
Type 2 Diabetes, a metabolic disorder associated with chronic hyperglycaemia and 
hyperlipidaemia, is characterised by an impairment of insulin secretion and production 
and β-cell death. This β-cell dysfunction is determined by different factors, among 
which inflammatory processes, characterised by increased expression of pro-
inflammatory cytokines and chemokines. Although some molecular mechanisms have 
been proposed to be involved in this β-cell dysfunction, they fail to explain the whole 
process. 
In this thesis, a combined approach of microarray, RNAseq, RT-qPCR and western blot 
will be used to elucidate the pathways affected under glucolipotoxicity, in order to 
discover novel molecules involved in the pathogenesis of T2D.  
We found that INS-1 cells exposed to 27 mM glucose, 200 µM oleic acid, 200 µM 
palmitic acid, show an overexpression of CD40, a TNF receptor involved in 
inflammation (more than 300% p<0.01), both at RNA and protein level. These data 
were validated in cultured human islets (p<0.05) and in islets of mice fed a high fat diet 
(p<0.05). We showed also that siRNA downregulation of CD40 is associated with 
increase in insulin secretion (p<0.05), revealing a potential new role of this receptor in 
β-cells. In addition, RNAseq analysis revealed a wide list of molecules differentially 
expressed in glucolipotoxicity, in particular molecules involved in inflammation, 
insulin/IGF pathway, fatty acids-cholesterol metabolism and biosynthesis. We focused 
our attention on potential novel targets, including the thyroid pathway, unknown 
microRNAs and novel genes, in order to discover new pathways involved in the 
impairment of insulin secretion in T2D. 
This work will open the way to future studies aiming to characterise these molecules and 
to understand their role in the insulin secretion process. Interesting candidates can then 
be used in the future as potential targets for the development of new and specific 
therapeutic strategies. 
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1.1 Pancreatic β-cell physiology 
 
Pancreatic β-cells are located in the islets of Langherans in the pancreas, making up 65-
80% of the total cells in the islets. The primary function of β-cells is to produce and 
store the hormone insulin, which is responsible for the regulation of the blood glucose 
concentration. This tight control is governed by the balance between glucose absorption 
from the intestine, production by the liver and uptake and metabolism by peripheral 
tissues. 
A dysregulation of the mechanisms responsible of the maintenance of glucose 
homeostasis and function leads to pathologic conditions, in particular diabetes mellitus. 
 
1.1.1 Insulin biosynthesis 
 
The secreted insulin consists of 51 amino acids with a molecular weight of 5.8 kDa. 
However, the insulin gene encodes a 110 amino acid precursor known as preproinsulin 
(Figure 1.1). 
Preproinsulin contains a hydrophobic amino-terminal signal sequence that is required in 
order for the precursor hormone to pass through the membrane of the endoplasmic 
reticulum for post-translational processing. Upon entering the ER, the preproinsulin 
signal sequence is proteolitically removed, generating proinsulin. Proinsulin then 
undergoes folding and formation of three disulphide bonds, a process requiring a diverse 
range of endoplasmic reticulum (ER) chaperone proteins. 
Subsequent to maturation of the 3 dimensional conformation, the folded proinsulin is 
transported from the ER to the Golgi apparatus where proinsulin enters immature 
secretory granules and is cleaved to yield the A chain (21 amino acids) and B chain (30 
aminoacids) of insulin and C-peptide (Figure 1.1). Insulin and C-peptide are then stored 
in the secretory granules together with islet amyloid polypeptide (IAPP or amylin) and 
other less abundant β-cell secretory products [1].  
Following their generation at the trans Golgi network and subsequent maturation, each 
dense-core granule ultimately needs to be transported to the cell surface, a process that 
22 
 
is activated by elevated glucose concentrations via Ca
2+
 dependent mechanisms [2] 
through the motor protein kinesin-1. 
 
 
Figure 1.1 Insulin biosynthesis. Insulin is translated as a 110 amino acids peptide called 
preproinsulin. Preproinsulin contains a hydrophobic amino-terminal signal sequence required for 
entering the ER. In the ER, the preproinsulin signal sequence is proteolitically removed, 
generating proinsulin. Subsequent to maturation of the three dimensional conformation, the 
folded proinsulin is transported from the ER to the Golgi apparatus where proinsulin enters 
immature secretory vesicles and is cleaved to yield the A chain and B chain of insulin and C-
peptide. Figure adapted from Beta Cell Biology Consortium website.  
 
1.1.2 Insulin secretion 
 
The β-cell responds to many nutrients in the blood circulation, including glucose, other 
monosaccharides, amino acids and fatty acids. 
Glucose is the main driver of insulin secretion and of proinsulin and insulin transcription 
and it is the most abundant sugar in our diet. It circulates in the blood and it is able to 
enter β-cells through transporters called GLUT. There are different isoforms of this 
receptor, with GLUT2 being the β-cell transporter responsible for constitutive glucose 
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uptake. Also hepatic glucose uptake is GLUT2 mediated. Skeletal muscle and adipocyte 
glucose uptake is mediated by GLUT4 transporters, which reside in intracellular storage 
pools and translocate to the surface in response to stimuli [3].  
Once glucose is internalised in the cell, it is phosphorylated by the enzyme glucokinase 
(GCK), to glucose 6-phosphate. This enzyme is a glucose sensor in the pancreatic β-cell 
[4]. After this process, glucose 6-phosphate then enters the glycolytic pathways 
eventually leading to ATP synthesis. Elevated ATP/ADP ratio induces closure of cell-
surface ATP-sensitive K
+
 (KATP) channels, leading to cell membrane depolarisation. 
This depolarisation triggers the opening of cell-surface voltage-dependent Ca
2+
 channels 
(VDCC), facilitating extracellular Ca
2+
 influx into the β-cell. A rise in free cytosolic 
Ca
2+
 triggers the exocytosis of insulin granules (Figure 1.2). 
 
 
 
Figure 1.2 Glucose stimulates insulin secretion. Glucose enters the β-cell through the 
transporter GLUT2 and it is metabolised to ATP. An elevated ATP/ADP ratio triggers the 
closure of ATP sensitive K
+
 channels and membrane depolarisation; this depolarisation opens 
voltage-dependent Ca
2+
 with the consequent Ca
2+
 influx that triggers insulin granules exocytosis. 
Figure from reference [5]. 
 
The initial (or first phase) exocytotic response can be replicated by any stimuli that 
increase intracellular Ca
2+
, causing the release of the insulin granules that are already 
associated to the plasma membrane. Sustained (or second phase) secretion, which is 
dependent on vesicles mobilisation and priming, can only be elicited by metabolisable 
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fuel secretagogues (i.e. pyruvate, glyceraldehyde, amino acids) [6].  In rat β-cell, 
glucose stimulates an increase in the number of insulin granules associated with the 
plasma membrane [7] and vesicles movement in the cytoplasm likely occurs along 
microtubules, mediated by the ATP dependent motor activity of the conventional 
kinesin KIF5B [8]. Disruption of the microtubule network impairs granules movement 
and the exocytotic response [9]. 
Fusion of exocytotic granules with the plasma membrane is mediated by SNARE 
proteins (soluble NH2-ethylmaleimide-sensitive fusion protein attachment protein 
receptor proteins). These include the plasma membrane proteins Syntaxin-1 and SNAP-
25 (synaptosome-associated protein of 25 kDa) and the vesicular protein VAMP2 
(synaptobrevin). Interaction of the coiled coil domains of these proteins to form a 
SNARE “pin” appears to provide both membrane selectivity and the thermodynamic 
driving force for membrane fusion [10]. Ca
2+
 sensitivity is conferred on the process by 
additional proteins such as members of the synaptogamin family, which are able to 
interact with the SNARE complex and with membrane phospholipids [11]. Cumulative 
evidence emphasizes the crucial role of synaptogamin VII and IX as mediators of 
glucose-induced insulin secretion [12]. In addition, calpain-10 (CAPN10), a member of 
calcium-dependant non-lysosomal cysteine proteases, has been shown to interact with 
SNARE proteins and be implicated in calcium mediated insulin exocytosis, through 
SNAP-25 proteolisis [13]. It has been proposed that under non-stimulating conditions 
granules are docked adjacent to L-Type calcium channels through their SNARE 
complex interaction, with intact SNAP-25 inhibiting fusion. The influx of calcium 
generated by secretagogue stimulation activates calpain-10, which cleaves SNAP-25 and 
leads to conformational changes within the SNARE complex, facilitating membrane 
fusion (Figure 1.3) [13-14]. 
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Figure 1.3 Proposed mechanism of insulin granules exocytosis. Under nonstimulating 
conditions granules are docked adjacent to L-Type calcium channels through their SNARE 
complex interaction, with intact SNAP-25 inhibiting fusion. The influx of calcium generated by 
secretagogue stimulation activates calpain-10, which cleaves SNAP-25 and leads to 
conformational changes within the SNARE complex, facilitating membrane fusion. Figure 
adapted from reference [13]. 
 
Prior to Ca
2+
-triggered and SNARE-mediated exocytosis, a docked insulin granule must 
be firstly primed for release, a chemical ATP-dependent modification. Intra-vesicular 
acidification by a V-type H
+
 ATPase plays an important role in insulin granule priming 
[15]. 
 
The β-cell responds to the increase in blood glucose by stimulating the rate of glucose 
metabolism and insulin secretion, as well as insulin biosynthesis.  
The mammalian insulin gene is exclusively expressed in the β-cell of the endocrine 
pancreas. Its promoter is regulated by the binding of some specific transcription factors 
(PDX-1, MafA, BETA2, E2A, STAT5) (see Figure 1.4) [16]. Insulin gene regulation 
results not only from specific binding combinations of these activators, but also from 
their relative nuclear concentrations. 
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Figure 1.4 Insulin gene regulation. The insulin gene transcription is a highly regulated process 
in which many transcription factors bind the gene promoter. The level of expression and the 
combination of these transcription factors determine the rate of transcription. Figure from 
reference [16]. 
 
Glucose metabolism is necessary for the stimulation of the promoter activity [17] and 
the insulin gene contains multiple elements that respond to glucose [18]. In particular, 
the most studied factor is the Pancreatic and Duodenal Homeobox 1 (PDX-1): 
experiments in a human cell line, NES2Y, which lacks PDX-1, show that the insulin 
promoter is not sensitive to glucose stimulation. Reintroduction of PDX-1 recovers the 
glucose effect on insulin transcription [19]. Moreover, also the transactivation potency 
of PDX-1 is modulated by glucose [20].  
The signalling pathways responsible for glucose induction of insulin gene transcription 
are not completely defined. Part of the stimulatory effect is determined by calcium, as 
indicated by the fact that insulin gene transcription is inhibited by calcium channel 
blockers [21]. Other pathways possibly involved are the cyclic AMP pathways, which 
have been shown to increase insulin mRNA level [21] or the activation of specific 
kinases or phosphatases that modify the phosphorylation status of sequence-specific 
transcription factors, such as protein kinase A (PKA), protein kinase C (PKC), members 
of the calcium calmodulin-dependent kinases (CaMK) and mitogen activated protein 
kinases (MAPK) [22]. 
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1.1.2.1 Other factors regulating insulin secretion 
 
In addition to carbohydrates, free fatty acids (FFAs) are also a critical metabolic 
constituent for normal β-cell function and insulin release. FFAs access the cytosol of the 
β-cell by freely diffusing through the plasma membrane, due to their lipophilic profile 
[23]. Once internalised, FFAs are metabolised to long-chain acyl-CoA (LC-CoA) by 
acyl-CoA synthase (ACS), then transported to the interior of the mitochondria by 
Carnitine Palmitoyl Transferase-1 (CPT-1), where they are oxidised via the β-oxidation 
pathway for energy production [24]. The ATP produced in this process sustains a basal 
release of insulin, in a K
+
 ATP-dependent manner [25].  
After a carbohydrate containing meal, fatty acid oxidation is inhibited, as citrate, 
generated from the glycolytic metabolism, is converted to malonyl-CoA by acetyl-CoA 
carboxylase (ACC). Malonyl-CoA sterically blocks CPT-1, inhibiting the transport of 
LC-CoA in the mitochondria (Figure 1.5) [26]. Accumulation of these intermediates in 
the cytosol leads to an increase in the intracellular calcium levels and to changes in the 
acylation state of proteins involved in the regulation of ion channel activity and 
exocytosis, amplifying insulin secretion [27]. In addition, LC-CoA can also enhance the 
fusion of insulin-secretory vesicles with the plasma membrane and insulin release, 
increasing membrane permeability [28]. Therefore, FFAs do not stimulate insulin 
secretion directly, but they are able to potentiate glucose stimulated insulin secretion 
(GSIS) in β-cells. 
The amount of malonyl-CoA is mainly regulated by AMP-activated kinase (AMPK), 
which inhibits ACC by phosphorylation, leading to reduced conversion of citrate to 
malonyl-CoA (Figure 1.5) [24]. This process reduces the expression of active malonyl-
CoA, facilitating FFAs esterification, increased entry in the mitochondria and enhanced 
β-oxidation. Indeed AMPK activity is inversely correlated with glucose concentration 
and is stimulated by palmitate in β-cell [29]. Downstream of AMPK, the transcription 
factor sterol-regulatory-element-binding-protein-1c (SREBP1c) regulates the 
transcription of genes involved in fatty acids synthesis, leading to enhanced lipogenesis 
[30]. 
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Esterification of LC-CoA to triacylglycerol (TAG) also occurs in β-cells in the presence 
of glycerol 3-phosphate provided by glucose metabolism (Figure 1.5). The purpose of 
this process may be to provide insulinotropic lipid signalling molecules by lipolysis that 
can aid insulin vesicle assembly and exocytosis.  
 
 
 
Figure 1.5 Effect of glucose on lipid partitioning in the β-cell. In the presence of glucose, the 
increase of malonyl-CoA derived from glucose metabolism inhibits the enzyme CPT-1 and 
consequently LC-CoA transport in the mitochondria is reduced. LC-CoAs accumulate in the 
cytosol where the esterification pathway is activated, generating phosphatidic acid (PA), 
diglycerides (DG), triglycerides (TG) and phospholipids (PL). 
 
Another proposed mechanism by which lipids can stimulate insulin secretion is via 
interaction with the G-protein coupled receptors (GPRs) [31]. It is thought that GPRs 
amplify GSIS by enhancing calcium efflux from the ER [26]. 
 
Individual amino acids at physiological concentrations are poor insulin secretagogues. 
However, certain combinations of amino acids can augment GSIS [32], for example the 
combination of glutamine with leucine. Leucine can activate glutamate dehydrogenase, 
which converts glutamate to α-ketoglutarate. Glutamine, after conversion into glutamate 
by glutaminase in the cytosol, can enter the TCA cycle via α-ketoglutarate, which results 
in ATP production and enhancement of insulin secretion. 
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In addition, some amino acids can indirectly influence β-cell insulin secretion. During 
the fasting period, proteins in the skeletal muscles are catabolized and free amino acids, 
like alanine and glutamine, are released in the blood, acting as glucagon secretagogues. 
This results in elevation of blood glucose levels, which then triggers insulin secretion. 
 
1.1.3 Insulin signalling and action 
 
Insulin increases glucose uptake in muscle and fat and inhibits hepatic glucose 
production. It also stimulates cell growth and differentiation, and promotes the storage 
of substrates in fat, liver and muscle by stimulating lipogenesis, glycogen and protein 
synthesis, and inhibiting lipolysis, glycogenolysis and protein breakdown. Insulin 
increases glucose uptake in muscle and adipose cells by stimulating the translocation of 
the glucose transporter GLUT4 from intracellular sites to the cell surface [33].  
Specifically, insulin binding to its receptor results in receptor autophosphorylation on 
tyrosine residues; this event results in the phosphorylation of the receptor substrates, 
among which insulin receptor substrates (IRS-1, IRS-2 and IRS-3) [34].  
This event allows the association of IRSs with the regulatory subunit of 
phosphoinositide 3-kinase (PI3K) through its SRC homology 2 (SH2) domains (see 
Figure 1.6). This kinase, once activated, phosphorylates phosphoinositides at the 3’ 
position of the inositol ring to produce phosphoinositides 3-phosphates, which bind to 
the pleckstrin homology (PH) domains of a variety of signalling molecules. It can also 
phosphorylate other proteins at serine residues. PI3K has a pivotal role in the metabolic 
and mitogenic actions of insulin and inhibitors of this enzyme or transfections with 
dominant negative constructs block most metabolic actions of insulin, including 
stimulation of glucose transport, glycogen and lipid synthesis [35]. In particular, PI3K 
activates the kinase 3-phosphoinositide dependent protein kinase 1 (PDK1), which in 
turn activates protein kinase B (PKB/Akt), a serine kinase [36]. PKB deactivates 
glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase and 
thus glycogen synthesis [37]. Activation of PKB also results in the translocation of 
GLUT-4 vesicles from their intracellular pools to the plasma membrane, where they 
allow the uptake of glucose into the cell. PKB also leads to activation of protein 
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synthesis mediated by the mammalian target of rapamycin (mTOR). mTOR is a member 
of the PI3K family of proteins that can control the mammalian translation machinery by 
direct phosphorylation and activation of p70 ribosomal S6 kinases as well as 
phosphorylation and inactivation of the initiation factor 4E for eukaryotic translation 
(eIF-4E) inhibitor [38]. 
In addition to PI3K activity, other signals seem to be required for insulin-stimulated 
glucose uptake, among which the pathway involving tyrosine phosphorylation of the Cbl 
protooncogene [39] (Figure 1.6). In most insulin-responsive cells, Cbl is associated with 
the adapter protein CAP, and upon phosphorylation, Cbl-CAP complex translocates to 
lipid rafts domains in the plasma membrane, recruiting the adapter protein CrkII. CrkII 
also forms a constitutive complex with the guanyl nucleotide-exchange protein C3G. 
Once translocated in the lipid rafts, C3G comes into proximity with the G protein TC10, 
and catalyses the exchange of GTP for GDP, activating the protein and providing a 
second signal to the GLUT4 proteins [40]. 
Other signal transduction proteins interact with IRS molecules, including GRB2 and 
SHP2, a tyrosine phosphatase (PTP) containing SH2 domains (Figure 1.6). GRB2, an 
adaptor protein, contains an SH3 domain, which is part of the cascade including RAS, 
RAF, MEK and extracellular signal-regulated kinase (ERK) that leads to activation of 
MAPK and mitogenic responses. Activated ERK can translocate into the nucleus, where 
it catalyses the phosphorylation of transcription factors such as p62, initiating a 
transcriptional programme that leads to cellular proliferation or differentiation [41]. 
SHC is another substrate of insulin receptor, which, when tyrosine phosphorylated, 
associates with GRB2 and can activate RAS/MAPK pathway independently of IRS-1. 
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Figure 1.6 Insulin signalling mechanisms. The insulin receptor is a tyrosine kinase that 
undergoes autophosphorylation and catalyses the phosphorylation of cellular proteins such as 
members of the IRS family. Downstream they activate diverse signalling pathways, including 
PI3K, Ras and MAPK, which result in the regulation of glucose, lipid and protein metabolism. 
Figure from reference [33]. 
 
Insulin also inhibits the production and release of glucose by the liver by blocking 
gluconeogenesis and glycogenolysis. It directly controls the activities of a set of 
metabolic enzymes by phosphorylation and dephosphorylation and also regulates the 
expression of genes encoding hepatic enzymes of gluconeogenesis and glycogenolysis 
[42].  
Insulin also promotes the synthesis of lipids and inhibits their degradation. Some studies 
suggest that many of these changes require an increase in SREBP-1c expression [43]. 
 
1.1.4 β-cell homeostasis 
 
In adults, β-cells have an estimated life-span of ~60 days after which they undergo 
programmed cell death [44]. The senescent β-cells are replaced by processes of 
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replication (proliferation) and by neogenesis of new β-cells derived from progenitor 
cells that bud from the ducts of the exocrine pancreas. This balance is an important 
aspect for the maintenance of glucose homeostasis because the ability of the pancreas to 
produce sufficient insulin to meet the body’s needs depends on the appropriate size of 
the β-cell mass [45]. Moreover, during adulthood, β-cell mass is highly adaptive to 
changes in metabolic homeostasis, as it is observed during the progression to diabetes. 
Many factors are implicated in the regulation of β-cell mass, including nutrients (in 
particular glucose and fatty acids), insulin and other growth factors signalling, and 
incretin hormones such as glucagon-like peptide 1 (GLP-1). 
 
It has been shown that glucose stimulates β-cell proliferation: mice subjected to glucose 
infusion demonstrated increased β-cell mass [46] and the same effect was also found in 
rat insulinoma cells (INS-1) [47]. One of the mechanisms responsible for this effect is 
the glucose dependent membrane depolarisation, calcium influx and the subsequent 
activation of the PI3K-Akt signalling pathways, which can induce cell survival and 
proliferation [48]. In addition, glucose can also induce mTOR signaling pathway, an 
important regulator of cell mass and proliferation [49]. Moreover glucose is able to 
increase β-cell function, stimulating insulin release. Finally, an increase in intracellular 
calcium could also play an important role in growth signals induced by glucose, through 
the activation of calcineurine, a calcium dependent phosphatase. It has been 
demonstrated that mice with a deletion in the regulatory subunit of calcineurine develop 
age-dependent diabetes, characterised by decreased β-cell proliferation and mass, 
reduced pancreatic insulin content and hypoinsulinemia [50]. 
FFAs are also able to influence β-cell homeostasis, as they are able to amplify GSIS and 
consequently to stimulate β-cell function. In addition, increased enteric nutrient supply, 
especially in the form of fats, may also result in β-cell mass expansion through increased 
GLP-1 production. GLP-1 is an incretin hormone, which has been shown to increase β-
cell proliferation and decrease β-cell apoptosis [51]. Most of its effects in the β-cell are 
due to the activation of the PDX-1 gene [52], whose expression is essential for 
pancreogenesis and for the regulation of genes associated with pancreatic cell 
differentiation and maturation (insulin,  GCK, GLUT2) [53]. 
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Together with nutrients, insulin like growth factors (IGF-I and IGF-II) and insulin itself 
play an important role in the regulation of β-cell homeostasis. IGF-I bind to IGF-I 
receptor, stimulating its intrinsic tyrosine kinase activity, which in turn phosphorylates 
members of the IRS family and activates the molecular pathways described in paragraph 
1.1.3. It has been shown that IGF-I and IGF-II are able to increase β-cell proliferation in 
rat islets and insulinoma cells in vitro [54]. In addition glucose enhances IGF-I mediated 
proliferation of insulinoma cells in culture through the activation of PI3K [47]. IGF-I is 
also able to activate the Ras/MAPK pathway and to induce mitogenesis in most 
mammalian cell types [55].  
The effects of insulin receptor signaling in the β-cell have been assessed both in vivo 
and in vitro. Insulin infusion in mice induces β-cell proliferation and increases β-cell 
mass [56]. In vitro, insulin receptor knock-down in MIN-6 cells leads to decreased 
proliferation [57]. In particular, IRS2 plays an important role as it stimulates PI3K/Akt 
and ERK1/2 pathways and animal models deficient in IRS2 develop T2D because of 
failed compensation [58]. 
Other growth factors have been shown to regulate β-cell proliferation, including 
prolactin, placental lactogen (PL) and growth hormone (GH). In vitro experiments in 
islets showed that incubation with these hormones leads to increased β-cell proliferation 
[59]. This is due to activation of the Janus Kinase (JAK)/Signal Transduction and 
Activators of Transcription (STAT) pathway, which leads to activation of Cyclin 2, 
essential for β-cell proliferation [60]. 
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Figure 1.7 Intracellular pathways implicated in β-cell growth and survival. IGF-I, IRS-2, 
PI3K, mTOR and STAT are important players in the regulation of β-cell homeostasis. The 
disruption of these pathways leads to β-cell dysfunction and apoptosis. Figure from reference 
[61]. 
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1.2 Diabetes Mellitus 
 
Diabetes mellitus is a metabolic disease characterised by high levels of glucose in the 
blood, which is defined “hyperglycemia”. This condition is caused by defects in insulin 
secretion, defects in insulin action for a diminished tissue response, or both.  Impairment 
of insulin secretion and defects in insulin action frequently coexist in the same person 
with diabetes, and it is often unclear which abnormality is the primary cause of the 
hyperglycemia [62].  
The chronic hyperglycemia of diabetes is associated with long-term damage and 
dysfunction of various organs, especially eyes, kidneys, nerves, heart and blood vessels. 
In almost all high-income countries, diabetes is the leading cause of cardiovascular 
diseases, blindness, kidney failure and lower limb amputation.  
There are two major types of diabetes. The causes and risk factors are different for each 
type: 
 Type 1 Diabetes (T1D) can occur at any age, but it is most often diagnosed in 
children, teenagers, or young adults. This disease results from an autoimmune 
destruction of pancreatic β-cells. The subsequent lack of insulin leads to 
increased blood and urine glucose.  
 
 Type 2 Diabetes (T2D) makes up 90% of diabetes cases. It most often occurs in 
adulthood. This form of diabetes develops often in people who are overweight 
and who do not exercise. T2D is considered a milder form of diabetes because of 
its slow onset (sometimes developing over the course of several years) and 
because it can be usually controlled with diet and oral medication. The 
consequences of uncontrolled and untreated T2D, however, are just as serious as 
those for T1D. Insulin injections are sometimes necessary if treatment with diet 
and oral medication is not working. 
 
The World Health Organization states that 347 million people worldwide were suffering 
from diabetes in 2008, which equates to 9.5% of the adult population [63] and the 
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incidence is dramatically increasing. For this reason, the understanding of the molecular 
mechanisms of this disorder is becoming critical, in order to develop novel treatments 
that effectively target specific molecules and pathways. 
 
The work in this thesis will focus its attention on the study of the molecular mechanisms 
of T2D. 
T2D is characterised by defects in insulin secretion, defects in insulin action and an 
increased hepatic glucose output. Symptoms for this disease include frequent urination, 
lethargy, weight loss and an excessive thirst and hunger. The typical treatment for this 
disorder includes changes in diet, physical exercise, oral medications and daily injection 
of insulin.  
It is generally agreed that T2D is a multifactorial disease, arising from the presence of 
T2D risk alleles in multiple genes and from environmental factors, which can also be 
responsible of modulation of the genetic risk [64]. 
Several lines of evidence support the principle of inherited genetic susceptibility as an 
important risk factor for T2D, but the mode of genetic transmission does not follow 
simple Mendelian patterns. Moreover, the risk of T2D is higher in certain ethnic groups, 
independent of metabolic risk factors profiles, such as Hispanics, African Americans, 
Pacific Islanders, and American Indians. Candidate gene association, linkage analysis 
and genome-wide association studies (GWAS) have identified some of the T2D 
susceptibility loci. Most of the T2D risk alleles identified correspond to gene that have 
impacts on glucose induced-insulin secretion: TCF7L2, ADAMTS9, ADCY5, 
CDC123/CAMK1D, CDKAL1, CAPN10, CDKN2A/B, CENTD2, FOXO1, HHEX, 
IGF2BP2, KCNQ1, PROX1, PPARG, NOTCH2, WFS1, PCSK1, APOB [65-67]. 
Sedentary lifestyles and high-fat diets are behavioural factors playing a role in the 
pathogenesis of the disease. It has been shown that lifestyle interventions (dietary 
modification, weight loss and exercise) in overweight adults with impaired glucose 
tolerance achieved 58% reduction in the incidence of diabetes [68].  
 
T2D has a slow onset, progressing from an early asymptomatic stage with insulin 
resistance to mild postprandial hyperglycemia to T2D requiring pharmacological 
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intervention. Understanding the progression of diabetes is fundamental for effective 
treatments regimens, specific for the different stages of the disease. 
 
1.2.1 Natural history of T2D 
 
Insulin resistance is considered to be an early primary defect in T2D. It is characterised 
by an inadequate response to a given concentration of insulin and by the inability to 
increase glucose uptake and utilisation.  
At first, the pancreatic β-cell is able to compensate this dysfunction, increasing the 
levels of insulin in a condition called hyperinsulinemia: higher levels of insulin 
correspond to higher insulin resistance. This compensation is able to keep glucose levels 
normalised for a period of time up to several years (Figure 1.8) [69] [70]. 
However, as insulin resistance worsens (due to genetic defects, obesity, decreased 
physical activity or aging), more global defects in insulin secretion occur, resulting also 
in increased hepatic glucose output. Together, these defects lead to a progressive 
elevation of fasting blood glucose, in an asymptomatic but still potentially pathologic 
stage characterised by mild hyperglycemia. 
The progression from this stage to early T2D is marked by a decrease in the β-cell 
function and subsequently a decline in insulin secretion. It is a gradual and progressive 
failure because, as long as the pancreatic β-cell is able to compensate for insulin 
resistance by increasing insulin production and secretion, glucose level remains normal 
or near normal. It is only when the β-cell begins to fail, and insulin secretion decreases, 
that hyperglycemia occurs (Figure 1.8) [71]. 
Also obesity has an impact on the progression of the diabetic state: obese diabetic 
patients have a more profound degree of insulin resistance and compensatory 
hyperinsulinemia compared to lean patients [72]. 
  
38 
 
 
 
Figure 1.8 Natural history of T2D. T2D progresses from an initial phase of insulin resistance 
characterised by an increased insulin production that maintains normal glucose levels, to a 
gradual dysfunction of the β-cell, with increased insulin resistance and hyperglycemia. 
 
Only a small fraction of obese individuals with insulin resistance progresses to T2D 
[73]. In addition, recent studies demonstrated that β-cell dysfunction is the critical 
determinant for T2D and it can occur also in absence of insulin resistance [74]. In 
particular, the United Kingdom Prospective Diabetes Study (UKPDS), which had the 
goal of understanding how to reduce long-term complications in patients with 
established diabetes, showed that treatments aimed to reduce insulin resistance were not 
able to stop the progression of β-cell dysfunction [75]. In general, the difficulty in 
maintaining normal glucose level has been attributed to the deterioration of β-cell 
function; such deterioration is the prerequisite to diabetes state, because many patients 
with intact β-cells are able to maintain normal glucose tolerance for their lifetimes. 
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1.2.2 β-cell compensation 
 
The development of T2D is characterised by changes in the number, morphology and 
function of the β-cells, which progressively lose their differentiation feature and become 
unable to cope with the needs of the organism.  
During the first phases of insulin resistance there is a compensation for the subnormal 
insulin function with an increase in β-cell mass and function, leading to increased 
insulin secretion (hyperinsulinemia). Increase in β-cell mass has been found in autopsy 
studies in obese humans [76] and rodent models of insulin resistance [77-78]. This is 
mostly due to increased cell number, but cell hypertrophy may also contribute.  
The stimulating factors implicated in the compensatory islet responses include the same 
factors responsible of the maintenance of β-cell homeostasis, specifically, increased 
nutrient supply (in particular glucose and fatty acids), insulin and other growth factors 
signalling, and increased levels and sensitivity to incretin hormones such as GLP-1 [79]. 
Glucose, in particular, is considered the dominant factor in β-cell compensation process. 
Studies of islet β-cell compensation show an upregulation of glucose pathways [80-82], 
such as increased level of GCK, pyruvate carboxylase and glucose transporter GLUT2. 
It has also been shown that GCK is essential for the compensatory β-cell hyperplasia, as 
GCK
-/-
 mice fed a high fat diet demonstrate decreased β-cell replication and hyperplasia 
[83]. 
 
However, with the progression of insulin resistance towards T2D, the β-cell is not able 
to cope anymore with the metabolic demand and hyperglycemia and hyperlipidemia 
negatively impact β-cell mass and function.  
The toxic effect generated by chronic exposure to high glucose and fatty acids on the β-
cell viability and function is generally called glucolipotoxicity and it is discussed in 
more details in the next paragraph (1.3). 
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1.3 Glucolipotoxicity 
 
Glucolipototoxicity refers to the combined and deleterious effects of elevated glucose 
and fatty acids levels on pancreatic β-cell function and survival [84]. 
There is still debate about which molecular mechanisms are responsible for the β-cell 
failure during progression of diabetes, and in particular, recent attention is focussed on 
the identification of the mechanisms of glucose- and fatty acids-induced impairment of 
insulin production and secretion. 
As discussed above, there is strong evidence of a gradual progression of the β-cell 
failure in glucolipotoxic conditions. In particular, after exposure to high concentrations 
of glucose and fatty acids, there is a compensatory phase during which there is increase 
of β-cell mass, leading to increased insulin gene expression and secretion. Upon 
prolonged exposure, the β-cell becomes unable to further compensate and this phase is 
characterised by reduced β-cell mass, reduction of insulin expression and secretion and 
ultimately β-cell failure. 
 
1.3.1 Effect of glucolipotoxicity on β-cell viability 
 
T2D is associated with a progressive decrease in β-cell mass and the inability to adapt to 
insulin resistance with an increase in β-cell replication and neogenesis. Rahier et al 
demonstrated that β-cell mass is 39% less in T2D subjects compared to matched 
controls [85]. It has also been shown that the pro-apoptotic genes Bad, Bid, and Bik are 
overexpressed in islets maintained in high glucose concentrations, while the anti-
apoptotic gene Bcl-xl is reduced [86].  
Many mechanisms could trigger β-cell apoptosis, including chronic hyperglycemia, 
chronic hyperlypidemia, increase in intracellular calcium, endoplasmic reticulum stress, 
oxidative stress and certain cytokines. 
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Glucotoxicity 
As discussed above, transient increases in glucose levels within physiological range (i.e. 
after a meal) induce insulin secretion and β-cell proliferation. On the other hand, chronic 
hyperglycemia has detrimental effects on β-cell function and mass [87]. Currently, it is 
thought that chronic glucose exposure leads to oxidative stress in β-cells and to 
accumulation of reactive oxygen species (ROS), causing β-cell dysfunction and 
apoptosis [88-92]. When glucose enters the cell, it is converted by glycolysis to 
pyruvate, which then enters tricarboxylic acid cycle to undergo oxidative 
phosphorylation, with formation of ATP and ROS. However, when excess glucose is 
available to the cell, glucose is driven to alternative pathways and excess ROS can be 
formed [87]. The pathways involved in the generation of oxidative stress include the 
non-enzymatic glycosylation reaction with increased production of advance glycation 
end products (AGE), the disruption of the electron transport chain in the mitochondria, 
and the hexosamine pathway, with subsequent changes in gene expression (Figure 1.9). 
Also the polyol pathway is an established contributor to oxidative stress because the 
enzyme aldose reductase (responsible for detoxification of aldehydes to alcohols), in the 
presence of hyperglycemia, reduces glucose to sorbitol, which is then oxidised to 
fructose, consuming large quantities of NADPH. The depletion of NADPH leads to 
oxidative stress since this is a major cofactor for glutathione regeneration and a known 
antioxidant defence at the cellular level [93] (Figure 1.9). 
The detrimental effects of oxidative stress in the β-cell might, in part, be caused by the 
activation of IκB kinase-β (IκKβ) and/or cyclooxygenase increasing the production of 
nitric oxide (NO) via NF-κB, activation of PKC, p38 mitogen-activated protein kinase 
and c-Jun N-terminal kinase (JNK) pathways [94-95]. Oxidative stress has also been 
shown to disrupt insulin signalling transduction (more details in paragraph 1.3.2).  
Another pathway by which ROS can induce β-cell dysfunction and death is through the 
NLRP3 inflammosome, a complex of proteins responsible of the generation of 
inflammatory responses [96]. It has been shown that ROS can induce NLRP3 activation, 
facilitating the oxidative stress mediator thioredoxin-interacting protein (TXNIP) 
binding to inflammosome and its subsequent activation. NLRP3 then activates caspase 
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1, which induces cleavage of pro-IL-1β to IL-1β and the generation of an inflammatory 
cascade (see paragraph 1.4) [97]. 
   
Because of the relatively low expression of antioxidant enzymes such as catalase and 
glutathione peroxidase, β-cells are highly sensible to oxidative stress [98-99]. Consistent 
with this, it has been shown that overexpression of antioxidant enzymes in isolated islets 
prevented islets dysfunction in conditions that mimic prolonged hyperglycemia [100]. 
 
 
 
Figure 1.9 Chronic hyperglycemia leads to oxidative stress. Schematic representation of the 
factors implicated in the generation of oxidative stress under conditions of hyperglycemia. 
 
In addition to oxidative stress, chronic hyperglycemia can induce ER stress (see below), 
increasing intracellular calcium and subsequent signalling. Chronic hyperglycemia leads 
to overstimulation and long term increase in cytosolic calcium that may be pro-apoptotic 
and induce β-cell dysfunction [101].  
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Moreover, high concentrations of glucose induce the production of interleukin-1 β (IL-
1β), triggering an inflammatory response (more details in paragraph 1.4) [102] and of 
Fas receptor, activating the apoptotic pathway [103]. 
Finally, one of the downstream factors that can be influenced by hyperglycemia is IRS-
2, which is especially involved in promoting β-cell survival. Increased IRS-2 expression 
can promote β-cell replication, neogenesis and survival, whereas decreased IRS-2 
expression causes β-cell apoptosis. The promotion of β-cell replication is triggered by 
IRS-2 tyrosine phosphorylation, while serine/threonine phosphorylation leads to IRS 
degradation [104]. Chronic hyperglycemia can lead to the chronic activation of the 
mTOR, which can phosphorylate and downregulate IRS-2 [105]. 
 
Lipotoxicity 
Long-term exposure of FFAs to β-cell has a more marked effect of inhibiting β-cell 
mitogenesis, as well as inducing β-cell apoptosis, especially in the presence of 
concomitant hyperglycemia. This can be explained by the fact that elevated glucose 
prevents fat oxidation via the AMPK/malonyl-CoA signalling network (see paragraph 
1.1.2.1) and therefore the detoxification of fat [106]. This concept is supported by the 
findings that treatment with an inhibitor of fat oxidation promotes β-cell death, while 
treatment with an AMPK activator protects β-cell from glucolipotoxicity [107]. 
At the same time there is intracellular accumulation of LC-CoA, products of lipid 
peroxidation and/or ceramide derivatives, which are cytotoxic. Ceramide accumulation 
in β-cells is implicated in the apoptotic pathway because it increases the expression of 
inducible nitric oxide synthase (iNOS) through activation of NF-κB, and therefore it 
augments the production of the toxic NO [108].  
Another potential mechanism by which FFAs may impair β-cell viability involves the 
expression of uncoupling protein-2 (UCP2), which is a mitochondrial carrier that 
regulates ATP production, catalysing the translocation of protons across the 
mitochondrial membrane. Chronic exposure of islets or insulinoma cells to elevated 
FFAs can induce an increase in UCP2 expression [109], increasing ROS production. 
In addition, FFAs are able to activate Toll-like Receptor 4 (TLR4) [110], a molecule 
involved in the activation of the innate immune system. It has been shown that TLR4 
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activated macrophages contribute to IL-1β secretion from mouse and human islets 
[111]. 
 
ER stress 
β-cell apoptosis can be further induced by endoplasmic reticulum stress. Because of the 
high secretory demand, the endoplasmic reticulum is very well developed and highly 
active in the β-cell. This also likely increases the susceptibility of these cells to ER 
stressors. ER stress might produce signals mediating glucose-induced impairment of 
function and death. 
The molecular mechanisms by which glucolipotoxicity-induced ER stress causes β-cell 
apoptosis are not well understood, but can involve depletion of ER calcium stores [112]. 
It has been reported that the Akita mouse (a mouse model of diabetes) carrying a folding 
mutation in proinsulin that activates the ER stress response, develops diabetes and loss 
of β-cell mass, suggesting that an excessive demand on ER could cause β-cell damage 
[113].  
Glucolipotoxicity also activates the Unfolded Protein Response (UPR), a mechanism 
that improves cellular ability to dispose unfolded proteins and increase the amount of 
chaperones in the ER. If unable to perform this task, the UPR triggers the apoptosis 
pathway [114]. 
ER stress can induce apoptosis by JNK, ATF-3 and inhibition of Bcl-2 [81]. In 
particular, activation of JNK could lead to suppression of the IRS/Akt signalling via 
serine phosphorylation of IRS-1, reducing survival and inducing apoptosis [115]. 
 
Mitochondrial dysfunction 
Increased metabolism of glucose and FFAs through mitochondrial oxidation results in 
an increased mitochondrial membrane potential and superoxide production [116]. This 
can increase cell exposure to ROS and lead to the activation of UCP2 [117], which help 
to safely dissipate the elevated mitochondrial membrane potential and promote fuel 
detoxification. However, this occurs at the expense of ATP synthesis efficiency and 
consequently insulin secretion. 
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Islet inflammation and amyloid deposition 
There is also strong evidence for the activation of inflammatory pathways in the 
presence of glucolipotoxicity. Chronic elevated glucose has been documented as 
inducing IL-1β production [102] and expression of Fas receptor [103]. A more detailed 
explanation of islet inflammation processes is presented in paragraph 1.4. 
Also cytotoxicity from accumulation of IAPP may also be a factor contributing to T2D: 
this is the major component of islet amyloid and is co-secreted with insulin from β-cell 
[118]. In T2D this peptide aggregates to form intracellular microfibrils that can be toxic 
to the islet tissue, but the mechanisms responsible of amyloid formation remain unclear. 
 
1.3.2 Effect of glucolipotoxicity on β-cell function 
 
Prolonged exposure of the β-cell to high concentration of glucose and fatty acids leads 
to a β-cell dysfunction and impairment of insulin secretion and production. This 
phenomenon has been observed in vivo in rats [119] and humans [120].  Moreover, in 
vitro [107, 121-123] and in vivo [124] studies have provided evidence that lipotoxicity 
only occurs in the presence of concomitantly elevated glucose levels. This can be 
explained by the effects of glucose on lipid partitioning (explained in paragraph 1.1.2.1) 
and with the inhibition of β-oxidation and the concomitant accumulation of toxic 
intermediates in the cytosol. 
In recent years, several potential mechanisms have been investigated that could be 
responsible for the impairment of insulin secretion in glucolipotoxicity. These include 
the upregulation of UCP2, the activation of novel isoforms of protein kinase C (PKCε), 
the activation of GPR40 and the effect on late exocytotic events. 
Some evidence suggests that UCP2 might modulate insulin secretion and production and 
consequently play a role in glucolipotoxicity. This is based on the observations that 
increasing UCP2 expression in β-cells impairs insulin secretion [125] and that UCP2-/- 
mice have increased circulating insulin levels and are protected from diabetes [126]. 
However, more recent studies show that the increase in UCP2 expression levels after 
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high fat exposure likely represents a cellular defense mechanism against fuel overload 
and oxidative stress rather than a deleterious response [127]. 
Activation of PKCε (a novel isotype of PKC, a calcium independent serine/threonine 
kinase) has also been suggested as a potential mechanism for the decrease in insulin 
secretion in glucolipotoxicity. Biden and coworkers demonstrated that islets from PKCε-
/-
 mice are protected from the deleterious effects of fatty acids on insulin secretion in 
vitro [128], probably due to the accumulation of lipolytic intermediates [129]. 
A role for GPR40 in mediating fatty acid inhibition of insulin secretion has been 
suggested by the observation that islets from GPR40
-/-
 mice are insensitive to the 
inhibitory effects of prolonged fatty acid exposure, whereas overexpression of GPR40 in 
β-cells of mice leads to impaired β-cell function, hypoinsulinemia and diabetes [130]. 
Finally, evidence suggests that fatty acids may also alter one or more late steps of 
insulin exocytosis in the β-cell. It has been shown that expression of granuphilin, a 
molecule that plays a role in the docking of insulin secretory granules to the plasma 
membrane, is increased in islets exposed to palmitate, as a consequence of upregulation 
of SREBP1c, a transcription factor that targets granuphilin promoter and controls fatty 
acids synthesis. By contrast, ablation of granuphilin by knock-down or knock-out 
restored insulin secretion in these islets [131]. 
Also the induction of oxidative stress has detrimental effects on the β-cell function. As 
explained before, oxidative stress generates from accumulation of glucose metabolites 
produced after chronic exposure to high glucose concentrations. Takahashi et al 
demonstrated that exposing rat islets to increasing concentrations of D-glyceraldehyde is 
associated with oxidative stress, decreased insulin content and inhibition of GSIS [132]. 
In a recent study, Somesh and colleagues used rat islets and NIT-1 cells to clarify the 
molecular mechanisms involved in the reduction of insulin secretion in 
glucolipotoxicity. They demonstrated that islets show an impaired glucose uptake, with 
reduction of GLUT2 and GCK mRNA levels, and an increased fatty acid uptake. This 
general suppression in glucose metabolism correlates well with a decrease in 
mitochondrial number and activity and reduction in cellular ATP content. In addition, 
cytosolic calcium mobilization is lost and insulin granule docking is reduced, with 
decreased expression of Rab27a, a small GTPase involved in vesicles transport [133]. 
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Prolonged exposure to fatty acids also impairs insulin gene expression in the presence of 
high glucose [121, 134], with distinct mechanisms from those involved in the 
impairment of insulin secretion. Generally, these mechanisms are not due to changes in 
mRNA stability, but to inhibition of glucose-induced insulin promoter activity [135]. 
This is associated with decreased binding activities and reduced expression of the 
transcription factors PDX-1 and MafA [136]. The accumulation of ceramide is 
considered as the leading mechanism in the impairment of insulin production and 
secretion. JNK is a known target of ceramide and can repress insulin gene transcription 
via inhibition of E1-mediated transcription and PDX-1 binding [137]. Moreover, 
ceramide formation from palmitate inhibits Akt activity [138], reducing the inhibition on 
the transcription factor Foxo-1, which translocates to the nucleus and activate 
gluconeogenesis. It has been shown that PDX-1 and Foxo-1 exhibit a mutually exclusive 
pattern of nuclear localization [139]. 
Also oxidative stress is able to decrease PDX-1 mRNA, PDX-1 protein, insulin mRNA 
and insulin content in HIT-T15 cells [140] and MafA binding [141]. 
ER stress is also associated with insulin transcription dysfunction, causing alterations in 
PDX-1 function [142] or insulin mRNA stability [143]. 
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1.4 T2D and inflammation 
 
Exposure of the β-cell to high concentrations of glucose and fatty acids can also induce 
the activation of inflammatory pathways. Initially, an inflammatory response is probably 
deployed to promote β-cell repair and regeneration. However, as it becomes chronic, 
auto-inflammatory processes can be activated that may become deleterious. Therefore 
T2D can also be considered an auto-inflammatory disease [144]. 
Supporting this hypothesis, inflammatory mediators such as cytokines and C-reactive 
protein have been shown to be elevated in patients with diabetes and they have been 
associated with the development and progression of cardiovascular complications [145-
146]. Patients with diabetes have evidence of low-grade inflammation and abnormal 
peripheral blood mononuclear cells (PBMCs), that could relate to long term 
complications and susceptibility to infections [147]. 
IL-1β and TNF-α, alone or in combination, have been implicated in sustaining 
autoimmune reaction against β-cell in T1D [148]. TNF-α is also considered a major 
cytokine implicated in the inflammatory response, as it has been shown to be 
overexpressed in adipose tissue in obesity [149], and possibly contributing to insulin 
resistance and consequently to the development of T2D [150]. 
 
Of interest is the predominant role of IL-1β, which is upregulated in islets of patients 
with both T1D and T2D [151]. Moderately elevated glucose concentrations are 
sufficient to induce transcriptional activation of IL-1β expression in human islets. More 
recently it has been found that oleate, palmitate and stearate, can also stimulate IL-1β 
expression when added individually or in mixtures. The combination of FFAs with 
elevated glucose concentrations further increases IL-1β expression and the release of 
various cytokines and chemokines [152]. 
Elevated glucose and FFA initially induce the expression and release of low levels of 
IL-1β, required for the adaptive response of islet cells (Figure 1.10). Continuous or 
prolonged stimulation with nutrients (metabolic stress) leads to the activation of IL-1R 
leading to a further increase of IL-1β by an autostimulatory process and to the 
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production of IL-1β-dependent cytokines and chemokines. Autocrine and paracrine 
activation leads to a broad inflammatory response including elevated cytokines and 
chemokines production, attraction of macrophages, apoptosis and amyloidosis, fibrosis 
and impaired insulin secretion (Figure 1.10). Consistent with an important role of IL-1β 
in inflammation, it has been shown that IL-1 receptor antagonist (IL-1Ra) is able to 
protect cultured human islets from these deleterious effects [144, 153-154]. 
 
 
Figure 1.10 Regulation of IL-1β in islets by metabolic stress. Il-1β auto-stimulatory loop is 
one of the key factors implicated in the inflammatory response in T2D. Elevated glucose and 
FFA initially induce the expression and release of low levels of IL-1β, required for the adaptive 
response of islet cells. Continuous or prolonged stimulation with nutrients leads to the activation 
of IL-1R leading to a further increase of IL-1β by an autostimulatory process and to the 
production of IL-1β-dependent cytokines and chemokines. Autocrine and paracrine activation 
leads to a broad inflammatory response including elevated cytokines and chemokines 
production, attraction of macrophages, apoptosis and amyloidosis, fibrosis and impaired insulin 
secretion. Figure from reference [144]. 
 
IL-1β pathway is activated due to IL-1R accessory proteins docking to the intracellular 
side of the receptor, with the recruitment of IL-1R activated kinase (IRAK) via the 
adaptor protein MyD88. IRAK then interacts with and activates TNF receptor associated 
factor 6 (TRAF6) [155]. TRAF6 can lead to the activation of mitogen-activated protein 
(MAP) kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase kinase 
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(MEKK1). MEKK-1 then leads to the activation of the group of MAP/stress-activated 
protein kinases (MAP/SAPK) as well as NF-κB [156]. MAP/SAKs, which include ERK, 
p38, and JNK, are able to phosphorylate a broad spectrum of cellular proteins including 
transcription factors of the activator protein 1 family, NF-κB inhibitors and PKC, which 
are pathways linked to apoptosis in β-cells (Figure 1.11). 
 
 
Figure 1.1 IL-1R signalling pathway. IL-1β pathway is activated with the recruitment of IL-
1R activated kinase (IRAK) via the adaptor protein MyD88. IRAK then interacts with and 
activates TNF receptor associated factor 6 (TRAF6). TRAF6 can lead to the activation of MAP 
kinase kinase (MKKs) or IKKs, which phosphorylates IkB, leading to its degradation. This 
activates NF-κB and its inflammatory pathway. 
 
As described before, IL-1β can be important for the consequent production of islets 
chemokines (IL-6, IL-8, MIP-1α, CXCL1) and their attraction of immune cells. These 
molecules are implicated in the stimulation of monocytes and neutrophils migration, and 
consequently in the increased number of islet-associated macrophages in T2D. This 
migration can be blocked by IL-8 neutralization [157]. All together, these factors lead to 
a chronic activation of the innate immune system. 
51 
 
IL-6 is another cytokine that is elevated in obesity and T2D and therefore it has been 
suggested as a predictive factor for the development of T2D. Both human and mouse 
islets respond to metabolic stress in vitro by increasing IL-6 release [144] and it has 
been shown that sustained treatment of human and rodent islets with IL-6 impairs GSIS 
[158]. 
IL-6 has also recently found to promote glucagon secretion from the pancreatic α-cell, 
induce α-cell proliferation and inhibit apoptosis [154]. Glucagon exerts opposite effects 
to insulin and it stimulates the release of glucose in the bloodstream.  Thus, in contrast 
to the negative effects on the β-cell, IL-6 acts as a growth and survival factor and it 
promotes glucagon secretion in the α-cells. Pancreatic islet pathology in T2D is 
characterized not only by reduced β-cell function and mass, but also an increased 
proportion of α-cells relative to β-cells, together with relative hyperglucagonemia as a 
result of dysregulation of α-cell function. 
 
Also IFN-γ has been shown to be involved in β-cell apoptosis and disruption of IFN-γ 
signalling pathway at the level of STAT1 prevents immune destruction of the β-cells 
[159]. 
These inflammatory effects are also amplified by the synergistic action of different 
cytokines at the same time; for example, TNF-α and IFN-γ works together to lead to 
caspase dependent apoptosis [160].  IFN-γ treatment confers susceptibility to TNF-α- 
induced apoptosis by STAT1 activation, followed by IFN regulatory factor (IRF)-1 
induction. IRF-1 plays a central role in IFN-γ/TNF-α induced cytotoxicity because 
inhibition of IRF-1 induction by antisense oligonucleotides blocks IFN-γ/TNF-α 
induced cytotoxicity [161].  
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1.5 Tumor Necrosis Factor Receptors 
 
Tumor necrosis factor (TNF) is a cytokine produced by many cell types, including 
macrophages, monocytes, lymphocytes, keratinocytes and fibroblasts, in response to 
inflammation, infection, injury and other environmental challenges. TNF-α is 
representative of a family of trimeric cytokines and cell surface proteins such as 
lymphotoxin-α (LT-α), Fas ligand (FasL), receptor-activator of NF-κB ligand 
(RANKL), CD40 ligand (CD40L), and TNF-related apoptosis-inducing ligand (TRAIL). 
These proteins display 25-30% sequence similarity mostly in the residues responsible 
for their trimerisation. By contrast, the external surface of the trimers, which accounts 
for receptor selectivity, shows little similarity [162]. These ligands bind to the respective 
receptors, triggering signalling cascades leading to cell proliferation, survival and 
differentiation. Most of the TNF/TNFR are expressed in the immune system, where their 
rapid and potent signalling capabilities are crucial in coordinating the proliferation and 
protective function of pathogen-reactive cells [163]. They have also roles in 
inflammation and apoptosis [164]. 
The different TNF receptors are listed in Table 1.1. 
 
RECEPTOR 
SYSTEMATIC 
NOMENCLATURE 
LIGANDS ADAPTOR PROTEINS 
TNFR1 TNFRSF1A TNF TRADD 
TNFR2 TNFRSF1B TNF TRAF1, TRAF2, TRAF5 
Lymphotoxin 
β-receptor 
TNFRSF3 
Lymphotoxin 
β2α1heterotrimer 
TRAF3, TRAF4, TRAF5 
OX40 TNFRSF4 OX-40 ligand 
TRAF1, TRAF2, 
TRAF3, TRAF5 
CD40 TNFRSF5 CD40 ligand 
TRAF1, TRAF2, 
TRAF3, TRAF5, TRAF6 
Fas TNFRSF6 Fas ligand FADD 
Decoy receptor TNFRSF6B LIGHT, TL1A, / 
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3 Fas ligand 
CD27 TNFRSF7 CD70 TRAF2, SIVA 
CD30 TNFRSF8 CD30 ligand 
TRAF1, TRAF2, 
TRAF3, TRAF5 
4-1BB TNFRSF9 4-1BB ligand TRAF1, TRAF2, TRAF3 
Death receptor 
4 
TNFRSF10A TRAIL FADD 
Death receptor 
5 
TNFRSF10B TRAIL FADD 
Decoy receptor 
1 
TNFRSF10C TRAIL / 
Decoy receptor 
2 
TNFRSF10D TRAIL / 
RANK TNFRSF11A RANK ligand 
TRAF1, TRAF2, 
TRAF3, TRAF5, TRAF6 
Osteoprotegerin TNFRSF11B 
RANK ligand, 
TRAIL 
/ 
Death receptor 
3 
TNFRSF25 TL1A TRADD 
TWEAK 
receptor 
TNFRSF12A TWEAK TRAF1, TRAF2, TRAF3 
TACI TNFRSF13B BAFF, APRIL TRAF2, TRAF5, TRAF6 
BAFF receptor TNFRSF13C BAFF TRAF3 
HVEM TNFRSF14 
LIGHT, LTA, 
BTLA 
TRAF2, TRAF3, TRAF5 
Nerve growth 
factor receptor 
TNFRSF16 
NGF, NT-3, 
BDNF, NT-4 
TRAF2, TRAF4, TRAF6 
BCMA TNFRSF17 BAFF, APRIL 
TRAF1, TRAF2, 
TRAF3, TRAF5, TRAF6 
GITR TNFRSF18 TL6 TRAF1, TRAF2, 
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TRAF3, SIVA 
TAJ TNFRSF19 LTA 
TRAF1, TRAF2, 
TRAF3, TRAF5 
RELT TNFRSF19L / TRAF1 
Death receptor 
6 
TNFRSF21 / TRADD 
/ TNFRSF22 / / 
/ TNFRSF23 / / 
Ectodysplasin 
A2 isoform 
receptor 
TNFRSF27 
ectodysplasin 
A2 
TRAF1, TRAF3, TRAF6 
Ectodysplasin 
1, anhidrotic 
receptor 
/ 
ectodysplasin 
A1 
TRAF1, TRAF2, TRAF3 
 
Table 1.1. List of TNF superfamily receptors. 
 
1.5.1 TNFR structure 
 
As their respective ligands, TNFRs undergo a trimerisation process following the 
binding of their ligands. Although different in their primary structure, the extracellular 
domains of all TNFR family members consist of cysteine-rich subdomains, which are 
thought to adopt a generally similar tertiary structure. The unique structural features of 
individual family members allow the TNFR family members to recognise their ligands 
with specificity and, in most cases, exclusivity [165]. 
TNFR-like receptors are type 1 transmembrane proteins that adopt elongated structures 
by a scaffold of disulfide bridges. The disulfide bonds arrange the typical cystein rich 
domains, responsive of ligand interaction. These 40 amino acids pseudorepeats are 
typically defined by 3 intra-chain disulfides generated by 6 well conserved cysteines 
[166]. The elongated receptor chains fit in the “grooves” within the ligand trimers 
(Figure 1.12) [163]. 
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The cytoplasmic domains are rather small (46-221 residues) and generally lack sequence 
homology among themselves, suggesting major differences in signalling mechanisms. 
None of these domains possesses sequences implying catalytic activity [166]. 
The ligands are type 2 proteins that can exist as membrane-embedded or cleaved, 
soluble forms. Both forms are active as self-assembling noncovalent trimers, whose 
individual chains fold as compact “jellyroll” β-sandwiches and interact at hydrophobic 
interfaces (Figure 1.12) [167]. Certain ligands and receptors can bind more than one 
partner with specific high affinity, thereby enhancing regulatory flexibility and 
complexity [168]. After ligand binding, the receptor cytoplasmic tails form a 3:3 internal 
complex with signalling proteins such as TRAF2 or FADD.  
 
 
 
Figure 1.12 TNFR and ligand interactions. A trimerized TNF ligand interacts with a 
trimerized TNF receptor on the cell surface, triggering a signalling cascade inside the 
cell. Figure from reference [169]. 
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1.5.2 TNFR signalling 
 
Signalling of TNF receptors occurs through two principal classes of cytoplasmic adaptor 
proteins: TRAFs (TNF-receptor-associated factors) and death domain (DD) molecules. 
In mammals, at least 6 TRAF molecules and 37 non-receptor DD molecules have been 
identified and their genomic localisation is spread throughout the genome. The specific 
signalling adaptor is selected by whether the cytoplasmic tail of the receptor contains a 
DD or a TRAF binding domain. Signalling is extremely rapid and highly specific 
(Figure 1.13). 
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Figure 1.13 TNFR signalling pathways. Activation of TNFR leads to the recruitment of 
different cytoplasmic molecules: FADD molecules, which activate the apoptotic pathway, and 
TRAF2 that instead activate NF-κB and MAPK pathways. The specific combination of 
signalling molecules determines the different effects on the cell response. Figure adapted from 
Invitrogen website.  
 
In the case of receptors containing DD domains, ligand engagement typically causes the 
association of adaptors such as Fas associated DD proteins (FADD) and TNFR-
associated DD proteins (TRADD) that ultimately lead to caspase activation and cell 
death [163]. For example, binding of TNF-α to TNFR1 induces receptor trimerization 
and recruitment of TRADD, which serves as a platform to recruit at least three 
additional mediators: receptor-interacting protein 1 (RIP1), FADD and TRAF2 [170]. 
TRAF2 plays a central role in early events that lead to IKK and MAPK activation. On 
the other hand, activation of TNFR2 induces directly the binding of TRAF2 and the 
subsequent signal cascade [171]. In the specific, TNFR1 activation induces the 
formation of two different complexes, either at the cell surface (complex I) or following 
internalisation (complex II). The formation of complex I requires TRAF2 and RIP, 
leading to kinase cascade and pro-inflammatory gene expression. Alternatively, 
complex II is formed to induce apoptosis, triggered by proteolysis and internalisation of 
the receptor, with recruitment of FADD and pro-caspase 8 [172-173]. 
Another characteristic feature of the members of the TNFR family is the activation of 
NF-κB, mediated by TRAFs. How TRAFs mediate NF-κB activation is not completely 
clear but it has been shown that TRAF2 interact with the NF-κB inducing kinase (NIK) 
that in turn can activate NF-κB [174]. Genes that are regulated by NF-κB can suppress 
apoptosis. Thus cytokines like TNF activate both apoptosis and anti-apoptosis pathways, 
accordingly to the signalling molecules involved.  
 
TRAFs recruitment 
TRAFs are adaptor proteins that share a common structural domain at the C-terminus. 
This conserved region allows TRAFs to interact with cell surface receptors or other 
signalling molecules. They are able to serve as adaptor proteins for a wide variety of 
receptors involved in regulation of cell death, survival and cell response to stress [175]. 
To date, six different TRAF molecules have been identified in mammalian species. 
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TRAF1 has been shown to interact indirectly with TNFR2 [171] and directly with 
several other TNFR family members. TRAF1 has been shown to suppress [176] or 
stimulate NF-κB [177]; an explanation of these apparently divergent roles may be in 
part provided by the fact that TRAF1 is a substrate for caspases activated by TNF family 
death receptors [178]. The C-terminal domain is able to bind TRAF2, sequestering it 
from the TNFR1 complex, suppressing NF-κB induction [179]. The N-terminal 
fragment or the uncleaved TRAF1 instead have no effect on TNFR1 or TRAF2- 
mediated NF-κB activation. TRAF1 is upregulated by ligands of the TNF family and its 
promoter contains several functionally important NF-κB binding sites [177]. 
TRAF2 has been the most extensively studied TRAF, both in term of structure and 
function. Mutational analysis of TRAF2 has shown that distinct domains are involved in 
interaction with other proteins and signalling functions [180]. It is possible to identify 
two distinct subdomains (TRAF-N and TRAF-C) that appear to independently mediate 
self-association and interaction with TRAF1 to form heterodimers (Figure 1.14). 
Interaction with TNFR2 and TRADD requires both the TRAF-C and the TRAF-N 
domains, whereas interaction with RIP1 occurs via sequences at the N-terminus of the 
TRAF-C domain. The N-terminal RING finger and two adjacent zinc fingers are 
required for NF-κB activation (Figure 1.14). TRAF2 is able to mediate NF-κB 
activation through interaction with NIK, which contains a TRAF binding domain [181]. 
TRAF2 is also able to regulate AP-1, a transcriptional activator usually formed from a 
homo- or heterodimer of Jun, Fos and activating transcription factor (ATF) family 
member [182]. TRAF2 can bind the kinase MEKK1 [183], which, following a 
phosphorylation cascade, can activate the JNK and p38 kinases [184], responsible for 
AP-1 activation.  
 
 
 
Figure 1.14 Schematic representation of TRAF2. TRAF2 is composed of four domains 
interacting with different proteins and signalling pathways. TRAF-N and TRAF-C are 
responsible for the association to the receptor and interaction with TRAF1. The N-terminal 
RING finger and the adjacent zinc fingers are required for NF-κB activation. 
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TRAF3 was first described as a molecule that binds CD40, in an interaction that is 
ligand dependent [185]. Its physical association with CD40 mediates its negative 
regulatory function, inhibiting CD40 signalling and NF-κB activation [186]. 
TRAF4 localises predominantly to the nucleus and has not been shown to regulate 
signalling through cell surface receptors [187].  
TRAF5 is implicated in NF-κB activation through interaction with lymphotoxin β 
receptor (LTbR) and CD40 [188]. 
TRAF6 was initially identified as a signal transducer for IL-1 and it can activate JNK 
and p38 when overexpressed [181]; moreover, its oligomerisation with TRAF2 has been 
shown to be important for JNK activation [183]. TRAF6 can also interact with CD40, 
using a different site than TRAF1, 2 and 3, near the membrane proximal region [189].  
 
MAPK activation 
As mentioned before, TRAF2 and TRAF6 are able to activate MAPKs, in particular 
JNK and p38 [181]. It has been demonstrated that JNK and p38 activation by TNF is 
dependent on TRAF2, because their activation is blocked in TRAF2
-/-
 cells [190]. Also 
MEKK1 is involved in TNF signalling [191] and it is also implicated in AP-1 and NF-
κB activation [192]; the N-terminal domain of TRAF2 can also activate MEKK1 in an 
oligomerisation-dependent manner [183]. Another kinase implicated in TNF signalling 
is ASK1 [184], that interacts with the C-terminal oligomerization domain of TRAF2 
[183]. The biological function of TNF-induced MAPK activation is under investigation, 
but it has been reported that JNK and p38 induce AP-1 activity, which contribute to the 
induction of TNF target genes [182]. 
 
NF-κB activation 
As mentioned previously TRAF2 and TRAF5 are able to activate NF-κB pathways via 
the recruitment of the IKK complex. Such activation is dependent on the 
phosphorylation of two serines within the activation loop of IKKβ [193]. Several MAPK 
were proposed to provide a connection between TRAF2 and TRAF5 and the IKK 
complex, possibly through the phosphorylation of the IKKβ activation loop. One of 
these kinases is NIK, identified as a protein binding TRAF2 and capable of activating 
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NF-κB upon overexpression [174]. However, subsequent analysis of NIK-/- mice 
indicated that this kinase is not essential for induction of NF-κB DNA binding or 
transcriptional activity by TNF-α [194].  
Another proposed mechanism of IKK activation is the recruitment of IKK to the TNFR1 
complex through binding of the intermediate domain of RIP1 to IKKγ/NEMO [195]. 
 
Caspase activation 
TNF-α is able to induce apoptosis through different pathways, among which the 
TRADD, FADD and caspase 8 pathway is the best characterised [196]. Upon activation 
by an apoptotic stimulus, the N-terminal prodomain of caspase 8 is cleaved, leading to 
an active heterodimeric enzyme, which in turn leads to activation of the downstream 
caspase 3, which in turn cleaves multiple cellular proteins, resulting in cell death [197]. 
The NF-κB pathway can be related to the apoptotic pathway through the activation of 
cellular inhibitors of apoptosis (cIAPs), which act as specific caspase inhibitors [198]. 
 
1.5.3 TNFR and Diabetes 
 
Members of the TNFR superfamily have a unique and pivotal role in regulating cell fate 
and determine whether pro-apoptotic or anti-apoptotic signalling pathways will be 
activated, as well as having a role in cell proliferation and inflammation regulation.  
Increasing evidence implicates dysregulation of TNF-α expression and signalling in the 
pathology of many diseases, including Crohn’s disease, rheumatoid arthritis and 
neuropathologies such as stroke, multiple sclerosis and Alzheimer’s disease [199]. 
The involvement of some members of the TNFR family in diabetes has been shown 
extensively in some studies on T1D. Walter et al reported increased expression of Fas 
and TNFR1 during the development of pancreatic inflammation (insulitis) in non obese 
diabetic (NOD) mice, a model for T1D [200]. In addition, NOD mice that are deficient 
for TNFR1 developed insulitis similarly to control NOD mice, but progression to 
diabetes was completely abrogated [201]. 
The TNFR pathway is also implicated in the pathogenesis of several processes involved 
in the development of insulin resistance. The principal role in obesity-related insulin 
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resistance is played by TNF-α, which is overexpressed in adipose tissue in many rodent 
models of obesity and it affects insulin sensitivity [149, 202]. Hossain and colleagues 
demonstrated an association of TNF-α with impaired insulin secretion and insulin 
resistance in a Bangladeshi population, and they suggested that it may have a causal 
relation with the insulin secretory defects in pre-diabetic patients [203]. It has also been 
demonstrated that TNF-α is able to induce insulin resistance in rat cells [150] and to 
reduce glucose-induced insulin secretion in INS-1 cells [204]. Solomon and coworkers 
showed also that treatment with anti-TNF-α agents improves fasting blood glucose 
values in the patients with T2D [205].  
Also TNFR2 is implicated in insulin resistance and in the pathogenesis and 
susceptibility of T2D [206]. Mutational variants in TNF and TNFR2 genes identified in 
different studies are indicative of a genetic basis in the pathogenesis of the metabolic 
syndrome [207]. Moreover, soluble levels of TNFR2 have shown to be increased in 
patients with T2D [208]. 
 
The TNF signalling pathway is therefore a valuable target in the therapy of 
autoinflammatory and autoimmune diseases, and TNF blockers have the ability to 
interfere with inflammatory processes at multiple levels. However, this therapy has also 
some drawbacks, including risk of infection and malignancy and the onset of new auto-
immune diseases. Some of these effects are caused by the fact that TNFR signalling can 
also have beneficial effects, related to the maintenance of the homeostasis of the 
immune system. For instance, the incidence of T1D is increased in anti-TNF treated 
patients with rheumatoid arthritis, due to dysregulation of T cell homeostasis [209-210], 
indicating that complete TNF inhibition is problematic. In such patients, TNFR1 
signalling should be blocked, but TNF-TNFR2 immunomodulating signalling should be 
preserved [211]. 
 
A better understanding of the signalling mechanisms used by TNFRs could result in the 
development of small molecules that can successfully modulate the biological activity of 
these cytokines and provide new avenues for therapeutic intervention. 
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1.5.4 CD40  
 
CD40 is a membrane glycoprotein and member of TNFR superfamily; as such it is 
sometimes referred to as TNFR5. It has the structure of a Type 1 transmembrane protein 
and it is a phosphorylated glycoprotein that migrates in SDS gel electrophoresis as a 48 
kDa polypeptide.  
The extracellular segment of CD40 is homologous to other members of TNFR family, in 
particular the 22 cysteine residues [165].  
Its natural ligand, CD40L (or CD154) is a Type 2 transmembrane protein and a member 
of the TNF-α protein family.   
 
 
 
Figure 1.15 Schematic representation of CD40 gene and protein.  
 
CD40 is expressed in many different immune and non-immune cell types. In B-
lymphocytes, macrophages and APC cells, binding of CD40 by CD40L plays a central 
role in the immune system, inducing differentiation, cell survival, and proliferation 
[212]. CD40 expression is also reported in non-hematopoietic cells, and its activation is 
mostly associated with inflammatory responses. These events engage costimulatory 
molecules, inducing cytokines/chemokines synthesis and secretion, which results in 
recruitment and activation of immune cells [213]. 
 
As for the other members of TNFR superfamily, CD40 signalling is mediated mainly by 
TRAFs, linking CD40 to downstream signalling pathways. The cytoplasmic domain of 
CD40 contains two independent membrane TRAF-binding domains: a proximal region 
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that binds TRAF6 and a distinct distal domain that binds TRAF-1/2/3/5. Different 
TRAFs binding to CD40 triggers distinct signalling pathways leading to a variety of 
functional outcomes, depending on the cell types involved. For example, they can 
activate the canonical and non canonical NF-κB signalling pathways, the MAPK, PI3K 
and phospholipase Cc (PLCc) pathways [214]. Moreover, signalling may also occur 
independently from TRAF proteins, as Janus family kinase 3 (Jak3) has been found to 
bind directly to the cytoplasmic domain of CD40, inducing phosphorylation of STAT5 
[215]. 
TRAF1 plays an important role in regulating the signalling of the other TRAF proteins, 
as it lacks the zinc finger domain and therefore it’s unable to activate the downstream 
signalling pathways. Its binding site motif in the CD40 cytoplasmic tail overlaps with 
the binding site for TRAF2 and TRAF3, and it appears that TRAF1 can bind weakly in 
the absence of TRAF2 [189], demonstrating the importance of TRAF oligomerisation 
process. It has been shown that the recruitment of both TRAF1 and TRAF2 to CD40 is 
required for the activation of NF-κB pathways [216]. 
The engagement of TRAF2 leads to the activation of JNK, p38 and Akt pathways 
(number 2 in Figure 1.16). This was shown using TRAF2-deficient mouse embryonic 
fibroblasts and B cells, which exhibited attenuated activation of these pathways after 
CD40 engagement [190, 217]. The intermediate kinase responsible for TRAF2 pathways 
activation is MEKK1 (number 1 in Figure 1.16), which drives the phosphorylation of 
JNK and p38 and activates the respective pathways [218]. On the other hand, activation 
of NF-κB is mediated by NIK (number 3 in Figure 1.16): without CD40 stimulation, a 
complex is formed between family members of the cellular inhibitor of apoptosis (cIAP) 
1 and 2, which interact with TRAF2, which in turn interacts with TRAF3 and NIK, 
inducing NIK degradation [219]. In contrast, after CD40/CD40L engagement, the 
complex is destabilised, leading to TRAF2 and TRAF3 binding to the cytoplasmic tail 
of CD40, with accumulation of NIK and activation of NF-κB (number 4 in Figure 1.16). 
The function of TRAF3 signalling is controversial, as it seems to have opposite roles in 
different cell types. In B cells, a TRAF3-dominant negative protein can lead to the 
induction of NF-κB and JNK signalling upon CD40 engagement [220], suggesting a 
negative regulation; in contrast, in epithelial cells the overexpression of TRAF3 can 
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induce the activation of NF-κB pathways during CD40 stimulation [221]. These 
contrasting roles can be determined by different conformations assumed by the receptor 
and TRAF3, which lead to different downstream signalling [222] or by mechanisms 
involving receptor-mediated TRAF3 degradation [223]. 
TRAF5 forms heterodimers with TRAF3 and its siRNA mediated downregulation in B 
cells leads to an ablation of NF-κB pathways, with reduction of antibody production, 
proliferation and costimulatory molecules expression [224].  
Finally, in mouse embryonic fibroblast of TRAF6
-/-
 mice or epithelial cells where 
TRAF6 has been silenced by siRNA, there is a reduction in the activation of NF-κB, 
Jnk, p38 and Akt upon CD40 engagement, suggesting the importance of TRAF6 in the 
activation of these pathways. It can also interact with TRAF2, positively regulating 
CD40 signalling [225]. 
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Figure 1.16 CD40 signalling pathway. CD40L binding to CD40 leads to TRAFs recruitment in 
the cytoplasmic tail of the receptor, with subsequent activation of NF-κB and MAPK pathways. 
The result is the induction of gene transcription in order to activate the inflammatory response. 
Figure adapted from SABioscience website.  
 
To summarise, the two major effects of CD40 activation appear to be the activation of 
NF-κB pathways and of protein kinases. Since many CD40 inducible genes, including 
AZO, IL-6, ICAM, have NF-κB consensus sites in their 5’ regulatory regions, it is likely 
that CD40-dependent NF-κB activation is responsible for the induction of these genes 
[226]. 
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1.5.4.1 Biological effects of CD40 activation 
 
CD40 activation drives the humoral immune response, in particular, the production of 
high titers of isotype-switched, high affinity antibodies and development of humoral 
immune memory. The engagement of CD40 expressed on the surface of antigen 
activated-B cells by CD40L expressed on activated CD4+ T cells triggers adhesion, 
sustains proliferation, expansion, differentiation and antibody isotype switching in vitro 
[226-227]. In vivo, CD40 engagement is required for germinal centre formation and 
progression, antibody isotype class switching and affinity maturation, in order to 
generate memory B cells and long-lived plasma cells [228]. 
The most compelling evidence for a critical role of CD40 activation in B-cell function is 
the observation that a fatal immunodeficiency in children (hyper-IgM syndrome), which 
is characterised by lack of circulating IgG and IgA and by the absence of germinal 
centres, can be attributed to a genetic defect in CD40L [229]. Consistent with this, mice 
deficient in either CD40 or CD40L display a phenotype similar to hyper-IgM syndrome 
patients [230]. In view of the critical role of CD40-CD40L interactions in humoral 
immune response, strategies have been developed to either decrease or increase these 
responses. Blocking anti-CD40L antibodies have been used in animal models to inhibit 
unwanted antibody production, for example in systemic lupus erythematosus (SLE) 
nephritis, and experimental autoimmune encephalomyelitis (EAE) [231-232]. On the 
other hand, administration of agonistic anti-CD40 antibodies can result in stronger 
isotype switched antibody responses [233]. 
It has also been shown that CD40 has a role in T cell priming [234], and have been 
suggested to inhibit tolerance induction. Therefore, interference with CD40 activation 
has been extensively investigated to prolong the survival of experimentally transplanted 
organs, including heart, skin, aorta and pancreatic islets [235]. 
In addition, CD40 and CD40L have a role in inflammation. CD40 engagement on 
macrophages induces the production of pro-inflammatory cytokines, including TNF-α, 
IL-6 and IL-1β [236]. Treatment with anti-CD40L antibodies has been shown to reduce 
the development of atherosclerosis [237] and to prevent pulmonary inflammation and 
fibrosis caused by oxygen-induced respiratory distress syndrome [238]. Moreover, 
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CD40 can promote IL-10 production from macrophages during Leishmania infections 
[239]. Platelets might also contribute to immunity and inflammation and CD40L-
positive T cells have been shown to enhance platelet activation [240]. Interestingly, 
CD40 is also present on fibroblasts and during fibrotic conditions (such as 
inflammation-induced lung fibrosis), fibroblasts are bound to T lymphocytes through 
surface CD40L [241]. 
 
1.5.4.2 CD40 in β-cells  
 
A functional CD40 is also expressed on the surface of mouse β-cells (mouse islets and 
NIT-1 insulinoma cells) and its expression is upregulated by a cocktail of pro-
inflammatory cytokines (IL-1β, IFN-γ, TNF-α). The receptor is active, as it is able to 
activate NF-κB [242]. CD40 is expressed also in pancreatic duct cells, but not in α-cells 
[243]. 
It has been demonstrated that CD40L binding triggers the secretion of pro-inflammatory 
cytokines/chemokines (IL-6, IL-8, MCP-1, MIP-1β) through Raf/MEK/ERK and NF-κB 
pathways [244]. Moreover, it has been reported that CD40 signalling activates pathways 
of MAPK involved in inflammatory responses. 
Additionally, activated CD40 enhances expression of intercellular adhesion molecule 
(ICAM)-1 (CD54) on the surface of β-cells: this molecule is known for its critical role in 
the patho-physiology of inflammation [244]. 
 
1.5.4.3 CD40 and diabetes 
 
Previous studies have suggested an emerging role for CD40-CD40L interactions in T1D, 
as established diabetogenic T cell clones are CD40 positive, whereas nondiabetogenic 
clones are CD40 negative. High levels of CD40 T cells were found in thymus, spleen 
and pancreas of NOD mice [245].  
In addition, interference with the CD40 pathway using blocking antibodies against 
CD40L inhibits the spontaneous development of T1D in NOD mice [246-247] and, 
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together with NF-κB blocking, prolongs allogeneic islet graft survival in rats [248] and 
in non human primates [249].  
Increased cellular CD40 and CD40L have been observed in patients with both T1D and 
T2D [250-251] and CD40L soluble levels may be related to the severity of the disease 
[251].  
No direct correlation to insulin metabolism has been elucidated so far, but Poggi et al 
demonstrated that obese CD40L
-/-
 mice have preserved insulin sensitivity and low 
plasma insulin levels compared to obese CD40L
+/+
 mice [247]. In addition, specific 
blockage of CD40-TRAF6 interactions improved insulin sensitivity, reduced adipose 
tissue inflammation and decreased hepatosteatosis in diet-induced obesity [252]. 
It has also been shown that diabetes-mediated hyperglycemia can result in monocyte 
recruitment associated with upregulation of CD40L in the vascular wall [253]. These 
processes might be integral with the development of atherosclerosis in patients with 
diabetes. 
Specific inhibition of CD40L-CD40 signalling may become a promising strategy to 
improve inflammation in diabetes mellitus, thereby reducing the occurrence of vascular 
complications. 
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1.6 Transcriptome profiling 
 
The transcriptome is the entire repertoire of transcripts of a cell and represents the key 
link between the information encoded in the DNA and the phenotype. To achieve 
mRNA regulation, a concerted action of multiple cis-acting proteins that bind to gene 
flanking regions is necessary [254]. In particular, core elements, located at exons’ 
boundaries, are strictly required to initiate the pre-mRNA processing events, whereas 
auxiliary elements, variable in number and location, are crucial for their ability to 
enhance or inhibit the basal splicing activity of a gene. Until 10 years ago, the 
transcriptome was considered to mainly consist of ribosomal RNA (rRNA, 80-90%), 
transfer RNA (tRNA, 5-15%), mRNA (2-4%) and a small fraction of intragenic and 
intergenic noncoding RNA (ncRNA, 1%) with undefined regulatory functions [255]. 
More recently, it has been shown that the amount of noncoding DNA increases with 
organism complexity, ranging from 0.25% in procaryotic genome to 98.8% in human 
genome [256]. Additional complexity is added by the fact that most of the transcripts 
identified so far have been found only in specific cell types, in particular growth 
conditions and in particular tissues. Based on this, discovering and interpreting the 
complexity of the transcriptome represent a crucial aim to understand the functional 
elements of a genome. The analysis of the complexity of the genetic code of living 
organisms will drive towards a more complete knowledge of many biological issues 
such as the onset of disease and progression. 
The main goal of transcriptome analyses is to identify, characterise and catalogue all the 
transcripts expressed within a specific cell/tissue, at a particular stage. This can also 
potentially determine the correct splicing patterns and the structures of the genes, and 
quantify the differential expression of transcripts in both physiological and pathological 
conditions [257]. 
With the completion of the human genome project, monitoring changes in the whole 
cellular transcriptome is an increasingly attractive method to dissect the molecular basis 
of a disease. 
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Tools for profiling RNA have been available for years, such as Northern Blots, reverse 
transcription PCR (RT-PCR), expressed sequence tags (ESTs), and serial analysis of 
gene expression (SAGE). However, the rapid and high-throughput quantification of the 
transcriptome became a possibility only with the development of gene expression 
microarrays (see paragraph 1.6.1). The development of these high-throughput 
techniques has allowed transcriptome profiling of model of diseases both in vitro and in 
vivo in an unbiased and highly sensitive manner, without previous knowledge of the 
genes involved in a particular disease. With the more recent advent of techniques for 
direct sequencing of the transcriptional output of the genome, it is now possible to 
perform a complete transcriptional characterisation of all organisms. 
 
1.6.1 Microarrays 
 
Expression microarrays are high throughtput techniques that allow the measurement of 
the expression of multiple genes simultaneously. The starting point for a microarray is a 
set of short oligonucleotide probes representing the genomic DNA. A typical modern 
microarray consists of patches of such probes complementary to the transcripts whose 
presence is to be investigated, and immobilised on a solid substrate. Probe design is 
based on genome sequence or on known or predicted open reading frames and usually 
multiple probes are designed per gene model. Transcripts are extracted from cells or 
tissues, labelled with fluorescent dyes, hybridised to the arrays, washed and scanned 
with a laser. Probes that correspond to transcribed RNA hybridise to their 
complementary target. Because transcripts are labelled with fluorescent dyes, light 
intensity can be used as a measure to quantify gene expression (Figure 1.17) [258]. 
Initially, microarrays designed by different companies appeared to produce different 
results with the same samples [259]. Moreover the fluorescent readout of hybridisation 
intensities varied between different laser scanners and there was lack of reproducibility 
between different laboratories. The recognition of these limitations and bias by 
individual laboratories and organisations, such as the Microarray Quality Control 
(MAQC) consortium, has led to the development of quality control standards that 
operate to ensure the running of a well performed microarray experiment [260]. 
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Specialised microarrays have also been designed, for examples arrays with probes 
spanning exon junctions can be used to detect and quantify distinct spliced isoforms 
[261]. In addition, genomic tiling microarrays (a microarray that uses a set of 
overlapping oligonucleotide probes for a subset of the whole genome), that represent the 
genome at high density and resolution, allow the mapping of transcribed regions to a 
very high resolution [262]. 
 
 
 
Figure 1.17 Microarrays technique. Short oligonucleotides probes are immobilised on a solid 
surface. Transcripts are extracted from cells or tissues, labelled with fluorescent dyes, hybridised 
to the microarrays, washed, and scanned with a laser. Figure adapted from Affymetrix website. 
 
Microarrays technique has been very successful and extensively used for the 
identification of differentially expressed genes in different conditions. For example, 
Wada et al used this technique to monitor gene expression in whole kidneys of 
streptozotocin (STZ)-induced diabetic mice and identified differential expression of 81 
genes (16 upregulated and 65 downregulated), 44 of which were novel genes [263]. 
Some studies investigated the effect of β-cell exposure to high concentration of glucose 
[264-265], identifying clusters of genes differentially expressed at specific glucose 
concentrations. 
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However, hybridisation-based approaches have several limitations because they need to 
rely on existing knowledge of genome sequence, they have high background levels due 
to cross-hybridisation, and a limited dynamic range of detection due to both background 
and saturation of signals. 
 
1.6.2 RNA sequencing 
 
Nucleic acid analysis has been recently revolutionised by the development of tools for 
massive parallel sequencing of DNA molecules. These techniques have then been 
extended to the analysis of the transcriptome, with a procedure called RNA-seq. This 
method has clear advantages over existing approaches and it is expected to revolutionise 
the way in which eukaryiotic transcriptomes are analysed. Rather than using molecular 
hybridisation to capture transcript molecules of interest, RNA-seq analyses transcripts 
present in the starting material by direct sequencing. Sequences are then mapped back to 
a reference genome. Reads that map back to the reference are then counted to assess the 
level of gene expression, as the number of mapped reads being the measure of 
expression level for that gene or genomic region.  
A schematic overflow of RNA-seq technique is presented in figure 1.18. A population 
of RNA (total or fractionated) is converted to a library of cDNA fragments with 
adaptors attached to one or both ends. For small RNAs such as miRNAs there is first a 
process of preferential isolation via a small RNA-enrichment method or size selection 
on an electrophoresis gel. 
Each molecule, with or without amplification, is then sequenced in a high-throughput 
manner to obtain short sequences from one end (single-end sequencing) or both ends 
(pair-end sequencing). The reads are typically 30-400 bp, depending on the sequencing 
technology used. Illumina’s Genome Analyser and HiSeq instruments as well as 
Applied Biosystems’ SOLID instruments and Roche 454 Life Science are the most 
common platforms used for high-throughput sequencing. 
After sequencing, the resulting reads are either aligned to a reference genome or 
assembled de novo without the genomic sequence to produce a genome-scale 
transcription map that consists of both the transcriptional structure and/or level of 
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expression for each gene [266]. Expression levels are obtained from the total amount of 
reads that map to the exons of a gene, normalised by the length of the exons. The 
presence and amount of each RNA can be calculated and subsequently compared with 
the amount in any other sequenced sample. 
Results obtained with this approach have shown close correlation with those of 
quantitative PCR and RNA-spiking experiments, which are normally used to calibrate 
measurements in DNA microarrays. 
 
 
 
Figure 1.18 A typical RNAseq experiment. Long RNAs are first converted to a library of 
cDNA fragments and sequencing adaptors are added to each extremity. The fragments are then 
sequenced and the obtained reads are then mapped to a reference genome. Figure from reference 
[266]. 
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There are some advantages in the use of RNA-seq compared to microarrays. Because 
RNA-seq provides direct access to the sequence with single base resolution, junctions 
between exons can be assayed without prior knowledge of the gene structure. 3’ 
boundaries can be mapped precisely by searching for poly(A) tags, and introns can be 
mapped by searching for tags that span GT-AG splicing sites [267]. 
RNA editing events can also be detected, and knowledge of polymorphisms can provide 
direct measurement of allele-specific expression. Because RNA-seq provides direct 
access to the sequence, this technique can be used on species for which a full genome 
sequence is not available. 
In addition to this, expressed regions of the genome that correspond to genes not 
currently identified (novel genes) might be easier to detect with sequencing than with 
microarrays, because detection depends only on where reads map in the genome and not 
on whether that region is annotated [268]. Gene annotation is the process of identifying 
the locations of genes and all the coding regions in a genome and determining what 
those genes do. 
Another strength of RNA-seq is the quantification of individual transcript isoforms and 
splicing diversity, as sequencing can provide direct access to reads that span exon/exon 
boundaries and in principle it makes possible to study the expression of different 
isoforms for a gene and to make comparisons of isoforms diversity and abundance. In 
humans 31618 known splicing events were confirmed by RNA-seq and 379 novel 
splicing events were discovered [268-269]. 
Moreover, RNA-seq has very low, if any, background signal because DNA sequences 
can been uniquely mapped to single regions of the genome.  
RNA-seq does not have an upper limit for quantification, indicating that it has a high 
dynamic range. By contrast, DNA microarrays lack sensitivity for genes expressed at 
very low or very high levels and they have a smaller dynamic range [266].  
RNA-seq data also show high levels of reproducibility for both technical (repeated 
measurements of the same sample) and biological (parallel measurements of 
biologically distinct samples) replicates. 
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On the other hand, currently, the main advantage of arrays is their relative low cost 
compared to sequencing. Another advantage is knowledge of biases in array data with 
the possibility of developing analysis strategies and experimental design to deal with 
them. By comparison, sources of bias in sequencing data are still being actively 
researched and at the same time RNA-seq continues to evolve. 
One of the most important concerns about sequencing RNA is the depth of sequencing 
to effectively analyse the transcriptome. This equates to how many times to sequence a 
sample. For highly expressed genes, small amounts of sequencing are sufficient, but for 
the middle and low end of expression levels, it is clear that many reads are needed. 
Failure to obtain sufficient coverage and check the representation of this coverage (that 
is the library complexity) will provide erroneous values of gene expression and lead to 
false inferences even for genes that are detected.  
Another source of bias in sequencing is the heterogeneity of reads across an expressed 
region, which is the uneven sequencing depth along the length of a transcript. This 
heterogeneity in coverage will influence expression estimates for transcripts and needs 
to be corrected. Coverage and heterogeneity are not an issue in microarrays because of 
the fixed nature of probes that capture the transcripts by hybridisation. 
A final consideration about arrays and sequencing is the quantity and size of the data. In 
expression arrays the raw data are composed of image files, typically TIFF files that 
may be around 30 MB per array. These TIFF files are then transformed into txt files that 
contain fluorescence intensities for each gene. The Illumina instrument instead generates 
sequence files that are an order of magnitude larger than those from arrays and because 
of the large file size, Python, Perl, Unix command line and other scriptings are 
necessary to sort and experiment with these files. Using spreadsheet softwares will not 
be an option and therefore bioinformatics support is necessary. 
 
RNA sequencing has been used to characterise the β-cell transcriptome, with the 
identification of β-cell specific genes, splicing events and intergenic RNA that could 
play important role in the regulation of the cell function [270]. In addition, long 
noncoding RNAs were also identified by RNA sequencing in human pancreatic islets 
and some of these transcripts were found to be dysregulated in diabetes [271]. 
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In a recent study, Cnopp et al investigated the effects of fatty acids exposure on the β-
cell. They observed that palmitate changed the expression of 1325 genes in human 
islets, in particular related to ER stress, ubiquitin and proteasome function, autophagy 
and apoptosis. Palmitate also inhibited transcription factors involved in the regulation of 
the β-cell phenotype (PAX4 and GATA6) and also shifted alternative splicing of 3525 
transcripts [272]. 
 
1.6.3 microRNAs 
 
As described before, the mammalian transcriptome is very complex and it contains a 
wide percentage of noncoding regulatory transcripts. Non-coding RNA genes include 
highly abundant and functionally important RNAs such as tRNAs and rRNAs, as well as 
small nucleolar RNAs (snoRNAs), microRNAs, siRNAs, small nuclear RNAs 
(snRNAs), extracellular RNAs (exRNAs) and Piwi interacting RNAs (piRNAs). 
In particular, miRNAs are endogenous ~22 nucleotides long RNAs that play important 
regulatory roles in animals and plants by targeting mRNAs for cleavage or translational 
repression. They normally bind to the 3’-UTR of their target mRNA through imperfect 
base pairing. miRNAs were firstly described in a nematode, Caenorhabditis elegans, in 
which it was discovered that two miRNAs, lin-4 and let-7 control the timing of the 
organism development [273-274]. 
Over 500 miRNAs have been found in the human genome [275] and it has been 
extimated that they could regulate 74-92% of all protein coding mRNAs. They can 
control both physiological and pathological processes such as development, metabolism, 
cancer and, relevant to this thesis, insulin resistance and diabetes [276]. 
 
1.6.3.1 miRNAs biogenesis 
 
Although miRNAs were initially described in Caenorhabditis elegans more than a 
decade ago, their presence in the vertebrates was confirmed only in 2001 [277]. In 
mammals, primary miRNAs are transcribed by RNA polymerase II [278], generating 
transcripts that are usually several kilobases long and contain local stem-loop structures 
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(Figure 1.19).  miRNAs are then edited by ADARs (adenosine deaminase acting on 
RNAs), an enzyme that modifies adenosine into inosine. Because base-pairing 
properties of inosine are similar to those of guanine, the editing process of miRNA 
precursors may change their sequence and target recognition abilities. 
miRNAs are subsequently processed in order to cleave the transcript at the stem of the 
hairpin structure, which release a small hairpin, termed pre-miRNA (Figure 1.19). This 
reaction takes place in the nucleus by the nuclear RNase III-type protein Drosha [279]. 
Together with a co-factor, DGCR8 (DiGeorge syndrome critical region gene 8), Drosha 
forms a large complex called Microprocessor complex. The two RNase domains of 
Drosha cleave the 5’ and 3’ arms of the pri-miRNA hairpin, whereas DGCR8 stably 
interacts with the pri-miRNA and functions as a molecular ruler to determine the precise 
cleavage site [280].  
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Figure 1.19 Biogenesis of miRNAs. miRNAs are 22 nt long transcripts generated by the 
cleavage of longer hairpin-structured RNAs performed in the nucleus by the enzyme Drosha. 
The pre-microRNA is then transported in the cytoplasm where it is processed by the protein 
Dicer to form the mature microRNA, which is recruited in the RNA-induced silencing complex 
(RISC) to perform translational repression or mRNA cleavage. Figure from reference [281]. 
 
However, Drosha mediated processing of pri-miRNAs is not the obligatory pathway. 
miRNAs derived from gene introns (mirtrons) are released from their host transcripts 
after splicing. If the intron resulting from the action of the splicing machinery has the 
appropriate size to form a hairpin resembling a pre-miRNA, it bypasses Drosha cleavage 
and is further processed in the cytoplasm by Dicer (Figure 1.20). 
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Figure 1.20 Formation of mirtrons. Splicing can replace Drosha processing if the miRNA 
derives from gene introns and it has the appropriate size. Figure from reference [281]. 
 
After nuclear processing, pre-miRNAs are exported to the cytoplasm. This process is 
mediated by exportin 5 (EXP5), a member of the nuclear transport receptor family 
[282]. EXP5 binds cooperatively to its target and to the GTP-bound form of the cofactor 
Ran in the nucleus, and subsequently releases the cargo in the cytoplasm with hydrolysis 
of GTP.  
After export from the nucleus, pre-miRNAs are cleaved near the terminal loop by Dicer, 
releasing ~22 nt duplexes with two nucleotides protruding as overhangs at each 3’ end 
[283]. Dicer is a highly conserved enzyme found in almost all eukaryotic organisms and 
it associates with some proteins: TRBP (TAR RNA-binding protein) and PACT (protein 
activator of PKR) that contribute to the formation of the RNA-induced silencing 
complex (RISC). TRBP and PACT are not essential for Dicer-mediated cleavage of the 
pre-miRNA but they facilitate it, and TRBP stabilises Dicer [284]. After Dicer cleavage, 
the resulting 22 nt is loaded into an Ago protein to complete the effector complex, 
RISC. One strand of the 22 nt RNA duplex remains in Ago as a mature miRNA (the 
guide strand or miRNA), whereas the other strand (the passenger strand or miRNA*) is 
degraded. Some evidence suggests that the miRNA duplex is released from Dicer after 
cleavage and the stable end of the duplex is bound to TRBP in the RISC, whereas the 
other end interacts with the Ago protein [285]. In principle, the miRNA duplex could 
give rise to two different mature miRNAs. However, only one strand is usually 
incorporated into RISC, while the other is degraded. This asymmetry depends on the 
termodinamic stability of the base pair at the end of the duplex: the miRNA strand with 
the less stable base pair at its 5’ end is loaded into RISC. Ago proteins exert multiple 
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functions in the miRNA pathway, as they are the RISC effector proteins mediating 
mRNA degradation, destabilisation or translational inhibition [286-287]. 
 
1.6.3.2 miRNAs function 
 
miRNAs can direct the RISC complex to downregulate gene expression by two post-
transcriptional mechanisms: mRNA cleavage or translational repression. According to 
the prevailing model, the choice of the post-transcriptional mechanism is determined by 
the identity of the target: once incorporated in the cytoplasmic RISC complex, the 
miRNA will specifically cleave the mRNA if there is sufficient complementarity or it 
will repress translation if the mRNA does not have sufficient complementarity [288]. 
When a miRNA guides cleavage, the cut occurs between the nucleotides pairing to 
residues 10 and 11 of the miRNA [289]. Therefore, the cut site appears to be determined 
by the miRNA residues, not miRNA:target base pairs. After cleavage of the 
corresponding mRNA, the miRNA remains intact and can guide the recognition and 
destruction of additional targets. 
When instead a miRNA induces transcriptional repression, the active single stranded 
miRNA enters the RISC complex, which interacts with the 3’UTR of target mRNAs. 
The miRNA-mRNA sequence mismatch impairs translation initiation, with mechanisms 
that frequently affect the initiation step, although regulation of later stages such as 
elongation, termination or release of the stable polypeptide has been reported. It was 
shown that mRNAs that are translationally repressed by miRNAs collect P bodies, 
within or adjacent to processing, and these are large cytoplasmic aggregates that serve as 
sites for mRNA degradation [290]. The detailed mechanisms by which miRNAs trigger 
sequestration of their mRNA targets in the P-bodies are not understood.  
Humphreys et al demonstrated that miRNAs can block the initiation phase of the 
translation via inhibition of the initiation factor 4E/cap and poly(A) tail function [291]. 
Another study conducted by Pillai et al [292] reported similar findings, namely that 
miRNAs can block the initiation phase of translation, possibly by interfering with the 
cap recognition step. 
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In contrast to miRNAs, short interfering RNAs (siRNAs) are not encoded by the 
genome but derive from exogenous or endogenous long, double stranded RNAs. They 
achieve gene silencing by promoting cleavage of the perfectly matched mRNAs. This 
different mode of action explains why siRNAs repress single genes, while miRNAs are 
promiscuous and can target up to 200 transcripts. 
Analysis of the miRNA target site indicates that genes with longer 3’UTRs usually have 
higher density of miRNA-binding sites and are mainly involved in development, 
whereas genes with shorter 3’UTRs usually have lower density of miRNA-binding sites 
and are involved in basic cellular processes [293]. This fact emphasizes the importance 
of the 3’UTR in the interaction with the miRNAs. 
 
1.6.3.3 miRNAs and diabetes 
 
In order to study the potential involvement of miRNAs in diabetes, a wide range of in 
vitro and in vivo strategies can be performed. A common and straight-forward approach 
is to expose cell lines or isolated primary cells to pathophysiological conditions, for 
example elevated concentration of glucose and/or FFAs, or cytokines. This method 
allows detailed analysis of the signalling pathways leading to changes in miRNAs 
expression, the study of the functional impact of individual miRNAs and the elucidation 
of the molecular mechanisms of their action. Another approach is to correlate the 
alterations in miRNA expression with the development of diabetes in animal models 
[294]. 
Some miRNAs have been shown to be involved in the pancreatic β-cell failure in T2D. 
A role for miRNAs in T2D was first estabilished by Poy et al, who showed that Mir-375 
is directly involved in the regulation of insulin secretion (see below) [295]. This study 
was one of the first to demonstrate that a miRNA could be tightly linked to a disease 
phenotype. Recently, many additional miRNAs have been identified as components of 
pathways involved in the aetiology of T2D. The discovery of novel miRNAs and their 
relative regulatory pathways will lead to a greater understanding of the disease and 
possibly provide novel diagnostic, prognostic and treatment alternatives.   
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Mir-375 is essential for β-cell development and function. Poy et al demonstrated that 
Mir-375 knock out in mice influences pancreatic α and β-cell mass, as Mir-375 regulates 
a cluster of genes involved in cellular growth and proliferation [296]. Specifically, in 
Mir-375
-/-
 mice, it has been observed a decrease of β-cell mass, accompanied by a 1.7 
fold increase in the number of α-cell, which suggests that Mir-375 could play different 
functions in α and β cells [296]. The levels of Mir-375 and Mir-7 increase during the 
development of human pancreatic islets, which correspond to an increase in insulin 
transcription level [297].  
Functional studies conducted in insulin secreting MIN-6 cells and primary β-cells 
revealed that Mir-375 is essential for insulin secretion. The overexpression of this 
miRNA impairs exocytosis of insulin-containing intracellular vesicles due to aberrant 
regulation of the Mir-375 target myotropin (also called V-1) [295], an antiapoptotic 
factor involved in maintaining β-cell viability and in exocytosis [298]. Another potential 
target of Mir-375 is PDK1 [299], a kinase involved in the PI3K pathway of regulation of 
cell survival and proliferation. Overexpression of Mir-375 attenuates proliferation and 
insulin gene transcription, reducing glucose-induced insulin secretion. This 
overexpression does not affect ATP production, nor the increase in intracellular calcium 
triggered by glucose, but it does affect a late step in the insulin secretory pathway 
through its effect on myotropin. In addition, Mir-375 is repressed by glucose via the 
cAMP-PKA pathway, which represents another way to enhance long-term insulin 
release. The transcription factor CREM is a potential mediator in this pathway, as it is 
activated by PKA through phosphorylation and is transcriptionally upregulated by 
glucose [300]. These studies revealed for the first time that nutrients can regulate the 
expression of miRNAs, particularly those related to β-cell. Moreover, the levels of Mir-
375 in pancreatic islets have found to be reduced in obese BTBR-ob/ob mice as well as 
in spontaneously diabetic GK rats [299, 301]. These data could seem controversial, as 
Mir-375 inhibits insulin secretion therefore it would be expected to be upregulated in 
diabetic conditions, but its reduction can be correlated to the loss of β-cell mass. 
Overall, it is becoming clear that Mir-375 targets genes that negatively regulate cellular 
growth and proliferation and that aberrant loss of this miRNA leads to reduction of β-
cell mass, leading to low levels of insulin, hyperglycemia and diabetes [296]. 
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Many other additional miRNAs play a role in insulin exocytosis in β-cell (Figure 1.21). 
Among those, Mir-9 regulates insulin secretion by repressing the transcription factor 
Onecut-2, and in turn, increasing the level of granuphilin/Slp4, a Rab GTPase effector 
associated with β-cell secretory granules, which exerts a negative control on insulin 
release. Plaisance et al demonstrated that overexpression of Mir-9 in insulin secreting 
cells causes a reduction in glucose or potassium stimulated exocytosis [302]. 
 
 
 
Figure 1.21 miRNAs involved in T2D and insulin release. The figure represents the miRNAs 
that directly or indirectly control the expression of key components required for insulin 
exocytosis machinery. Figure from reference [294].  
 
Mir-96 negatively regulates insulin exocytosis by targeting granuphilin and reducing the 
level of Noc2 (a protein involved in insulin exocytosis) in MIN6 cells, resulting in lower 
ability of cells to respond to secretagogues [303]. 
Mir-124a is upregulated in the β-cell in the presence of glucose [304], and this leads to 
reduced glucose induced-insulin secretion, through targeting the transcription factor 
Foxa2. This protein downregulates PDX-1, which directly regulates insulin gene 
transcription. Moreover, Mir-124a also decreases levels of Rab27 and Noc2 and 
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upregulates Snap25, Rab3a, and Synapsin1a, which regulate the late steps of insulin 
exocytosis [303-304]. 
Mir-187 has been connected to diabetes, as its expression is increased in human islets 
from individuals with T2D and it is associated with decreased GSIS [305]. This 
correlation was also observed, in the same study, in primary rat islets and INS-1 cells, 
where overexpression of Mir-187 decreased GSIS [305]. A possible target for this 
miRNA is homeodomain–interacting protein kinase-3 (HIPK3), a known regulator of 
insulin secretion, whose expression resulted reduced in islets from individuals with 
T2D. 
Another candidate miRNA in the pathogenic pathway to β-cell dysfunction and T2D is 
Mir-34a. Fatty acids are able to induce Mir-34a expression and, consequently, its levels 
are elevated in islets of obese mice [301]. It has been shown that Mir-34a is involved in 
the fatty acids-induced apoptotic process, probably by inhibition of the anti-apoptotic 
gene Bcl-2 [306]. It has also been demonstrated that Mir-34a can directly inhibit the 
translation of VAMP2 (vesicle-associated membrane protein 2), a SNARE protein 
involved in exocytosis. This inhibition can be responsible for the reduced insulin 
secretion in the presence of fatty acids [303]. Therefore, it is possible that Mir-34a 
overexpression in islets of obese mice can induce a reduction of insulin secretion and 
participate in the lipotoxic effects observed in obesity and metabolic syndrome, leading 
to defective β-cell function and cell death. 
As described before, T2D is characterized also by an inflammatory status with 
upregulation of different cytokines and chemokines, with a detrimental effect on the 
pancreatic β-cell. Global miRNAs profiling perfomed on the insulin secreting cell line 
MIN6 treated with pro-inflammatory cytokines revealed a strong induction of Mir-21, 
Mir-34-a, Mir-146 [307]. In particular, Mir-21 is upregulated in vivo and in vitro in 
inflammatory conditions and targets Pclo, a protein involved in vesicle trafficking [308]. 
Moreover, a blockade of these miRNAs using antisense molecules prevents the 
reduction in glucose-induced insulin secretion induced by cytokine exposure. Blockade 
of Mir-34-a prevents the reduction in Bcl2 expression, whereas the blockade of Mir-
146-a allows the attenuation of c-Jun induction triggered by cytokines [307]. 
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Tang and colleagues studied the differential expression of a large set of miRNAs after 
exposure of the pancreatic cell line MIN6 to high levels of glucose. In particular, Mir-
124-a, Mir-107 and Mir-30-d result to be upregulated in hyperglycemic conditions, 
whereas Mir-296, Mir-484 and Mir-690 are downregulated. Overexpression of Mir-30-d 
causes a reduction in insulin gene expression [304]. 
 
Specific miRNAs have been recently demonstrated to abundantly and stably exist in 
serum and to be potentially disease-specific. Evidence suggests that miRNAs are not 
present in the blood in the native form but are released in microvesicular structures, such 
as exosomes or apoptotic bodies, and circulate inside these vesicles that protect them 
from degradation. Zampetaki et al showed that a plasma signature of 5 miRNAs (Mir-
15a, Mir-29b, Mir-126, Mir-223, Mir-28-3p) can accurately differentiate patients with a 
high likelihood of developing diabetes from healthy controls [309]. Similarly to this, 
Pescador et al found that the combined down-regulation of Mir-138 and Mir-503 in 
plasma can effectively distinguish between patients with T2D and obese patients and 
healthy controls [310]. 
 
Considering that T2D is often associated with obesity, miRNAs in adipose tissue are 
strongly dysregulated in response to obesity-induced molecular changes and 
environmental signals. For example the Mir-29 family of miRNAs is induced by 
hyperglycemia and hyperinsulinemia in adipose tissue [311], Mir-320 increases insulin 
sensitivity in insulin resistant adipocytes [312] and Mir-27b impairs human adipocyte 
differentiation [313]. Therefore, dysfunction of these miRNAs in insulin targeting 
tissues can reflect the degree of disturbance and deregulation in diabetes. 
 
1.6.3.4 miRNAs as potential targets for diabetes 
 
As outlined before, serum circulating miRNAs can be used as biomarkers for T2D. It 
has been suggested that these miRNAs could be not only useful indicators of early 
disease onset, but they can also be responsible for the disease progression [314]. This 
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idea makes them a good target for an early intervention, and restoration of miRNA 
functions to normal levels is an attractive therapeutic strategy.  
Different chemically modified oligonucleotides have been used to modulate miRNAs 
expression. MiRNA mimic oligonucleotides increase the expression of the miRNA of 
interest, whereas anti-miRs, antagomirs and morpholinos are efficient inhibitors of 
miRNA functions and are also effective in vivo [315-316]. The use of oligonucleotides 
for gene therapy has to face different obstacles because these molecules are relatively 
unstable and their effects are transient. Therefore, they need to be injected at high doses 
and with repeated deliveries. They also need a cell-specific targeting. 
One method to obtain a temporally controlled elevation of miRNA expression in vivo is 
the generation of vectors in which miRNA mimics are placed under the control of an 
inducible promoter, which can be activated only in a specific-cell type. Kota et al used 
this vector to overexpress Mir-26a in liver cancer cell, showing an important protection 
from hepatic cancer progression without toxic effects [317]. Also, adenoassociated virus 
(AAV) vectors have shown promising results for gene therapy and the use of an insulin 
promoter can specifically deliver the vector to pancreatic β-cells [318]. This method 
opens an interesting prospective on the use of AAV-miRNA strategy for miRNAs 
highly expressed in normal tissues and underexpressed in T2D. 
On the other hand, the most promising approach to reduce miRNA activity involves the 
use of “miRNA sponges”. These are artificial structures that bind and hold native 
miRNAs, competing with their natural targets, thus creating a loss of function of the 
miRNA of interest [319]. This approach has been used in vivo to decrease the activity of 
Mir-31 and to investigate its role in cancer development [320]. 
The discovery of novel miRNAs involved in T2D and the identification of their 
functions in the insulin secreting system could open the way to new therapeutic 
strategies that can be able to treat the disease at an early stage. 
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1.7 Aim of the thesis 
 
The incidence of T2D continues to grow at an alarming rate, and individual 
pharmacological intervention therapies often become less effective in patients over time. 
For this reason, there is an urgent need to better understand the causes of diabetes and to 
develop novel treatments that effectively targets specific molecules and pathways 
associated with diabetogenesis. With the advent of new techniques for transcriptome 
profiling, there has been a huge progress in the understanding of the molecular 
mechanisms involved in the pathogenesis of diabetes. In particular, some studies have 
been perfomed using transcriptome profiling to identify molecules differentially 
expressed in β-cells or islets exposed to glucose or fatty acids. However, these projects 
relied only on microarrays results (while RNA sequencing would give a more complete 
view of the effects of glucolipotoxicity) or they only considered the effects of exposure 
to high glucose or fatty acids alone.  
The aim of this thesis is to define the molecular mechanisms involved in 
glucolipotoxicity, with the purpose to discover novel molecules implicated in the 
impairment of the β-cell function that could be potential targets for therapeutic 
strategies. 
To address this aim, a combined approach of microarray, RNAseq, RT-qPCR and 
Western Blots has been used to elucidate the pathways affected after chronic exposure 
to high concentrations of both glucose and fatty acids.  
Particular attention has been focussed on the TNFR pathway, which is involved in the 
inflammatory process in T2D. This thesis focusses especially on CD40 and its signalling 
pathway, in order to understand its involvement in glucolipotoxicity and insulin 
secretion. 
RNAseq has been used to confirm and expand the microarray analysis, as this next 
generation technique is the instrument of choice to determine differential expression 
between experimental conditions and discover novel genes at the same time. This will 
open the possibility of discovering unknown proteins involved in T2D. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 Reagents and solutions 
 
2.1.1 Reagents 
 
Unless otherwise stated, all the reagents were purchased from Sigma Aldrich, UK. All 
the plasticware was purchased from VWR, UK. 
 
2.1.2 Solutions and buffers 
 
SOLUTION COMPOSITION 
Krebs-Ringer 
solution 
125 mM NaCl, 1.2 mM KH2PO4, 5 mM KCl, 2 mM Mg SO4, 1.67 
mM glucose, 0.1% BSA, 25 mM HEPES 
NP40 buffer 500 mM Tris HCl, 1 M NaCl, 1% Triton X-100, pH 7.2 
Sample buffer 
40% glycerol, 240 mM Tris HCl, 8% SDS, 0.04% Blue 
Bromophenol, 5% β-mercaptoethanol, pH 6.8 
Lower buffer 1.5 M Tris HCl, 0.4% SDS, pH 8.8 
Upper buffer 1.5 M Tris HCl, 0.4% SDS, pH 6.8 
Running Buffer 0.25 M Tris HCl, 2.5 M glycine, 1% SDS, pH 8.3 
Transfer buffer 1 M Tris Base, 1 M glycine, 2% SDS, 20% methanol 
Ponceau solution 5 ml acetic acid, 90 ml water, 5 g Ponceau 
PBS 10X 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 
Stripping buffer 
6.25 ml Tris HCl 0.5M pH 6.8, 5 ml SDS 20%, 347 μl β-
mercaptoethanol 
 
Table 2.1 List of solutions and buffers. 
 
2.2 Cell culture  
 
2.2.1 Cell line 
 
The cell line used in the experiments performed in this thesis was the following: 
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CELL 
LINE 
ORGANISM CHARACTERISTICS 
INS-1 Rat 
Rat insulinoma cell line immortalized by radiation. INS-1 
cells respond to glucose in the physiological range and they 
contain a relatively high amount of insulin. They require β-
mercaptoethanol in culture medium for their growth [321]. 
 
Table 2.2 Description of the cell line used. 
 
2.2.2 Cell culture and propagation 
 
INS-1 rat pancreatic β-cells were cultured in RPMI-1640 media supplemented with 11 
mM glucose, 26 mM sodium bicarbonate, 10 mM HEPES, 50 µM β-mercaptoethanol, 
pH 7.4. Medium was supplemented with 10% v/v foetal bovine serum (FBS) (Life 
Technologies, UK), 1% v/v sodium pyruvate (Life Technologies, UK), 1% v/v 
Penicillin/Streptomycin/Glutamine (Life Technologies, UK).  
Cells were plated in T75 flasks and incubated at 37°C in a 95% air/5% CO2 atmosphere.  
 
2.2.3 Cell amplification and passage 
 
Cell lines were passaged when 80-85% confluent. Growth medium was aspirated and 
cells were washed in 5 ml of sterile phosphate buffered saline solution (PBS) and then 
incubated in 5 ml Trypsin-EDTA (Life Technologies, UK) for 3 minutes at 37°C to 
detach cells. Cells were then harvested in 5 ml of complete growth media and gently 
pipetted up and down before being collected by centrifugation at 200 RCF for 5 minutes 
at room temperature. Cell pellets were resuspended in the appropriate amount of growth 
media and re-plated as required in new tissue culture flasks or plates. 
 
2.2.4 Cryo-conservation and recovery of cells 
 
INS-1 cells were collected when 80-85% confluent. Growth medium was aspirated and 
cells were washed in sterile PBS and then incubated in 5 ml Trypsin-EDTA (Life 
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Technologies, UK) for 3 minutes at 37°C to detach cells. Cells were then harvested in 5 
ml of complete growth media and pipetted up and down before being collected by 
centrifugation at 200 RCF for 5 minutes at room temperature. Cells pellets were 
resuspended in 1 ml of 90% FBS: 10% DMSO (Sigma Aldrich, UK) and the total 
volume transferred in cryovials. Cells were stored in -80°C for at least 24h before being 
transferred in liquid nitrogen for long-term storage. 
 
2.2.5 Mycoplasma check 
 
All cells used in this thesis were regularly tested for Mycoplasma infection, using 
VenorGeM Mycoplasma detection kit (Cambio Ltd, UK). This system utilizes a PCR 
reaction to detect Mycoplasma infections in cell cultures. The primer set is specific to 
the 16s rRNA coding region in the mycoplasma genome and the generated amplicon 
shows a size of approximately 267 bp. 
Templates for PCR analysis were prepared by incubating the supernatant of cell cultures 
for 5 minutes at 95°C and subsequently centrifuged for 5 seconds to pellet cellular 
debris. 
The reaction was set up as follow: 
 
REAGENT x 1 REACTION x 3 REACTIONS 
PCR grade water 14.3 µl 42.9 µl 
10X reaction buffer (for Platinum Taq 
Polymerase, Invitrogen) 
2.5 µl 7.5 µl 
Primers/Nucleotide Mix 2.5 µl 7.5 µl 
Internal control 2.5 µl 7.5 µl 
Platinum Taq Polymerase, Invitrogen 0.2 µl 0.6 µl 
MgCl2 1 µl 3 µl 
 
Table 2.3 PCR reaction for Mycoplasma detection. 
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2 µl of samples and controls (one positive and one negative control) were added 
respectively and the tubes centrifuged briefly, taking care of avoiding cross-
contaminations. 
The PCR program used was the following: 
 
1 cycle 94°C for 2 min 
39 cycles 
94°C for 30 sec 
55°C for 30 sec 
72°C for 30 sec  
Cool down to 4°C 
 
Table 2.4 PCR reaction program for Mycoplasma detection. 
 
Samples were then run on a 1.5% agarose gel in TBE buffer 1X (Life Technologies, 
UK) for 20 minutes at 100 V. We expected a 191 bp band for the internal control and a 
265-278 bp band for Mycoplasma. 
Figure 2.1 shows an example of not contaminated cells. 
 
 
Figure 2.1 Detection of Mycoplasma infections by PCR. PCR reaction was performed on the 
supernatant of cultured cells. In this picture cells show a band at 191 bp, corresponding to the 
internal control. In case of contamination, cells show a band at 270 bp, in correspondence to the 
positive control. 
 
 
 
negative 
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350 
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2.2.6 Decontaminating cells from Mycoplasma 
 
In order to clean cells from Mycoplasma infections, we used MycoZap, Mycoplasma 
elimination reagent (Lonza Ltd, UK). This solution eliminates Mycoplasma using a 
combination of antibiotic and antimetabolic agents. 500 μl of the specific Reagent 1 was 
added to the cell culture medium, containing not more than 5% v/v FBS and cells were 
grown for 2-3 days. Cells were than passaged in normal culture medium, adding 500 μl 
of Reagent 2 for the following 3 passages. After the end of the treatment with Reagent 2, 
cells were free from Mycoplasma infections. 
 
2.3 Mice 
 
2.3.1 Mice strains 
 
The mice used in these experiments were C57Bl/6 mice (Charles River, UK). They were 
fed a high-fat diet (60% fat-58Y1; Test Diets, USA) or a standard rodent diet (CON) for 
10 weeks. After 10 weeks, mice were killed in the fed state (between 08.00 h and 10.00 
h) by overdose of anaesthetic for isolation of pancreatic islets. Mice were maintained on 
a 12 h light/12 h dark cycle.  All animal experiments were conducted in accordance with 
the UK Home Office Animals (Scientific Procedures), 1986, with local ethical 
committee approval. cDNA from islets of mice fed high fat diet was prepared by Paul 
Caton (Blizard Institute). 
 
2.3.2 Islet extraction and digestion 
 
Islets were isolated by collagenase digestion using a modified technique first described 
by Lacy and Kostianovskey (1967). Ice-cold 1 mg/ml collagenase P (Roche Applied 
Science; Basel, Swtzerland) and 0.15 mg/ml DNAse 1 (Roche Applied Science; Basel, 
Swtzerland) in RPMI-1640 was injected into the pancreas using a 1 ml syringe and G25 
needle. After the pancreas was inflated, it was excised and placed in a 5 cm Petri dish 
containing ice-cold RPMI on ice and cut into very small pieces with surgical scissors. 
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The resultant solution containing pancreas pieces and collagenase was transferred into a 
25 ml conical flask and sealed with parafilm. The sealed flask was incubated at 37°C for 
7 minutes under static conditions, with vigorous shaking by hand every 2 minutes and at 
the end of the incubation period, until the pancreas tissue was digested adequately. The 
digested pancreas solution was then transferred to a 15 ml falcon tube on ice and topped 
up with RPMI and allowed to settle. Then the supernatant was removed and the solution 
containing islets was transferred into a black bottomed Petri dish and free islets were 
handpicked under a microscope using a p200 pipette. The free islets were collected into 
a Petri dish containing RPMI and incubated at 37°C. 
 
2.4 Human islets 
 
2.4.1 Human islets extraction and digestion 
 
Islets were similarly extracted post-mortem from human donors with local Ethics Board 
approval, in Piero Marchetti laboratory (University of Pisa, Italy). Islets were hand-
picked into RPMI 1640 media (containing 11 mM glucose, supplemented with 10% 
(v/v) heat-inactivated FBS; 100 U/ml penicillin and 100 g/ml streptomycin; all Sigma 
Aldrich, UK). Isolated islets were then picked into RPMI and immediately lysed for 
either RNA extraction or protein separation. 
 
2.5 Preparation of experimental conditions 
 
2.5.1 Preparation of BSA conjugated fatty acids and media conditions 
 
To replicate diabetic extracellular glucolipotoxicity conditions in vitro, INS-1 cells were 
incubated for 72h in RPMI medium containing 27 mM glucose, 200 µM oleic acid, 200 
µM palmitic acid, either alone or in combination. The experimental conditions were 
chosen accordingly to [123]. The high glucose concentration used (27 mM) was 
determined by the fact that INS-1 cells were cultured in 11 mM glucose in normal 
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conditions. This justifies the use of experimental glucose concentrations much higher 
than the physiological concentrations in human blood. The fatty acids concentrations 
used were not so elevated in comparison to other studies [107], but we wanted to 
recreate experimental conditions that did not affect cell viability. In physiological 
conditions, fatty acids concentrations range from around 300-600 μM in the overnight 
fasting state to 1300 mM after a 72h fast [322]. These concentrations decrease during 
the fed state, due to the secretion of the hormone insulin, which exerts an antilipolytic 
action.  
Stock solution of oleic acid and palmitic acid conjugated to fatty acids free BSA (Roche 
Applied Science; Basel, Swtzerland) were prepared as follows. One hundred millimolar 
solutions of oleic acid dissolved in 50% ethanol and of palmitic acid dissolved in 100% 
ethanol were used to supplement the RPMI-1640 media prior to experimental 
incubation. This media was supplemented with 2% BSA and filtered with 0.2 µM filters; 
after the addition of fatty acids, the solution was incubated at 37°C for 1 h, to allow fatty 
acids binding to BSA. Individual experimental glucose and fatty acid concentrations are 
indicated in the text and figures. Control and high glucose conditions were 
supplemented with the corresponding amounts of ethanol and BSA. 
 
2.6 Cell function analysis 
 
2.6.1 Cell counting 
 
Cells were seeded in 6 or 12 well plates and incubated in the desired conditions for 72h. 
In all the experiments described, cells were washed with PBS and detached using 
Trypsin EDTA (Life Technologies, UK). Trypsin was neutralised using 1 volume of 
complete growth media and the cell suspension was transferred in an Eppendorf tube. 
Cells were centrifuged at 2000 RCF for 5 minutes. The supernatant was then removed 
and the pellet was resuspended in 1 ml of culture media. Cells were counted manually 
using a Neubauer chamber, using 10 μl of cells suspension. Three of the big squares 
indicated as 1 in Figure 2.2 were counted and cell number was calculated with the 
formula: 
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                                                                 Number of cells x 10000 
Concentration = –––––––––––––––––––––––––––––– 
                                                              Number of squares x dilution 
 
 
 
Figure 2.2 Schematic representation of a Neubauer chamber. Neubauer chamber was used 
for cell counting. Three of the big squares indicated as 1 were counted and multiplied by 10000 
to obtain the cell concentration. Figure adapted from Celeromics website. 
 
2.6.2 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
 
MTT assay was used to assess cell viability, in particular mitochondrial metabolic 
activity. The principle of the MTT assay is that for most viable cells mitochondrial 
activity is constant and thereby an increase or decrease in the number of viable cells is 
linearly related to mitochondrial activity. The mitochondrial activity of the cells is 
reflected by the conversion of the tetrazolium salt MTT into formazan crystal, which can 
be solubilised for homogenous measurements. Thus, an increase or decrease in the 
number of viable cells can be detected by measuring formazan concentration, reflected 
in optical density measurements. 
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Cells were seeded in 12-well plates and allowed to grow in the desired conditions. At 
the indicated time, 100 µl of MTT solution 5 mg/ml (Sigma Aldrich, UK) was added to 
the cells, followed by 2 hours incubation at 37°C in a 95% air/5% CO2 atmosphere. 
After the incubation period, DMSO was added to the cells for 15 minutes on a shaking 
rotor. The absorbance was read at 570-650 nm using a spectrophotometer. 
 
2.6.3 Caspase 3 activity assay 
 
The activation of caspase 3 (CPP32/apopain), which has substrate specificity for the 
amino acid sequence Asp-Glu-Val-Asp (DEVD), has been shown to be important for the 
initiation of apoptosis. For the detection of its activity we used EnzCheck Caspase-3 
Assay Kit #2 (Life Technologies, UK). The basis for the assay is rhodamine 110 bis-(N-
CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-110), which 
contains DEVD peptides covalently linked to each of R110’s amino groups, suppressing 
the dye’s visible absorption and its fluorescence. Upon enzymatic cleavage, the 
nonfluorescent bisamide substrate is converted in the fluorescent product, with peak 
excitation and emission wavelengths of 496 nm and 520 nm. 
The assay was performed following manufacturer’s instructions. Briefly, cells were 
harvested after the desired length of time and washed in PBS. Each cell sample was then 
resuspended in 50 µl of 1X lysis buffer and incubated on ice for ~30 minutes. Lysed 
cells were centrifuged to pellet cellular debris at 8000 rpm for 5 minutes and 50 µl of the 
supernatant of each sample was transferred to a 96 wells plate. 50µl of the 2X substrate 
working solution (containing Z-DEVD-100 substrate) was added to each sample and 
control. The samples were then incubated at room temperature for approximately 30 
minutes. Fluorescence (excitation/emission ~496/520 nm) was measured using a 
spectrophotometer. Because the assay is continuous, measurements could be made at 
multiple time points. 
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2.6.4 Fluorescence-activated cell sorting (FACS) 
 
Cell cycle analysis 
 
Cell-cycle analysis experiments were performed using flow cytometry to distinguish 
cells in different phases of the cell cycle. Before analysis, cells were permealised and 
treated with a fluorescent dye (propidium iodide) that stained DNA quantitatively. The 
fluorescence intensity of the stained cells at certain wavelength therefore correlated with 
the amount of DNA they contain. 
In the specific, cells were seeded in T25 flasks and incubated with the desired conditions 
for 24, 48 or 72 hours. Cells were then washed with PBS, harvested and fixed in ice cold 
70% ethanol, added with a Pasteur pipette on a vortex. Cells were then incubated at 4°C 
from 30 minutes to a week. At the time of analysis cells were pelletted and washed 
twice in PBS. 400 μl of a solution of 100 μg/ml RNAse (Sigma Aldrich, UK) and 50 
μg/ml Propidium Iodide (PI) (Sigma Aldrich, UK) was added to each sample. Samples 
were then incubated at RT for 15 minutes and subsequently analysed by flow cytometry 
collecting 25000 events per sample. 
 
2.6.5 Insulin secretion assay 
 
Cells were seeded in poly-D-lysine coated 6-well plates and allowed to grow near 
confluency (2x10
6
 cells/well) in each of the test media conditions for 72h. Cells were 
then washed with Krebs-Ringer solution (see table 2.1) and subsequently incubated for 
2h in Krebs-Ringer solution with or without insulin secretagogue cocktail (10 mM 
glucose, 1 µM phorbol 12-myristate 13-acetate, 1 mM isobutyl-methylxanthine, 1 mM 
tolbutamide, 10 mM leucine, 10 mM glutamine, all Sigma Aldrich, UK). Supernatant 
was collected and spun down to remove cell debris and insulin concentration determined 
following standard ELISA kit protocols (Mercodia, Uppsala, Sweden). Cellular protein 
content was assayed with BCA kit protocol (Thermo Fisher Scientific, Waltham, MA) 
and used to normalise secretion data (see paragraph 2.8.1). 
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2.6.6 Insulin content assay 
 
Cells were grown in 6-well plates in the desired test media conditions for 72h. The total 
protein content was measured using BCA kit (Thermo Fisher Scientific, Waltham, MA) 
and used to normalize insulin values obtained. Media was removed from the remaining 
wells of each plate and 500 μl of extracting solution containing 1.5% hydrochloric acid 
(37%), 18.5% distilled water, 80% ethanol (95%) were added to each well. After 24 
hours at 4°C, 500 μl of 0.1 M sodium hydroxide was added to neutralise the samples, 
which were then assayed for insulin content using standard ELISA protocols (Mercodia, 
Uppsala, Sweden). 
 
2.7 RNA analysis 
 
2.7.1 RNA extraction 
 
Total RNA was extracted from cells and whole islets using the Pure Link RNeasy mini 
kit (Life Technologies, UK). Briefly, cells were harvested and lysed in the appropriate 
volume of lysis buffer, before centrifuging the samples at maximum speed for 3 
minutes. An equal volume of 70% ethanol was added to the supernatant, thoroughly 
mixed and vortexed and transferred to the RNeasy spin columns. Once the RNA in the 
sample had bound to the column, a series of washes followed, each time discarding the 
flow-through. Finally, the bound RNA was eluted with 30-50 µl of nuclease free water 
and stored at -80°C. 
 
2.7.2 RNA quantification and quality assessment 
 
Total RNA was analysed using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA) to determine concentration and quality. The NanoDrop 
calculates RNA concentration by measuring the absorbance at 260 nm; absorbance 
correlates with concentration in a linear manner (Beer-Lambert law). RNA absorbs at 
260 nm while proteins and other contaminants (such as phenol and ethanol) absorb at 
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280 nm. Therefore the ratio of absorbance at 260 nm over 280 nm shows RNA purity: a 
ratio of 2 or above is indicative of a pure RNA sample. 
 
2.7.3 Reverse transcription 
 
2 μg of total RNA for each sample were used to be reverse-transcribed to cDNA using 
cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA). The reaction was set up 
as follow: 
REAGENT X 1 REACTION X 10 REACTIONS 
Oligo dT primers 1 μl 10 μl 
Reaction buffer 5X 4 μl 40 μl 
RNAse inhibitor 1 μl 10 μl 
dNTPs 2 μl 20 μl 
M-MULV RT 2 μl 20 μl 
 
Table 2.5 PCR reaction for reverse transcription. 
 
RNAse free water was added to reach a total volume of 20 μl for each sample. 
The PCR reaction was performed at 37°C for 60 minutes, followed by 5 minutes at 
70°C. Once reverse transcribed, cDNA was diluted 1:5 in RNAse free water. 
 
2.7.4 Quantitative PCR  
 
Real time qPCR is a technique that permits to measure the amount of PCR product after 
each round of amplification, using a fluorescence label. During amplification a 
fluorescence dye binds, either directly or indirectly via a labeled hybridazing probe, to 
the accumulating DNA molecules, and fluorescence values are recorded during each 
cycle of the amplification process. The fluorescence signal is directly proportional to the 
DNA concentration over a broad range, and the point at which fluorescence is first 
detected as statistically significant above the background is called the threshold cycle or 
Ct value. The higher the initial amount of sample DNA, the sooner the accumulated 
product is detected in the fluorescence plot and the lower the Ct value. 
101 
 
 
 
 
Figure 2.3 Plot representing qPCR amplification. The fluorescence signal is directly 
proportional to the DNA concentration over a broad range, and the point at which fluorescence 
is first detected as statistically significant above the background is called the threshold cycle or 
Ct value. Figure adapted from Sigma Aldrich website. 
 
qPCR primers design 
 
Primers were designed using the program Primer 3 (http://primer3.ut.ee/). Specific 
intron spanning or intron flanking qPCR primers were designed of 18-25 bp long, with a 
GC content of 30-80% and a melting temperature (Tm) of 55-62°C. Designing intron 
spanning or intron flanking primers prevented the amplification of genomic DNA.  
Specificity of the primers was determined by nucleotide blast-search. The corresponding 
amplicons were between 100 and 150 bp, to obtain a high level of fluorescence without 
compromising PCR efficiency. 
To assess primer quality and specificity, a consecutive melt curve was acquired at the 
end of the qPCR reaction. A single peak for every sample is indicative of good primers 
specificity (Fig 2.4 A), instead the presence of different peaks is indicative of formation 
of primers dimers or aspecificity (Fig 2.4 B). 
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Figure 2.4 Melt curve to assess primer specificity. A) A single peak for every sample is 
indicative of good primers specificity; B) the presence of different peaks is indicative of 
formation of primers dimers or aspecificity. 
 
The primers used in this thesis are listed in Appendix A. 
 
Reaction set-up 
 
Real-time qPCR reactions were performed using Maxima SYBR Green/ROX qPCR 
Master Mix (Thermo Fisher Scientific, Waltham, MA) and the primers specific for each 
gene. 1-5 μl of cDNA were added to the reaction composed of: 
 
REAGENT X 1 REACTION X 10 REACTIONS 
Primer Forward 1 μl 10 μl 
Primer Reverse 1 μl 10 μl 
Maxima Master Mix 10 μl 100 μl 
 
Table 2.6 qPCR reaction set-up. 
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RNAse free water was added to reach a total volume of 20 μl for each sample and the 
reactions were performed in Optical 96 well plates (Applied Biosystems, Life 
Technologies, UK). 
The 7500 Software v2.0.6 (Applied Biosystems, Life Technologies, UK) was used for 
the Real Time reaction and analysis. The following thermal profile was used:  
 
1 cycle 50°C for 2 min 
1 cycle 95°C for 10 min 
40 cycles 
95°C for 15 sec 
60°C for 1 min 
Melting curve 
95°C for 15 sec 
60°C for 1 min 
95°C for 15 sec 
60°C for 15 sec 
 
Table 2.7 qPCR reaction program. 
 
Data analysis 
 
Data were analysed using the comparative delta delta Ct (ΔΔCT) method. This relative 
quantisation requires calculation of the ratio between the amount of target template and 
a reference template in a sample. The advantage of this technique is that using an 
internal standard can minimize potential variation in sample preparation and handling. 
In this thesis every gene expression is normalised to 18s expression. 
Having obtained a Ct value for each well, the ΔCT equation can be used to calculate fold 
change relative to the control sample, known as calibrator. In these experiments the 
control conditions or the transfection with a scrambled siRNA were used as calibrators. 
The fold change relative to the calibrator sample was calculated as follows: 
1. ΔCT = Ct target gene – Ct endogenous control (normalisation to housekeeping 
gene to minimize sample to sample variations) 
2. ΔΔCT = ΔCT sample - ΔCT calibrator  
3. 2 ΔΔCT = fold change relative to the calibrator sample. 
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2.8 Protein analysis 
 
2.8.1 Protein samples preparation from cell lysates 
 
Cells were plated in 6 well plates and treated with the required media solution. After the 
incubation time (usually 72h) cells were washed twice in PBS and lysed in 300 μl of 
cold NP-40 lysis buffer (see Table 2.1), containing 1X protease and phosphatase 
inhibitors tablets (Roche Applied Science, Basel, Swtzerland). Scrapers were used to 
detach the cells from the plates and destroy cellular integrity. Lysates were collected in 
1.5 ml tubes and centrifuged at 8000 rpm for 5 minutes, in order to clear from cell 
debris. The supernatants were transferred in a clean 1.5 ml tube and used for subsequent 
analysis. 
 
BCA protein assay 
 
Protein concentration was determined using Pierce™ BCA (bicinchoninic acid) Protein 
Assay Kit (Thermo Fisher Scientific, Waltham, MA). The principle of this system is that 
the peptide bonds in the proteins are able to reduce the Cu
2+
 ions from the cupric sulfate 
to Cu
+
 and the amount of Cu
2+
 reduced is proportional to the amount of protein present 
in the solution. Subsequently two molecules of bicinchoninic acid are able to chelate 
with Cu
+
 ions forming a purple-colored product that absorbs light at 562 nm. This 
absorbance is nearly linear with increasing protein concentrations over a broad working 
range (20-2000 μg/ml). 
Bovine Serum Albumin (BSA) included in the kit was used to establish a standard 
calibration curve for protein quantification as seen in Table 2.8. 
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VIAL 
VOLUME OF 
DILUENT (l) 
VOLUME AND 
SOURCE OF BSA (l) 
FINAL BSA 
CONCENTRATION 
(g/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 375 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0=blank 
 
Table 2.8 List of calibrators. Preparation of BSA calibrators for the generation of a standard 
curve. 
 
An adequate volume of Working solution was prepared following manufacturer 
instructions, mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B. 200 μl 
of Working solution were added to each well of a 96-well plates and subsequently 10 μl 
of samples and calibrator were pipetted thoroughly in the solution. The plate was 
covered and incubated at 37°C for 30 minutes and absorbance was read at 562 nm. 
The linear equation for the standard curve was set using Microsoft Excel, plotting BSA 
concentration (X axis) and absorbance values (Y axis). The concentration values of the 
samples were extrapolated from this graph. 
Protein samples were normalised and diluted in 5X denaturating sample buffer and 
heated at 95°C for 5 minutes. The denaturated protein samples were used for 
Polyacrylamide gel Electrophoresis and Western Blot analysis. 
 
2.8.2 Western Blot 
 
SDS gels preparation 
 
Small gels were hand poured using the BioRad system. Briefly, a running gel mix was 
prepared as listed in table 2.8, poured between the assembled glasses and allowed to set. 
Subsequently the stacking gel mix was poured onto the running gel with a ten or fifteen 
teeth comb in place. 
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Alternatively, pre-casted gels (Life Technology, UK) were used, together with the 
Invitrogen apparatus, following manufacturer procedures. 
 
INGREDIENTS FOR 12.5% GEL (8 ML) RUNNING GEL STACKING GEL 
Water 2.5 ml 2.6 ml 
40% Acrylamide Bis-Acrylamide 
29:1 
3.3 ml 1 ml 
Lower buffer 2.08 ml 1.3 ml 
Temed 8 μl 50 μl 
APS 10% 80 μl 5 μl 
 
Table 2.9 Preparation of a 12.5% polyacrylamide gel. 
 
Loading and separation of protein samples 
 
The gels were placed in an electrophoretic tank containing running buffer and the comb 
removed. 20-30 µg of denatured protein samples were loaded per lane alongside a 
protein molecular weight marker and run with a constant voltage of 110V for 90 
minutes. Subsequently the proteins were transferred to a nitrocellulose membrane using 
a semi dry Hoefer TE transfer unit soaked in transfer buffer. 
 
Immunoblotting  
 
Membranes were blocked with 5% (w/v) milk in PBS to prevent non specific binding 
for 45 minutes and incubated with the specific primary antibody (see Table 2.9) diluted 
in PBS + 0,1% Tween-20 (v/v) overnight at 4°C. The following day the membranes 
were washed 3 times in PBS + 0,1% Tween (v/v) and incubated with the appropriate 
infra-red (IR) secondary antibody (anti mouse, goat or rabbit IgG) for 1 hour at room 
temperature. The membranes were then washed 3 times in PBS + 0,1% Tween (v/v) and 
1 time in PBS and the signals revealed using LI-COR Odyssey system.  
Alternatively, after washing, membranes were incubated with the appropriated 
peroxidise-conjugated (HRP) secondary antibody, diluted in PBS 0.1% Tween-20 (v/v). 
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Membranes were then washed 3 times in PBS 0.1% Tween-20 (v/v) and once in PBS 
before being incubated with ECL Plus Mix solution (Amersharm, GE Healthcare, UK) 
for 1 minute, sealed in a plastic sheet and exposed to a chemioluminescence sensitive 
film (Kodak, Rochester, NY). 
 
ANTIGEN MANUFACTURER 
CAT 
NUMBER 
CD40 Santa Cruz Biotechnology, USA sc-975 
Actin Santa Cruz Biotechnology, USA sc-1616 
NF-κB p65 Santa Cruz Biotechnology, USA sc-372 
TRAF sampler kit (TRAF1, 
TRAF2, TRAF3, TRAF6) 
Cell signalling Technologies,  
Danvers, MA 
8347 
Anti Rabbit IgG-IR Li-COR Biosciences, UK 926-32211 
Anti Goat IgG-IR Li-COR Biosciences, UK 926-68024 
Anti Rabbit IgG-HRP 
Cell signalling Technologies,  
Danvers, MA 
7074 
 
Table 2.10 List of antibodies. 
 
Stripping membranes 
 
Membrane were incubated in stripping solution (see Table 2.1) for 20 minutes at 37°C 
and then washed repetitively in PBS and subsequently re-incubated with the desired 
primary antibody. 
 
2.8.3 Immunofluorescence 
 
Cells were seeded in 12-well plates onto coverslips for 72h in different media 
conditions. After the incubation period cells were fixed in 4% paraformaldehyde in PBS 
for 30 minutes and subsequently washed 3 times in PBS and store at 4°C overnight.  The 
following day, cells were permeabilized by exposure to 0.1% Triton X-100 in PBS for 5 
minutes to create pores in the membrane and allow the entrance of the antibody and 
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washed once in 0.1% Triton in PBS. The specific primary antibody was then added, 
diluted 1:500 in PBS + 30 mg/ml BSA + 0.1% Triton X-100 and cells incubated for 2h 
at room temperature on a shaker. 
Coverslips were then washed 3 times in PBS + Triton X-100 and then incubated with 
the specific secondary antibody conjugated with a fluorescence dye (AF488) diluted 
1:500 in PBS + 30 mg/ml BSA + 0.1% Triton X-100, for 1h at room temperature. 
After the incubation period, cells were washed 3 times in PBS + 0.1% Triton for 5 
minutes.  
Nuclei were stained by incubating cells in 1 µg/ml DAPI (Life Technologies, UK) in 
PBS for 1 minute and then washed in PBS + 0.1% Triton. After that, cells were washed 
again 3 times in PBS, to remove any trace of Triton and the coverslips washed in water, 
dried and put on glass slides. 
Images have been taken with the microscope Leica DM5000 epi-fluo. 
 
2.9 siRNA transfection 
 
2.9.1 Transfection with Lipofectamine RNAi max 
 
Transient knock-down of target genes was achieved using siRNA duplex technology. 
Efficient transfections of CD40 siRNAs were performed using Lipofectamine 
RNAiMAX (Life technologies, UK) and siRNA purchased from Dharmacon, GE 
Healthcare, UK. During the optimisation process, Lipofectamine 2000 (Life 
Technologies, UK) and siRNA purchased from Qiagen (Venlo, Netherlands) were also 
used. See table 2.10 for the list of sequences used. 
In this procedure, INS-1 cells were plated in 6 well plates in order to have 40-50% 
confluence at the time of transfection. The following day siRNA-Lipofectamine 
complexes were prepared for each transfection sample (one well of a 6 well plate) as 
follows: in a sterile 1.5 ml tube, 7 µl of siRNA (20 µM) were diluted in 243 µl of 
Optimem (Invitrogen) without serum and mixed gently. In a separate sterile 1.5 ml tube, 
7 µl of Lipofectamine RNAimax were added to 243 µl of Optimem without serum and 
mixed gently. These solutions were incubated for 8 minutes at room temperature. After 
109 
 
the incubation period, the diluted siRNA was combined with the diluted Lipofectamine 
RNAimax and mixed gently with the pipette. The solution was incubated for 25 minutes 
at room temperature. Media was removed from cells and 1.5 ml of RPMI with serum but 
without antibiotics was added. 500 µl of transfection solution was then added to each 
well. 
After 24h, media was removed and replaced with complete RPMI. Knock-down was 
detected 48-72h after transfection. 
 
SiRNA TARGET SEQUENCE MANUFACTURER 
Rn_Tnfrsf5_1 AGCCGGGAAACCGACTAGTTA Qiagen, Venlo, Netherlands 
Rn_Tnfrsf5_2 CACCGACACTGCGAACTCAAT Qiagen, Venlo, Netherlands 
Rn_Tnfrsf5_3 CCGCGGTTTCAGACACTGTTT Qiagen, Venlo, Netherlands 
CD40 5 GATTTGTGCCAGCCGGGAA 
Dharmacon, GE Healthcare, 
UK 
CD40 6 GAGATGTCTTGCTGCGGTT 
Dharmacon, GE Healthcare, 
UK 
CD40 7 GCTGATGGTCCTACGGGAA 
Dharmacon, GE Healthcare, 
UK 
CD40 8 GGTAAAGAGAGTCGCATCT 
Dharmacon, GE Healthcare, 
UK 
Non-targeting 
siRNA 
TGGTTTACATGTCGACTAA 
Dharmacon, GE Healthcare, 
UK 
 
Table 2.11 List of siRNA sequences. 
 
2.9.2 Transfection with Amaxa nucleofector 
 
During the optimisation process, transfections were performed also using 
electroporation with Amaxa Nucleofector II. Briefly, cells were resuspended in 100 µl 
of nucleofector solution (Nucleofector kit V; Lonza, Basel, Switzerland) and the specific 
siRNA was added to a final concentration of 1 µM.  The samples were transferred into 
an Amaxa certified cuvette and inserted in the machine where the specific program was 
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run (T-020). Cells were then resuspended in pre-warmed medium and plated in 6-wells 
plates. 
 
2.10 RNA sequencing 
 
RNA sequencing is a high-throughput sequencing method for both mapping and 
quantifying transcriptomes, namely the complete set of transcripts in a cell. It involves 
direct sequencing of complementary DNAs (cDNAs) using high-throughput DNA 
sequencing technologies followed by the mapping of the sequencing reads to the 
genome. It is a very informative technique, because it allows the identification of exons 
and introns, the mapping of their boundaries, the identification of the 5’ and 3’ ends of 
genes and of the transcription start sites. It is also a genome-wide technique, allowing 
the study of the effects of a certain treatment on global transcriptome regulation. It is 
therefore possible to compare the genome-wide effects of a treatment to control 
conditions. 
 
2.10.1 RNA extraction 
 
Cells were incubated in the appropriate conditions for 72h, then harvested and RNA 
extracted using mirVana miRNA isolation kit (Life Technologies, UK). This specific kit 
was used because the same samples were used subsequently for miRNAs extraction. 
Briefly, 1 ml of Binding Buffer was added to cell pellets and the solution vortexed to 
disperse any aggregates. 100 μl of miRNA homogenate additive were added and mixed 
well inverting the tube several times; the solution was then incubated on ice for 10 
minutes. Subsequently, a process of phenol-chloroform extraction was performed, 
adding 1 ml of acid-phenol:chloroform solution to each sample and mixing well by 
vortexing. After centrifugation at 10000 g for 5 minutes at RT aqueous and organic 
phases were separated. The aqueous phase was kept for the subsequent RNA extraction. 
1250 ml of 100% ethanol were added to the solution and the mixture was transferred 
into a filtered column. Once the RNA in the sample had bound to the column, a series of 
washes followed, each time discarding the flow-through. Finally, the bound RNA was 
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eluted with 100 µl of nuclease free water and stored at -80°C. 1 μl of RNAse OUT (Life 
Technologies, UK) was added to the RNA solution, to avoid RNA degradation. 
 
2.10.2 DNAse treatment 
 
In order to remove contaminant genomic DNA from the RNA solution, samples were 
DNAse treated using DNA-free, DNA removal kit (Life Technologies, UK). 
Briefly, 0.1 volume of 10X DNAse buffer was added to the RNA solution, mixed gently 
and incubated at 37°C for 10 minutes. 0.1 volumes of DNAse inactivation agent was 
added and incubated at RT for 2 minutes, mixing occasionally. Samples were then 
centrifuged at 10000 g for 1.5 minutes and RNA transferred to a fresh tube. 
 
2.10.3 Assess RNA quality using Agilent Bioanalyser 
 
Before performing a genome-wide analysis using RNA sequencing, it is compulsory to 
check the high quality of the extracted RNA. Quality of RNA can be detected using 
NanoDrop 1000 spectrophotometer (Thermo Scientific), reading the 260/280 ratio: a 
ratio of 2 or above is indicative of a pure RNA sample. However, this system is not able 
to assess other parameters of RNA quality, like RNA degradation. For this purpose, in 
this thesis, RNA integrity was determined with improved accuracy using a technology 
developed by Agilent (Santa Clara, CA), in which the abundance of two rRNA species 
are used to assess the integrity of RNA. In this system a microfabricated chip is used to 
perform elecrophoretic separation of RNA samples. Because of a constant mass-to-
charge ratio and the presence of a sieving polymer matrix, the molecules are separated 
by size. Dye molecules intercalate into RNA strands and these complexes are detected 
by laser-induced fluorescence. Data is translated into gel-like images (bands) and 
electropherograms (peaks). Total RNA shows two distinct ribosomal peaks 
corresponding to 18s and 28s and a relatively flat baseline between 5s and 18s ribosomal 
peaks. 28s and 18s exist in equal concentrations in the cell, but 28s is double 
fluorescent. As RNA degradation occurs, there is a gradual decrease in the 18s to 28s 
ribosomal band ratio and an increase in the baseline signal between the two ribosomal 
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peaks and the lower marker. Consequently, a 28s/18s ratio of two is considered to be 
good quality RNA. 
 
 
 
Figure 2.5 Electropherogram and gel images showing RNA integrity. Total RNA shows two 
distinct ribosomal peaks corresponding to 18s and 28s. As RNA degradation occurs, there is a 
gradual decrease in the 18s to 28s ribosomal band ratio and an increase in the baseline signal 
between the two ribosomal peaks and the lower marker. Consequently, a 28s/18s ratio of two is 
considered to be good quality RNA.  
 
RIN number 
 
In order to standardize the process of RNA integrity interpretation, Agilent 
Technologies has introduced a new tool for RNA quality assessment: the RNA Integrity 
Number (RIN). The RIN software algorithm allows for the classification of total RNA 
based on a numbering system from 1 to 10, with 1 being the most degraded profile and 
10 being the most intact. 
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Figure 2.6 RNA integrity number. RIN number is a tool to assess RNA quality and integrity. 
It is based on a numbering system from 1 to 10, with 1 being the most degraded profile and 10 
being the most intact. Figure adapted from Agilent Technologies website. 
 
Agilent method 
 
RNA samples were analysed using a RNA 6000 Nanochip (Agilent, Santa Clara, CA), 
in accordance to the manufacturer’s instructions. Briefly, wells were preloaded with the 
appropriate gel and a fluorescent dye. Subsequently, 1 μl of each sample and of a 
molecular weight ladder were added to the chip. Once the wells and channels are filled, 
the chip becomes an integrated electrical circuit. The chip was then vortexed and 
analysed using the Agilent Bioanalyzer software.  
All samples used in this study were assigned a RIN number of 8 or above. 
 
2.10.4 Library preparation 
 
High quality RNA was then sent to Sarah Lamble laboratory in Oxford for the 
subsequent stages of library preparation and sequencing, using an Illumina mRNA seq 
Sample preparation kit (Illumina, San Diego, CA). 
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Briefly, RNA was initially ribo-depleted, to remove the vast majority of rRNA and to 
allow a better analysis of smaller changes in trascriptomes and less abundant sequences.  
Library was then generated with the fragmentation of the mRNA in small pieces using 
divalent cations under elevated temperature and the fragments were converted to first 
strand cDNA using reverse transcriptase and random primers. Subsequently the RNA 
template was removed and a replacement cDNA strand was synthesized, generating a 
double strand-cDNA. The fragments were then end-repaired, in a process that converts 
the overhangs into blunt ends, using T4 DNA polymerase and Klenow DNA 
polymerase. The 3’ to 5’ exonuclease activity of these enzymes removes 3’ overhangs 
and the polymerase activity fills in the 5’ overhangs. 3’ ends were then adenylated, 
adding an A base to the 3’ end of the blunt phosphorylated DNA fragments, using the 
polymerase activity of Klenow fragment. This step prepares the DNA fragments for the 
ligation to adapters, which have a single T base overhang at their 3’ end. 
Adapters were then ligated to the end of the DNA fragments, preparing them to be 
hybridised to a single read flow cell. Subsequently, cDNA samples were purified on a 
gel to select a size range of templates (around 200 bp) for downstream enrichment. The 
purified cDNA templates were enriched using PCR to amplify the cDNA in the library, 
using primers that anneal to the ends of the adapters. 
The library was then validated performing a quality control analysis to quantify DNA 
concentration, using Agilent Bioanalyzer. 
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Figure 2.7 RNAseq library preparation workflow. RNA was ribodepleted, fragmented in 
small pieces and converted to cDNA using reverse transcriptase and random primers. The 
fragments were then end-repaired, polyadenylated and adapters were added, preparing them to 
be hybridised to a single read flow cell. Figure adapted from Ilumina website. 
 
2.10.5 Sequencing 
 
Library was used to perform paired end sequencing over one lane of a flow cell on an 
Illumina-HiSeq 2000 instrument in Oxford. This sequencing technology relies on the 
attachment of randomly fragmented genomic DNA to a planar, optically transparent 
surface. Attached DNA fragments were extended and bridge amplified to create an 
ultra-high density sequencing flow cell with hundreds of millions of clusters, each 
containing ~1000 copies of the same template. The templates were sequenced using a 
robust four-colour DNA SBS (sequencing by synthesis) technology that employs 
reversible terminators with removable fluorescent dyes. 
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Figure 2.8 Illumina Hi-Seq 2000 platform. After library preparation, the fragments were 
amplified to create clusters, each containing ~1000 copies of the same template. The samples 
were then sequenced using SBS (sequencing by synthesis) technology. Figure adapted from 
Illumina website. 
 
2.10.6 Data analysis  
 
Raw RNAseq data were analysed by Dr. Rob Lowe (Blizard Institute). In the 
sequencing process, the Illumina instrument produced quality-scored base calls during 
the run. The sequencing output files (compressed FASTQ files) were then used for the 
secondary analysis.  
Reads were aligned to an annotated reference genome using Top Hat v 2.0.9: 
http://tophat.cbcb.umd.edu. Reads aligned to exons, genes and splice junctions were 
counted using the reference genome “rn4”, extracted from UCSC 
(http://genome.ucsc.edu/goldenPath/credits.html#rat_credits).  
Data visualisation and interpretation, calculating gene as well as transcript expression, 
then reporting differential expression, was done using the HTseq-count program: 
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html).  
Normalisation process, which correct for in-sample distributional differences within the 
read counts, such as differences in total counts (sequencing depths), and within sample 
gene-specific effects, such as gene length or GC-content effects, was performed using 
the program DEseq: 
(http://www.bioconductor.org/packages/devel/bioc/html/DESeq.html) 
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The statistical significance of fold changes was calculated by comparing the 
experimental read values to the control samples and the p values were subsequently 
adjusted at genome wide level using Bonferroni formula. 
 
2.10.7 Pathways analysis 
 
In order to identify enriched pathways and functions between our differentially 
expressed genes, data were loaded in pathways analysis programs: PANTHER 
(http://www.pantherdb.org/), Metacore (http://thomsonreuters.com/metacore/), Gene 
Venn (http://genevenn.sourceforge.net/).  
PANTHER and Metacore allow the identification of enriched pathways, molecular 
functions, biological processes, cellular components, protein classes and associated 
diseases among a given list of genes. The programs calculate the number of genes that 
are enriched with a specific pathway and give also the statistical significance of any 
enrichment. Enrichment is considered statistical significant when there are more genes 
in the list associated with a particular pathway than it would be expected by chance 
based on the total number of genes associated with that pathway. 
GeneVenn was used to draw Venn diagrams and to identify logical relations between 
our sets of data. 
 
2.11. Small RNA analysis 
 
2.11.1 miRNAs extraction 
 
Total RNA was previously extracted using mirVana miRNA isolation kit (Life 
Technologies, UK) (see paragraph 2.10.1). Small RNAs were then separated from total 
RNA following manufacturer’s instructions. Briefly, total RNA was mixed with 5 
volume of binding buffer. 1/10 volume of miRNA homogenate additive was added and 
the samples mixed well by vortexing. Samples were then incubated on ice for 10 
minutes. 1/3 volume of 100% ethanol was added and the mixture was pipetted onto a 
filter column. After centrifugation at 5000 rpm for 1 minute, the filter contained the 
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RNA fraction depleted of small RNAs. Small RNAs passed through the filter and, in 
order to purify them, 2/3 volume of 100% ethanol was added and the mixture transferred 
to a second filter column. Once the small RNA in the sample had bound to the column, a 
series of washes followed, each time discarding the flow-through. Finally, the bound 
RNA was eluted twice with 50 µl of nuclease free water and stored at -80°C. 1 μl of 
RNAse OUT (Life technologies, UK) was added to the small RNA solution, to avoid 
RNA degradation. 
 
2.11.2 miRNA reverse-transcription 
 
Small RNAs were retro-transcribed to cDNA using TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Life Technologies, UK) with the specific assay 
for each miRNA. 
A RT master mix was prepared using the following reagents: 
 
REAGENT X 1 REACTION X 10 REACTIONS 
100 mMdNTPs 0.15 μl 1.5 μl 
MultiScribe™Reverse 
Transcriptase, 50 U/μL 
1 μl 10 μl 
10x reverse transcription  
Buffer 
1.5 μl 15 μl 
RNase inhibitor, 20 U/μl 0.19 μl 1.9 μl 
Nuclease-free water 4.16 μl 41.6 μl 
 
Table 2.12 PCR reaction for miRNAs reverse transcription. 
 
For each reaction, 5 μl of RNA (1-10 ng) were then added, followed by addition of 3 μl 
of the specific RT primer. Tubes were incubated on ice for 5 minutes, before performing 
the following reaction: 
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30 min 16°C 
30 min 42°C 
5 min 85°C 
Cool down to 4°C 
 
Table 2.13 PCR reaction program for miRNAs reverse transcription. 
 
2.11.3 Taqman miRNA assay  
 
Taqman miRNA assay kit (Applied Biosystems, Life Technologies, UK) was used to 
perform a qPCR on the cDNA retro-transcribed from the small RNA. Each reaction was 
performed as follows: 
 
REAGENT X 1 REACTION 
Taqman microRNA assay 20x 1 μl 
Product from RT reaction  
(minimum 1:15 dilution) 
1.33 μl 
Taqman 2X universal PCR master Mix 10 μl 
Nuclease-free water 7.67 μl 
 
Table 2.14 qPCR reaction for miRNAs. 
 
The reaction was set up as follows: 
 
Hold stage 95°C for 10 minutes 
40 cycles 
95°C for 15 seconds 
60°C for 60 seconds 
 
Table 2.15 qPCR reaction program for miRNAs. 
 
Data were then analysed using the comparative delta delta Ct (ΔΔCT) method (see 2.7.4). 
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2.12 Statistical analysis 
 
All the values were expressed as mean + standard deviation. Statistical analyses were 
carried out using two-tailed, unpaired t-test using Microsoft Excel and a p-value of 
<0.05 was considered significant. 
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Chapter 3 
 
 
Glucolipotoxicity of the pancreatic 
 β-cell 
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3.1 Introduction  
 
T2D is a metabolic disorder characterised by insulin resistance and pancreatic β-cell 
dysfunction and β-cell death due to molecular mechanisms mainly generated by chronic 
exposure to high concentrations of glucose and fatty acids. 
Different factors can be responsible for β-cell dysfunction (in particular for the 
impairment of insulin secretion and production) including glucotoxicity, lipotoxicity, 
ER stress, mitochondrial dysfunction and inflammation. 
It has been shown that after exposure to glucose and fatty acids, the β-cell initially 
responds with a compensation process, in which it increases β-cell mass and insulin 
production and secretion [76, 78, 80]. However, recent studies demonstrated that β-cell 
dysfunction is the critical determinant for T2D and it can occur also in absence of 
insulin resistance [74]. In general, prolonged exposure of the β-cell to high 
concentrations of glucose and fatty acids leads to β-cell dysfunction, impairment of 
insulin secretion and production and ultimately β-cell death [119]. Moreover, different 
studies have provided evidence that lipotoxicity only occurs in the presence of 
concomitantly elevated glucose levels [121, 123]. This can be explained by the effects 
of glucose on lipid partitioning and with the concomitant accumulation of toxic 
intermediates. After a carbohydrate containing meal, fatty acid oxidation is indeed 
inhibited, as citrate, generated from the glycolitic metabolism, is converted to malonyl-
CoA by ACC. Malonyl-CoA sterically blocks CPT-1, inhibiting the transport of LC-
CoA in the mitochondria and inducing its accumulation in the cytosol. 
Also inflammation is involved in the glucolipotoxicity process in T2D, and elevation of 
inflammatory markers as cytokines and C-reactive protein have been shown to be a 
feature of diabetes pathogenesis [145]. As a consequence, also some inflammatory 
mediators can be implicated in the process of impairment of insulin secretion or 
production, for example TNF-α [323] and IL-6 [324]. 
Although some molecular mechanisms have been proposed to be involved in this β-cell 
dysfunction [125, 128, 130-132], additional studies are required to completely 
understand this process, in order to discover new molecules involved in the process of 
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impairment of insulin production and secretion and to identify novel targets for specific 
therapeutic strategies. 
 
The aim of this study was to characterise the effects of chronic exposure to high 
concentrations of glucose and fatty acids on β-cell dysfunction. Since we were 
specifically interested in defining the mechanisms of glucolipotoxicity-induced β-cell 
dysfunction, we focussed on experimental conditions that were able to impair insulin 
secretion, but that did not affect massively cell viability. We then focussed on gene 
expression changes in these conditions in order to identify novel molecules involved in 
the process of glucolipotoxicity, which can lead to identify novel potential targets for 
future therapeutic strategies at an early stage of the disease.  
 
3.2 Effect of glucolipotoxicity on cell viability 
 
In order to study the effects of glucolipotoxicity on the pancreatic β-cell, we used rat 
insulinoma cells (INS-1), which are pancreatic β-cell immortalised by radiation. They 
are a simple and reliable model of study and they show a good insulin response to 
glucose. 
To replicate the chronic glucolipotoxic conditions, INS-1 cells were incubated for 72 
hours in the presence of the following experimental conditions: 
1- Control (RPMI-1640 containing 11 mM glucose); 
2- High glucose (RPMI-1640 containing 27 mM glucose); 
3- High fat (RPMI-1640 containing 11 mM glucose, 200 µM oleic acid, 200 µM 
palmitic acid); 
4- High glucose, high fat (RPMI-1640 containing 27 mM glucose, 200 µM oleic 
acid, 200 µM palmitic acid).  
In particular, we decided to test the effects of glucose and fatty acids alone or in 
combination. Firstly we investigated the effects of these experimental conditions on 
cell viability, assessing cell morphology, apoptosis, cell cycle progression and 
mitochondrial activity. 
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3.2.1 Effect of glucolipotoxicity on cell morphology 
 
INS-1 cells were cultured for 72h in the 4 experimental conditions of glucolipotoxicity. 
Images were taken after 72h to assess any visible change in cell morphology in the 
different conditions. We did not observe major changes in cell morphology when cells 
were incubated in the presence of high glucose, whereas a slight increase in cell size was 
detected in cells in the presence of fatty acids (Figure 3.1). When INS-1 cells viability is 
compromised, cells start to change their morphology, assuming a rounded shape and 
reducing adherence to the plate [325-326]. This effect was not observed in our 
experimental conditions. 
 
 
 
Figure 3.1 Effect of glucolipotoxicity on cell morphology. INS-1 cells were incubated for 72 
hours in the presence of high glucose (27 mM glucose), high fat (200 µM oleic acid, 200 µM 
palmitic acid) or the combination of the two. Images were taken using a microscope with 
camera, with a 10x objective. These are representative images of 3 independent experiments. 
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3.2.2 Effect of glucolipotoxicity on caspase 3 activation 
 
Since it has been previously reported that glucolipotoxic conditions can induce 
apoptosis in β-cells, we next determined whether incubation for 72h in the 4 different 
conditions was able to activate this process. Apoptosis was determined measuring 
caspase 3 activity with the appropriate kit (EnzCheck Caspase-3 Assay Kit #2, Life 
Technologies, UK). Caspase 3 is a member of the cysteine-aspartic acid protease 
(caspase) family, which plays a central role in the execution phase of cell apoptosis. 
Caspase 3 is activated by initiation caspases (caspases 8, 9 and 10) and in turn executes 
apoptosis by cleaving targeted cellular proteins. An increased caspase 3 activity reflects 
an increase in the apoptotic process.  
Figure 3.2A shows the effect of incubation of INS-1 cells for 24h with 5 μM of 
staurosporine, as a positive control. Staurosporine is a protein kinases inhibitor, known 
to induce apoptosis. As a confirmation of the validity of the assay, staurosporine 
induced 14 fold change in activation of caspase 3 in this experimental system. No 
increase in the caspase 3 activity was detected in any of the 3 experimental conditions in 
comparison to control (Figure 3.2B). Consequently no activation of apoptosis was 
observed in these conditions. Although it appeared that there was a reduction in caspase 
3 activity in presence of fatty acids, these fluctuations were due to the fact that basal 
caspase 3 activity in control conditions was very low, almost undetectable.  
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Figure 3.2 Effect of glucolipotoxicity on caspase 3 activation. A) Cells were incubated for 
24h in normal RPMI and in RPMI containing 5 μM staurosporine and apoptosis was determined 
by caspase 3 activity. Data represent fluorescence values at ~496/520 nm normalised to total 
protein concentration and are expressed as fold change compared to cells grown in control 
conditions. Values are from 1 experiment. B) Cells were incubated for 72h in the 4 experimental 
conditions and apoptosis determined by caspase 3 activity. Data represent fluorescence values at 
excitation/emission ~496/520 nm normalised to total protein concentration and are expressed as 
fold change compared to cells grown in RPMI containing 11 mM glucose (control). Values are 
means + SD from 3 independent experiments performed in duplicate.  
 
3.2.3 Effect of glucolipotoxicity on cell cycle progression 
 
Consistent with data obtained in the caspase assay, we did not detect any difference in 
the percentage of cells in subG1 phase by FACS analysis. Specifically, cells were 
incubated for 72h in the 4 experimental conditions, fixed and incubated in a solution of 
propidium iodide. Cells were then sorted using a FACS machine, which separate them 
based on their DNA content.  
 
CONTROL HIGH GLUCOSE HIGH FAT 
HIGH GLUCOSE 
HIGH FAT 
1.6 % 1.5 % 1.7 % 1.3 % 
 
Table 3.1 Percentage of cells in subG1. Values are from one experiment representative of 2 
independent experiments. 
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Table 3.1 shows the percentage of cells in subG1 phase after FACS sorting. There was 
no significant change in the amount of fragmented DNA, therefore neither apoptosis nor 
necrosis could be detected. 
No significant change in the percentage of cells at each phase of the cell cycle could be 
detected in any of the conditions (Figure 3.3). 
 
 
 
 
Figure 3.3 Effect of glucolipotoxicity on cell cycle progression. Cells were incubated for 72 h 
in the 4 experimental conditions and cell cycle analysed by FACS, using propidium iodide as 
DNA marker. Data are from one experiment representative of 2. 
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3.2.4 Effect of glucolipotoxicity on mitochondrial activity 
 
Cell viability was measured also using an MTT assay, which assesses cell metabolic 
activity and therefore reflects the number of viable cells. Cells were incubated for 72h in 
the 4 different conditions and subsequently incubated with the appropriate MTT solution 
for 2 hours. Cell viability was measured by the absorbance read at 570 nm minus the 
absorbance at 650 nm, to subtract the background. There was a slight increase (10%) of 
the absorbance with high concentrations of glucose, and a slight reduction of cell 
viability in presence of high concentrations of fatty acids (20% with high fat, p<0.05, 
23% with high glucose high fat, p<0.05) (Figure 3.4). These results shows that, in 
presence of fatty acids, cells started to have impairment in their metabolic activity, but 
this reduction was not reflected in an increased apoptosis. 
 
 
 
Figure 3.4 Effect of glucolipotoxicity on mitochondrial activity. INS-1 cells were incubated 
for 72 h in the four experimental conditions and cell viability was determined using a MTT 
assay. Data show absorbance values at 570-650 nm and are expressed as a fold change 
compared to cells grown in RPMI (control). Data are means + SD from 3 independent 
experiments performed in duplicate (*p<0.05). 
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3.3 Effect of glucolipotoxicity on pancreatic β-cell function 
 
In order to study if conditions of glucolipotoxicity impair the normal β-cell function, we 
determined the effects of high concentrations of glucose and fatty acids on insulin 
secretion, insulin content and insulin biosynthesis. The production and secretion of 
insulin is a specific feature of the β-cell and the impairment of these functions in 
glucolipotoxicity leads to the loss of mechanisms important for the β-cell homeostasis. 
 
3.3.1 Effect of glucolipotoxicity on insulin secretion 
 
INS-1 cells were incubated for 72 hours in the 4 experimental conditions of 
glucolipotoxicity and basal and stimulated insulin secretion was measured using 
standard ELISA protocols (Mercodia, Uppsala, Sweden). Basal insulin secretion was 
measured after incubation of cells with Krebs buffer, which induces the release of the 
docked insulin vesicles. Insulin secretion was then stimulated by incubation in a 
secretagogue cocktail (10 mM glucose, 1 µM phorbol 12-myristate 13-acetate, 1 mM 
isobutyl-methylxanthine, 1 mM tolbutamide, 10 mM leucine, 10 mM glutamine). 
Incubation was for 2h in order to induce the release of the pool of vesicles not associated 
with the plasma membrane. 
There was a decrease in stimulated insulin secretion when INS-1 cells were cultured 
with high concentrations of glucose (55% decrease) (Figure 3.5). Fatty acids exerted a 
slight effect, with a small reduction of stimulated insulin secretion compared to control 
(17% decrease) (Figure 3.5). The combination of high glucose and fatty acids caused a 
further decrease in insulin secretion (68% decrease), confirming the observations that 
fatty acids exert a negative effect on β-cell function only in presence of concomitant 
high glucose concentrations (Figure 3.5). Based on this data, high glucose appeared to 
be the main driver of insulin secretion impairment.  
In addition, Figure 3.5 shows also a reduction (20% decrease) in basal insulin secretion 
in all conditions compared to control, but no differences could be detected between the 
conditions.  
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These results indicate that our experimental conditions did not affect cell viability, as 
demonstrated previously, but were able to impair β-cell function. 
 
 
 
Figure 3.5 Effect of glucolipotoxicity on insulin secretion. Cells were incubated for 72h in the 
4 experimental conditions and basal and stimulated insulin secretion was measured using 
Mercodia ELISA kit. Data indicate ng of insulin secreted per μg of total protein. Data are means 
+ SD from 3 independent experiments performed in duplicate (*p<0.05, ***p<0.005, 
****p<0.001). 
 
3.3.2 Effect of glucolipotoxicity on insulin content 
 
We next investigated whether the decreased secretion was due to decreased synthesis of 
insulin or to a defect in the secretory machinery, measuring the total amount of insulin 
in the cell.  Specifically, INS-1 cells were cultured for 72 hours in condition of 
glucolipotoxicity and subsequently lysed by acid-ethanol extraction. Total insulin 
content was measured using standard ELISA protocols (Mercodia, Uppsala, Sweden), 
normalizing the values obtained to the total protein content.  
Figure 3.6 shows that high concentrations of glucose induced a 47% decrease in insulin 
content (p<0.05), whereas fatty acids induced a 31% decrease, but not statistically 
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significant. A further decrease in insulin content was observed when glucose and fatty 
acids were combined (57% decrease, p<0.005). 
These data indicate that glucolipotoxicity reduces β-cell insulin content, which 
eventually leads to reduced insulin secretion. 
 
 
 
Figure 3.6 Effect of glucolipotoxicity on insulin content. Cells were incubated for 72h in the 4 
experimental conditions and subsequently lysed by acid-ethanol extraction. Insulin content was 
measured using Mercodia ELISA kit. Data indicate ng of insulin secreted per μg of total protein. 
Data are means + SD from 3 independent experiments (*p<0.05, ***p<0.005). 
 
3.3.3 Effect of glucolipotoxicity on insulin mRNA 
 
We next investigated whether the decreased insulin content was due to the degradation 
of insulin protein or to a decreased level of insulin mRNA transcription. INS-1 cells 
were cultured for 72h in RPMI containing high glucose and fatty acids in different 
combinations. Cells were lysed, total RNA was extracted and insulin mRNA levels 
measured by a RT-qPCR using insulin specific primers. Our data showed a decrease in 
insulin mRNA in the presence of high glucose (59% decrease, p<0.005), a slight 
decrease in the presence of fatty acids (31%) and a slightly higher reduction when 
glucose and fatty acids were combined (61%, p<0.0005) (Figure 3.7). 
These data indicate that glucolipotoxicity is able to impair insulin biosynthesis and 
production, and therefore to affect insulin secretion.    
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Figure 3.7 Effect of glucolipotoxicity on insulin mRNA levels. Cells were incubated for 72h 
in the 4 experimental conditions and subsequently lysed and total RNA extracted. RT-qPCR was 
performed using primers specific for the insulin gene. Data represent ∆∆Ct values expressed as 
fold change compared to cells grown in RPMI (control). Data are expressed as means + SD of 3 
independent experiments (***p<0.005, *****p<0.0005). 
 
3.3.4 Insulin mRNA gradually decreases with the progression of glucolipotoxicity 
 
During the progression to diabetes, the β-cell is subjected to different changes in 
function, culminating in a gradual impairment of insulin secretion and production. In 
order to determine if the reduction of insulin mRNA was due to a gradual impairment of 
the β-cell function during the 72 hours of incubation, we performed a timecourse 
experiment. INS-1 cells were incubated for 24, 48 and 72h in presence of 27 mM 
glucose and 200 μM oleic acid, 200 μM palmitic acid (high glucose, high fat). Cells 
were lysed, total RNA extracted and RT-qPCR performed using primers specific for the 
insulin gene. Figure 3.8 shows a gradual decrease of insulin mRNA, with a 15% 
decrease after 24h, which progressively decreased to 29% after 48h, to reach a 55% 
decrease after 72h. 
This result shows that the β-cell function is gradually impaired upon exposure to chronic 
glucolipotoxic conditions, similarly to what is observed in patients with diabetes. 
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Figure 3.8 Timecourse of insulin production in glucolipotoxicity. INS-1 cells were incubated 
for 24h, 48h and 72h in conditions of 27 mM glucose, 200 µM oleic acid, 200 µM palmitic acid, 
lysed and total RNA extracted. RT-qPCR was performed using primers specific for the insulin 
gene. Data represent ∆∆Ct values expressed as fold change compared to cells grown in RPMI 
(control) at each time point. Data are expressed as means + SD of 3 independent experiments. 
 
3.4 Effect of glucolipotoxicity on gene expression 
 
Data so far indicate that exposure of INS-1 cells to high concentrations of glucose 
and/or fatty acids does not affect cell viability but impairs β-cell function. In particular, 
we observed a decrease in insulin biosynthesis, content and secretion, driven mainly by 
high glucose. 
In order to gain further insight into the complex nature of the β-cell dysfunction in 
diabetogenesis and to discover novel mechanisms that can affect insulin secretion, a 
transcriptome profiling of the β-cell in conditions of glucolipotoxicity compared to 
control conditions was performed. In particular, previously in my group, Dr. C. Marshall 
and Dr. W. Ogunkolade performed an Affymetrix microarray screening in order to 
identify pathways involved in glucolipotoxicity.  
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3.4.1 Affymetrix array and pathway analysis 
 
In order to investigate how chronic exposure to high glucose and fatty acids might 
trigger impairment of the β-cell function, in this previous experiment, INS-1 cells were 
incubated for 72h in RPMI-1640 media supplemented with 27 mM glucose, 200 μM 
oleic acid, 200 μM palmitic acid. RNA was isolated, converted to cDNA, fragmented 
and hybridised overnight at 45°C to Affymetrix high density GeneChip RatGenome 230 
2.0 arrays. Chips were then washed and stained with streptavidin-phycoerythrin (SAPE). 
The fluorescent pixel intensities for each probe were determined using a confocal laser 
scanner, processed, quantified, background adjusted and scaled using Affymetrix 
Microarray Suite 5.0 software. Data analysis was compared using three independent 
experiments. 
When statistically significant data (p<0.05) were analysed for expression change, it was 
found that approximately 10% of INS-1 transcripts underwent 2-fold or greater change 
in expression. Of relevance to preservation of β-cell mass and function, it was found that 
expression of a number of genes linked to apoptosis and related signalling pathways, 
biological oxidation, and fidelity of nucleic acid processing and repair was affected by 
glucolipotoxic conditions (Figure 3.9). 
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Figure 3.9 Altered gene expression in glucolipotoxicity. Pathway analysis of altered gene 
expression in INS-1 cells incubated for 72h in RPMI-1640 media supplemented with 27 mM 
glucose, plus 200 µM oleic acid, and 200 µM palmitic acid compared to cells grown in normal 
conditions. Cells were lysed, RNA extracted, and hybridised to Affymetrix® high density 
microarrays each containing 31,000 probe set. Significant differentially expressed genes were 
determined using Partek® software, based on a p value < 0.05 and with a fold change > 2 from 
three independent experiments. These were then grouped based on their biological function. 
 
Validation of some of the results obtained in the array revealed that the expression of 
TNFR members and their associated factors was affected by glucolipotoxic conditions. 
Of these, TNFRSF5, the gene encoding TNFR5 (also known as CD40), was found to be 
the most highly upregulated, with a 2.23 fold increase in its expression (Table 3.2). 
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TNFRSF1 
 
TNFRSF5/CD40 TNFRSF6 
 
N.S. 
 
2.23 (p<0.0001) 1.59 (p<0.05) 
 
Table 3.2 TNFR family members. Analysis of individual expression data for the TNFR 
superfamily members TNFRSF1, TNFRSF5, and TNFRSF6 based on Affymetrix array data. 
 
3.4.2 CD40 mRNA levels are increased in glucolipotoxicity 
 
As TNFR5/CD40 resulted to be the most upregulated member of TNFR family from the 
Affymetrix array, we decided to focus our investigations on this receptor. In addition, 
the potential role of CD40 in diabetes and glucolipotoxicity has not been described 
before, which makes it an interesting subject for further investigations. 
In order to validate the Affymetrix data, INS-1 cells were incubated in 27 mM glucose, 
200 μM oleic acid, 200 μM palmitic acid in different combinations, lysed and total RNA 
extracted. RT-qPCR was performed using primers specific for CD40. Figure 3.10A 
shows the increased expression of CD40 in conditions of glucolipotoxicity. We detected 
a 4.5 fold increase (p<0.0.5) in CD40 expression when INS-1 cells were incubated in 
high concentrations of glucose. Fatty acids alone did not exert any effect, whereas the 
combination of glucose with fatty acids triggered increased CD40 expression more than 
glucose alone, reaching a 6-fold increase (p<0.05) (Figure 3.10A).  
Figure 3.10B shows the effects of fatty acids taken singularly in combination with 
glucose. Palmitic acid, a saturated fatty acid, exerted a slight stronger effect than oleic 
acid in increasing CD40 expression, but, in all the conditions studied, high glucose was 
the main driver of expression changes.  
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A 
 
B 
 
Figure 3.10 CD40 mRNA levels are increased in glucolipotoxicity. INS-1 cells were 
incubated for 72h in glucolipotoxic conditions, subsequently lysed and total RNA extracted. RT-
qPCR was performed using primers specific for CD40 gene. Data represent ∆∆Ct values 
expressed as a fold change compared to cells grown in RPMI (control). Data are expressed as 
means + SD of 3 independent experiments (*p<0.05). A) Incubation of INS-1 cells in control 
(11 mM glucose), high glucose (27 mM glucose), high fat (200 µM oleic acid, 200 µM palmitic 
acid) and high glucose high fat (27 mM glucose, 200 µM oleic acid, 200 µM palmitic acid); B) 
Incubation of INS-1 cells in control (11 mM glucose), high glucose (27 mM glucose), high 
glucose plus oleic acid (27 mM glucose plus 200 µM oleic acid), high glucose plus palmitic acid 
(27 mM glucose plus 200 µM palmitic acid) and high glucose plus oleic and palmitic acid (27 
mM glucose, 200 µM oleic acid, 200 µM palmitic acid). 
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3.4.3 CD40 protein is overexpressed in glucolipotoxicity 
 
To determine whether the increase in mRNA results in increased protein levels we 
incubated INS-1 cells for 72h in the glucolipotoxic conditions listed above. Cells were 
then lysed and protein separated on a 12.5% SDS PAGE, transferred to nitrocellulose 
membranes and immunoblotted with anti CD40 polyclonal antibody.  
The combination of glucose and fatty acids induced the strongest (2-3 fold, p<0.05) 
upregulation in the CD40 protein (Figure 3.11). In particular, palmitate was the most 
powerful fatty acid, and it was able to induce a 1.7 fold increase, but the variability of 
the response did not lead to a statistical significance. 
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Figure 3.11 CD40 protein is overexpressed in glucolipotoxicity. Cells were incubated for 72h 
in 27 mM glucose, 200 µM oleic acid, 200 µM palmitic acids in different combinations. Cells 
were subsequently lysed and lysates separated on 12.5% polyacrylamide gels. Membranes were 
then incubated with CD40 specific antibody. A) Representative image of a Western Blot, 
representative of 3 indipendent experiments; B) Quantification of anti-CD40 western blot bands, 
normalised to internal actin control. Data are expressed as means + SD of 3 independent 
experiments (*p<0.05). 
 
This biochemical data was also supported by immunofluorescence experiments (Figure 
3.12), in which a strong increase in CD40 intensity (green) in INS-1 cells incubated for 
72h in the presence of high glucose and both fatty acids could be detected.  
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Figure 3.12 CD40 is overexpressed in glucolipotoxicity. Cells were incubated for 72h in 
RPMI with or without 27 mM glucose, 200 µM oleic acid, 200 µM palmitic acids. Cells were 
subsequently fixed and stained with CD40 antibody followed by incubation with AF488 
secondary antibody (green) and DAPI (blue) to identify the nucleus. Images were taken with a 
Leica Epi-fluo microscope using a 20x objective (first row) and 40x objective (second row). 
Representative image of 3 independent experiments. 
 
Taken together these data indicate that chronic exposure of INS-1 cells to elevated 
levels of glucose and fatty acids leads to the upregulation of CD40 at both mRNA and 
protein level. 
 
3.4.4 CD40 expression gradually increases in glucolipotoxicity 
 
Upregulation of CD40 expression in all the experiments so far was evaluated after 72h 
of incubation in glucolipotoxic conditions. In order to define the timecourse of CD40 
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overexpression, INS-1 cells were incubated for 24, 48 and 72h in RPMI-1640 
supplemented with 27 mM glucose, 200 μM oleic acid, 200 μM palmitic acid. Cells 
were then lysed, total RNA extracted and RT-qPCR performed using CD40 specific 
primers. Interestingly we observed that CD40 mRNA levels increased in cells grown in 
normal medium for 72h (2.3 fold, p<0.05) (Figure 3.13A).  In addition, CD40 mRNA 
further increased in glucolipotoxic conditions at each time point investigated (Figure 
3.13B). Specifically we detected a 3-fold increase (p<0.01) after 24h that gradually 
reached a 7-fold increase (p<0.01) after 72h. Consequently, the basal levels of CD40 
mRNA increased during the incubation period and it was further increased under 
glucolipotoxic conditions.  
These results were also confirmed at the protein level, as INS-1 cells were cultured in 
glucolipotoxic conditions, lysed and protein separated on a 12.5% SDS PAGE gel. A 
slight increase in CD40 protein expression was detected after 48h and a further increase 
in chronic conditions, after 72h (Figure 3.13C).  
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Figure 3.13 Timecourse of CD40 expression.  A) INS-1 cells were incubated for 24, 48 and 72 
h in control RPMI-1640. After the respective incubation times, cells were lysed, total RNA 
extracted and RT-qPCR performed using CD40 specific primers. Data represent ∆∆Ct values 
expressed as a fold change compared to cells cultured for 24h. Data are expressed as means + 
SD of 4 independent experiments (*p<0.05). B) INS-1 cells were incubated for 24, 48 and 72 h 
in control RPMI-1640 and RPMI supplemented with 27 mM glucose, 200 μM oleic acid, 200 
μM palmitic acid. After the respective incubation times, cells were lysed, total RNA extracted 
and RT-qPCR performed using CD40 specific primers. Data represent ∆∆Ct values expressed as 
a fold change compared to cells cultured in RPMI (control) at each timepoint. Data are 
expressed as means + SD of 4 independent experiments (*p<0.05, **p<0.01). C) INS-1 cells 
were cultured in control (-) and glucolipotoxic conditions (+) for 48 and 72h, lysed and protein 
separated on a 12.5% SDS PAGE gel. The image is a representative western blot of 3 
indipendent experiments. Actin was used as loading control. 
 
3.4.5 Increased level of CD40 mRNA in vivo 
 
INS-1 cells offer a consistent response to experimental manipulation, which makes them 
an ideal choice for microarray analysis where large numbers of repeat experiments are 
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costly. However, transformed β-cell lines are not fully representative of primary β-cell 
biology, so it became important to determine whether these results were representative 
of whole animal physiology.  
To this end, we determined the levels of CD40 mRNA in cDNAs extracted from the 
pancreatic islets of C57BL/6 mice fed a high fat diet for 10 weeks (kindly donated from 
Dr. Paul Caton, Blizard Institute). RT-qPCR was performed using specific primers for 
CD40. Consistent with our results obtained in INS-1 cells, RT-qPCR analysis of 
extracted RNA indicated a 3-fold increase (p<0.05) in CD40 mRNA levels in the high 
fat fed mice relative to lean controls (Figure 3.14).  
 
 
 
Figure 3.14 Increased level of CD40 mRNA in vivo. C57BL/6 mice were fed a high fat diet 
for 10 weeks prior to sacrifice, pancreas removed and total RNA extracted from isolated islets. 
RT-qPCR was performed using specific primers for CD40. Data represent ∆∆Ct values 
expressed as a fold change compared to the expression in mice fed a control diet. Data are 
expressed as means + SD of 3 independent experiments (*p<0.05). 
 
3.4.6 Increased level of CD40 mRNA in human islets 
 
In collaboration with Prof. Piero Marchetti (University of Pisa, Italy), CD40 mRNA 
levels were then measured in islets isolated post-mortem from human donors. These 
islets were incubated for 24h in RPMI-1640 supplemented with 0.5 mM palmitate, total 
RNA extracted and RT-qPCR performed using primers specific for CD40. All these 
experiment were perfomed at University of Pisa. Consistent with previous data, we 
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observed a statistically significant upregulation of CD40 (1.4 fold, p<0.05) (Figure 
3.15). This indicates a similar pattern of upregulation of CD40 in rodent and human 
islets exposed to a glucolipotoxic environment. 
 
 
 
Figure 3.15 Increased levels of CD40 mRNA in human islets. Islets were isolated post-
mortem from human donors and left untreated (control) or incubated for 24h in RPMI-1640 
supplemented with 0.5 mM palmitate. Total RNA was extracted and RT-qPCR was performed 
using primers specific for CD40. Data represent ∆∆Ct values expressed as a fold change 
compared to islets incubated in normal RPMI (control). Data are expressed as means + SD of 6 
independent experiments (*p<0.05). 
 
3.5 Discussion 
 
The concept of glucolipotoxicity refers to the combined and deleterious effects of 
elevated glucose and fatty acids levels on pancreatic β-cell function and survival [84]. 
Prolonged exposure of the β-cell to high concentrations of glucose and fatty acids leads 
to a progressive impairment of β-cell function and gene expression and, ultimately, to β-
cell death. In particular, glucolipotoxicity affects the β-cell function, namely insulin 
secretion and production [119-120]. In humans, oleate (C18:1), palmitate (C16:0), and 
stearate (C18:0) comprise around 80% of the circulating FFA at a ratio of 1.6:1:0.5. 
Oleate is the most prominent FFA in the human pancreas [327]. 
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Therefore, to recreate conditions of glucolipotoxicity, we incubated rat pancreatic β-
cells, INS-1 cells, in the presence of 27 mM glucose, 200 μM oleic acid, 200 μM 
palmitic acid, in different combinations for 72h.  
We demonstrated that these conditions were not able to affect negatively cell 
morphology (Figure 3.1) and cell cycle (Figure 3.3), and we detected no activation of 
caspase 3 (Figure 3.2) and induction of apoptosis after 72h (Table 3.1). Fatty acids alone 
were able to slightly affect mitochondrial activity, as we observed a 20% decrease of 
cell viability measured by MTT assay (Figure 3.4), which was not reflected in an 
increased in apoptosis via caspase 3.  
Previous studies had reported an increase in apoptosis in INS-1 cells after incubation 
with high concentrations of glucose and fatty acids. In particular Zhou et al, 
demonstrated that INS-1 cells incubated with 30 mM glucose and 200 µM palmitic acid 
for 72h showed an increased apoptosis with progressive activation of caspase 3 [328]. 
One possible explanation of our contrasting results is the fact that these authors did not 
use oleic acid in their experimental conditions, and it has been shown previously that 
oleate can partly protect from the deleterious effects of palmitate [329]. Considering that 
oleate is the most abundant fatty acids in human diet, our experimental conditions are 
more representative of a real physiological condition. Similarly, El-Assaad et al, showed 
that incubation of INS-832/13 with different combinations of glucose and fatty acids 
induced apoptosis [107]. However, in this study, they used different concentrations of 
fatty acids, and they showed apoptosis with 300-400 µM palmitic acid, which are double 
the concentration that we used in our study. 
Our data showed that incubation of INS-1 cells for 72h in RPMI-1640 supplemented 
with 27 mM glucose, 200 μM oleic acid and 200 μM palmitic acid induced a decrease in 
insulin secretion (Figure 3.5), content (Figure 3.6) and mRNA levels (Figure 3.7). In 
particular, our data indicates that high glucose appeared to be the main driver in the 
reduction of insulin levels and secretion, whereas fatty acids alone exerted little or no 
effects. On the other hand, the combination of glucose and fatty acids together 
potentiated the effect of glucose in impairing insulin secretion and production. These 
results are in line with previous investigations showing that fatty acids exert a negative 
effect on insulin only in the presence of concomitant elevated glucose concentrations 
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[121-124]. Moreover, the detrimental effect of glucolipotoxicity on insulin biosynthesis 
could be detected already after 24h of incubation (Figure 3.8).  
In conclusion, our experimental conditions of glucolipotoxicity do not affect cell 
viability, but impair β-cell function, namely insulin secretion and production. As a 
consequence, the β-cell is at an early stage of its dysfunction, in which cells are not 
dying but mitochondrial activity is slightly reduced in presence of fatty acids and β-cell 
function is impaired.  
As these experimental conditions affect insulin secretion and production at an early 
stage of β-cell dysfunction, the study of the differential gene expression can lead to the 
discovery of novel molecules involved in the early stages of β-cell failure. Affymetrix 
microarray analysis performed previously in the group had identified several genes 
differentially expressed in conditions of 27 mM glucose, 200 µM oleic acid, 200 µM 
palmitic acid compared to control. Among them we focussed our attention on CD40, a 
member of the TNFR superfamily, implicated in immune response and inflammation. A 
functional CD40 protein is also expressed in mouse and human pancreatic β-cells and is 
able to induce inflammatory responses [242-244]. The Affimetrix array showed that 
CD40 was upregulated more than 3 times in glucolipotoxic conditions (Table 3.2). 
In this study we demonstrated that CD40 was upregulated 6 times at the mRNA level 
(Figure 3.10) especially with the combination of high glucose and fatty acids. Its 
overexpression was detectable also at the protein level, as shown by western blot and 
immunofluorescence (Figure 3.11, Figure 3.12). Moreover its upregulation was highly 
sensitive to chronic exposure to a glucolipotoxic environment, as CD40 expression was 
higher after 72h of incubation (Figure 3.13). 
As a confirmation of the results in the cell line, CD40 mRNA levels resulted 
upregulated also in islets of mice fed a high fat diet compared to lean controls (Figure 
3.14), as well as in human islets cultured for 24h in 500 µM palmitate (Figure 3.15). All 
these results confirm the upregulation of CD40 in glucolipotoxicity in different systems, 
suggesting, for the first time, an important role for CD40 in glucolipotoxicity conditions 
and possibly in glucolipotoxicity-induced inflammation, as observed in diabetes. 
Exposure of β-cells to high levels of glucose and fatty acids results in an increase in 
CD40 expression, which has been reported to induce the activation of inflammatory 
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pathways and NF-κB, leading to cell death [243-244]. Previous work has shown that 
subjects from India with diabetes have approximately 3 times higher soluble CD40L 
levels in their plasma than individuals with normal glucose tolerance [330]. Similar 
findings were also reported in a subsequent study in Europeans with T2D [331]. As a 
consequence, the combination of high soluble CD40L levels in diabetes along with 
upregulated expression of functional receptor in β-cells suggests that CD40 signalling 
can have an important role in the development of inflammation in glucolipotoxicity 
induced diabetes. 
These preliminary studies open the way to the investigations performed in the next 
chapter, in order to characterise CD40 and its function in the β-cell in relation to 
glucolipotoxicity. 
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New role for CD40 in pancreatic  
 
β-cell 
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4.1 Introduction 
 
CD40 is a membrane glycoprotein and member of the TNFR superfamily, as such as it 
is sometimes referred to as TNFR5. 
CD40 is expressed in many different immune and non-immune cell types. In B-
lymphocytes, macrophages and APC cells, binding of CD40 by CD40L plays a principal 
role in the immune system, inducing differentiation, cell survival, and proliferation. 
CD40 expression is also reported in non-hematopoietic cells, and its activation is mostly 
associated with non-specific inflammatory responses. A functional CD40 is also 
expressed in mouse and human pancreatic β-cells and is able to induce inflammatory 
responses [242-244]. These events activate inflammatory pathways, inducing 
cytokine/chemokine synthesis and secretion, which results in recruitment and activation 
of immune cells and downstream activation of NF-κB [213].  
Like other members of TNFR superfamily, CD40 signalling is mediated principally by 
TRAFs, that link CD40 to downstream signalling pathways [213]. The cytoplasmic 
domain of CD40 contains two independent membrane TRAF-binding domains: a 
proximal region binding TRAF6 and a distinct distal domain that binds TRAF-1/2/3/5. 
Different TRAFs binding to CD40 triggers distinct signalling pathways leading to a 
variety of functional outcomes, depending on the cell types involved. For example, they 
can activate the canonical and non canonical NF-κB signalling pathways, the mitogen 
MAPK, PI3K and phospholipase Cc (PLCc) pathways [214].  
 
In the previous chapter we demonstrated that CD40 expression is upregulated in INS-1 
cells after chronic exposure to high concentrations of glucose and fatty acids. These 
results were confirmed in vivo, in islets of mice fed a high fat diet and in human islets 
cultured in palmitate. 
These data suggest a role for CD40 in the development of glucolipotoxicity-induced 
inflammation during the progression to T2D and it opens the possibility that CD40 has a 
potential new role in regulation of β-cell function.  
In this chapter, we aimed to characterise the role of CD40 in the β-cell. In particular, we 
investigated whether CD40 had a role in cell viability and β-cell function. We analysed 
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if CD40 was able to influence insulin secretion and production and if it regulated the 
expression of downstream genes in its pathway, in particular TRAF proteins. 
 
4.2 CD40 is able to activate NF-κB 
 
Previous studies demonstrated that activation of CD40 with pro-inflammatory cytokines 
is able to activate NF-κB [244]. NF-κB is a transcription factor composed of different 
subunits. When it is activated by an inflammatory stimulus, NF-κB subunit p65 
translocates to the nucleus where it is able to activate the transcription of downstream 
genes. As a consequence, NF-κB p65 expression in the nucleus is a good readout of its 
activation. Downstream NF-κB activation is important in regulating cellular responses 
and it controls many genes involved in inflammatory processes. Its prolonged activation 
is partly responsible for the inflammatory status and β-cell failure observed during the 
progression to T2D [144]. 
Here, we investigated if CD40 was able to activate NF-κB in our experimental system, 
in order to determine if CD40 upregulation and activation in glucolipotoxicity could 
induce NF-κB responses. We used immunofluorescence to analyse NF-κB p65 subunit 
translocation in the nucleus and we activated CD40 using CD40L.  
 
4.2.1 Activation of CD40 induces NF-κB p65 translocation in the nucleus 
 
In order to determine if the activated CD40 is able to activate NF-κB, INS-1 cells were 
cultured onto coverslips and incubated with CD40L (1 μg/ml) for 6h. This timepoint 
was chosen according to experiments performed previously in my group, showing 
activation of CD40 after 6h incubation with CD40L. Cells were then fixed and stained 
with NF-κB p65 polyclonal antibody (green) and DAPI (blue).  
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Figure 4.1 Activation of CD40 can induce NF-κB p65 translocation to the nucleus. INS-1 
cells were cultured onto coverslips and incubated with CD40L (1 μg/ml) for 6h. Cells were then 
fixed and stained with NF-κB p65 polycolonal antibody (green) and DAPI (blue). A) Images 
were taken with a Leica EpiFluo microscope with a 63x objective (representative image of 3 
independent experiments). B) Quantification of p65 translocation in the nucleus using the 
program Image J. Data are expressed as mean + SD of 10 cells from one experiment.  
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Figure 4.1A shows that, in control conditions, no p65 staining (green) was detected in 
the nucleus, indicating that p65 was located mainly in the cytoplasm. Instead, in 
presence of CD40L, we observed a quantitative increase of the green signal in the 
nucleus. P65 translocation was also quantified using the program ImageJ, which is an 
image processing program that allows the quantification of the fluorescence signals. 
Figure 4.1B shows a 20% increase in p65 signal in the nucleus when INS-1 cells were 
incubated with CD40L. This result indicates that CD40 activation by CD40L is able to 
induce p65 translocation in the nucleus and, consequently, NF-κB activation, which will 
likely induce the transcription of the target genes.  
These data were also confirmed by other experiments performed by Dr. Nedjai in my 
group, who measured NF-κB p65 translocation in the nucleus using Transam NF-κB 
ELISA kit (Active Motif, Carlsbad, CA). Briefly, oligonucleotides containing NF-κB 
consensus binding site were immobilized onto 96-well plates and p65 subunit activity 
detected in INS-1 cells treated with either high glucose, TNF-α, or CD40L. These data 
showed that 72h incubation of INS-1 cells in 28 mM glucose resulted in an increased 
level of NF-κB activity similar to that observed following 2h exposure of cells to 100 
ng/ml of TNF. INS-1 cells incubated under standard glucose concentrations elicited a 
half-maximal induction of NF-κB activity when exposed for 6h to 1 µg/ml CD40L 
(Figure 4.2). As a consequence CD40 upregulation and activation could be responsible 
of most of the NF-κB activation in glucolipotoxicity. 
These results were consistent with previous data reported in the literature [243-244]. 
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Figure 4.2 Activation of CD40 is responsible of most of NF-κB activation in 
glucolipotoxicity. INS-1 cells were cultured in RPMI containing 11 or 28 mM glucose and 
subsequently incubated with CD40 ligand (1 μg/ml) or TNF-α (100 ng/ml) for 6h. Lysates were 
then used to measure NF-κB p65 translocation in the nucleus, using Transam NF-κB ELISA kit 
(Active Motif, Carlsbad, CA). Data are expressed as mean + SD of 3 independent experiments 
performed in duplicate. 
 
4.3 Effect of CD40 downregulation on cell viability 
 
While the role of CD40 in NF-κB activation has already been reported, nothing is 
currently known on the effect of CD40 on cell viability and function in the context of 
the β-cell and in relation to glucolipotoxicity. The most straightforward way to 
investigate this would be to overexpress CD40, therefore simulating the situation 
observed in glucolipotoxicity, and to determine the effects of this overexpression in the 
β-cell. However, INS-1 cells are quite difficult to transfect, therefore it would have been 
difficult to obtain a good level of gene overexpression. For this reason we decided to 
perform the opposite approach, i.e. downregulating CD40 using siRNA technology to 
investigate the effects on the β-cell.  
Specifically, in these experiments, we aimed to determine if CD40 has a role in the 
regulation of cell number, apoptosis, mitochondrial activity and cell cycle progression. 
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4.3.1 CD40 knock-down optimisation 
 
To investigate the effect of CD40 silencing on the β-cell viability and function, it is 
necessary to obtain at least a 75% knock-down of the gene of interest at RNA level, in 
order to see the biological effects at the protein level in the cells. Therefore, an 
optimisation process was required to identify the optimal experimental conditions for 
CD40 downregulation. 
First we used specific siRNAs purchased from Qiagen (Venlo, Netherlands), using 
electroporation as a transfection method. INS-1 cells were transfected with 1 μM (5 μl 
from stock 20 μM) of a “scrambled”, not targeting siRNA and 3 different siRNAs 
specific for CD40. Cells were lysed after 72h and total RNA extracted. RT-qPCR was 
performed using primers specific for CD40. Figure 4.3 shows a slight decrease in CD40 
expression using siRNA1, but it reached only a 25% of knock-down, which was not 
enough to see an effect at the protein level. 
 
 
 
Figure 4.3 CD40 downregulation using electroporation and Qiagen siRNAs. INS-1 cells 
were transfected with 5 µl of a scrambled and 3 different siRNAs and after 72h lysed and total 
RNA extracted. RT-qPCR was performed using primers specific for CD40. Data represent ∆∆Ct 
values expressed as a fold change compared to not transfected cells (control). Data are from one 
experiment. 
We then tested whether CD40 downregulation could be achieved by chemical 
transfection, using Lipofectamine 2000 or RNAiMax (Life Technologies, UK) as 
transfection reagents. INS-1 cells were transfected with 80 or 320 nM of siRNA1 and 
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Lipofectamine 2000 or RNAimax, lysed after 72h and total RNA extracted. RT-qPCR 
was performed using primers specific for CD40. No effect on CD40 mRNA levels was 
detected using these experimental conditions (Figure 4.4). 
 
 
 
Figure 4.4 CD40 downregulation using lipofectamine and Qiagen siRNAs. INS-1 cells were 
transfected with 80 or 320 nM of siRNA1 using Lipofectamine or RNAimax as transfection 
reagents (10 μl). After 72h cells were lysed and total RNA extracted. RT-qPCR was performed 
using primers specific for CD40. Data represent ∆∆Ct values expressed as a fold change 
compared to not transfected cells (control). Data are from one experiment. 
 
As the Qiagen sequences were not very effective in our experimental system, we 
decided to try different sequences, purchased from Dharmacon (GE Healthcare, UK), 
and to transfect them using either electroporation or Lipofectamine RNAimax. In Figure 
4.5A, INS-1 cells were transfected with 200 nM of a “scrambled” and 4 different 
siRNAs specific for CD40, using 30 μl RNAimax. Cells were lysed after 72h and total 
RNA extracted. RT-qPCR was performed using primers specific for CD40. Using this 
protocol, siRNAs 6 and 8 were able to downregulate CD40 mRNA levels compared to 
the scrambled sequence (55% knock-down). On the other hand, siRNA 7 led to a 45% 
downregulation and siRNA 5 had no effect at all. In Figure 4.5B INS-1 cells were 
transfected by electroporation with 1 μM of the 4 different siRNAs specific for CD40.  
Cells were lysed after 72h and total RNA extracted. RT-qPCR was performed using 
primers specific for CD40. In these experimental conditions only siRNA 6 led to a 20% 
downregulation, whereas the other siRNAs had no effect.  
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Considering that chemical transfection gave better results than electroporation in this 
experimental system, we decided to use RNAimax as a transfection reagent for all the 
future experiments. We needed, however, to further optimise the conditions, varying the 
concentrations of siRNA and RNAiMax, in order to obtain a more efficient 
downregulation. 
 
 
 
Figure 4.5 CD40 downregulation using Dharmacon siRNAs. A) INS-1 cells were transfected 
with 200 nM of a “scrambled” and 4 different siRNAs specific for CD40, using 30 μl RNAimax.  
After 72h cells were lysed and total RNA extracted. RT-qPCR was performed using primers 
specific for CD40. B) INS-1 cells were transfected with 1 μM of 4 different siRNAs specific for 
CD40, by electroporation. Cells were lysed after 72h and total RNA extracted. RT-qPCR was 
performed using primers specific for CD40. Data represent ∆∆Ct values expressed as a fold 
change compared to not transfected cells (control). Data are from one experiment. 
 
Based on the data in Figure 4.5A, we decided to further optimise siRNA 6 and 8 which 
proved to be the most effective in inducing CD40 downregulation. We used also siRNA 
5 as a negative control. We changed the amounts of lipofectamine and siRNA used, in 
order to optimise the protocol, transfecting INS-1 cells with 70 nM of a “scrambled” and 
3 different siRNAs specific for CD40, using 7 μl of RNAimax. RT-qPCR was 
performed as before. Figure 4.6 shows that this protocol induced a strong 
downregulation in cells transfected with siRNA 6 (85% knock-down) which would be 
sufficient to see a biological effect in the β-cell. Therefore, these conditions were used 
in all the subsequent experiments presented in this chapter. 
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Figure 4.6 CD40 downregulation optimisation using RNAimax. INS-1 cells were transfected 
with 7 μl of a “scrambled” and 3 different siRNAs specific for CD40, using 7 μl of RNAimax. 
Cells were lysed after 72h, total RNA extracted and RT-qPCR was performed using primers 
specific for CD40. Data represent ∆∆Ct values expressed as a fold change compared to not 
transfected cells (control). Data are from one experiment. 
 
4.3.2 Validation of CD40 downregulation at the protein level 
 
Given that RNA expression does not always equate to protein expression, it became 
necessary to check if also CD40 protein expression decreases after 72h of transfection 
with siRNA 6. INS-1 cells were transfected with a “scrambled” and a siRNA specific 
for CD40. After 72h cells were lysed in Triton-X100 buffer and protein separated on a 
12.5% SDS PAGE gel. The gel was then transferred to nitrocellulose and 
immunoblotted with anti CD40 polyclonal antibody. Figure 4.7 shows that siRNA6 was 
able to induce a 50% reduction of CD40 protein expression compared to scrambled 
siRNA, indicating that CD40 was successfully downregulated at protein level. 
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Figure 4.7 CD40 downregulation at the protein level. INS-1 cells were transfected with 
RNAiMax alone (TR), “scrambled” (SCR) and a siRNA specific for CD40. Cells were 
lysed in Triton-X100 buffer after 72h and protein separated on a 12.5% SDS PAGE gel. 
The gel was then transferred to nitrocellulose and immunoblotted with anti CD40 
polyclonal antibody. Actin was used as a loading control. Image is representative of 3 
independent experiments. 
 
4.3.3 Effect of CD40 downregulation on cell number 
 
In order to assess if CD40 has a role on cell viability in control conditions, INS-1 cells 
were transfected with a “scrambled” and a siRNA specific for CD40. After 72h cells 
were collected and counted using a Neubauer chamber. Figure 4.8 shows no change in 
cell number upon CD40 downregulation, indicating that CD40 is not involved in cell 
viability. 
 
 
 
Figure 4.8 Effect of CD40 downregulation on cell number. INS-1 cells were transfected with 
a scrambled and a siRNA targeting CD40 gene. After 72h cells were collected and counted 
using a Neubauer chamber. Data represent number of cells expressed as absolute value. Data are 
means + SD of 3 independent experiments performed in duplicate. 
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4.3.4 Effect of CD40 downregulation on caspase 3 activation 
 
We demonstrated above that CD40 downregulation does not affect cell number, and, as 
a consequence, it does not stimulate or reduce cell proliferation. In addition to this, we 
further investigated if CD40 downregulation could have an effect on apoptotic events, 
such as the activation of caspase 3. 
In order to test this, INS-1 cells were transfected with a scrambled and a siRNA 
targeting CD40 gene. After 72h, cells were lysed and caspase 3 activity was measured 
using EnzCheck Caspase-3 Assay Kit #2 (Life Technologies, UK). No significant 
changes in caspase 3 activity were detected upon downregulation of CD40 (Figure 4.9). 
 
 
 
Figure 4.9 Effect of CD40 downregulation on caspase 3 activation. INS-1 cells were 
transfected with a scrambled and a siRNA targeting CD40 gene. After 72h cells were lysed and 
apoptosis determined via caspase 3 activity. Data represent fluorescence values at 
excitation/emission ~496/520 nm normalised to total protein concentration and are expressed as 
fold change compared to cells transfected with only the transfection reagent. Values are means + 
SD from 3 independent experiments performed in duplicate. 
 
4.3.5 Effect of CD40 downregulation on cell cycle 
 
Consistent with data obtained with caspase 3 assay, no change in the number of cells in 
subG1 phase was observed by FACS. Cells were transfected for 72h with a “scrambled” 
and a siRNA specific for CD40, fixed and incubated in a solution of propidium iodide. 
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Cells were then sorted using a FACS machine, separating them according to their DNA 
content to determine the percentage of cells in the distinct phases of the cell cycle.  
 
TRANSFECTION 
REAGENT 
SCRAMBLED CD40 siRNA 
2.2 + 0.9 % 2 + 0.7 % 2.3 + 1.0 % 
 
Table 4.1 Percentage of cells in subG1. Numbers represents the percentage of cells in subG1 
phase. Values are mean + SD from 3 independent experiments. 
 
Table 4.1 shows the percentage of cells in subG1 phase and indicates that there was no 
significant difference in the number of cells in subG1 upon CD40 downregulation, 
indicating no activation of apoptosis. 
Figure 4.10 shows the results of cell cycle analysis upon CD40 downregulation. Data 
indicate a slight increase of cells in G1 phase and decrease in G2 phase in cells lacking 
CD40, compared to scrambled cells. During G1 phase cells increase their size and 
synthesize mRNA and proteins. Given these results, we can hypothesise that the 
downregulation of CD40 induced a slight increased cell activity that could influence 
also β-cell function. 
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Figure 4.10 Effect of CD40 downregulation on cell cycle progression. Cells were transfected 
for 72h with a scrambled and a siRNA specific for CD40, fixed and sorted by FACS to analyse 
the cell cycle. Values are means + SD from 3 independent experiments. 
 
4.4 CD40 and insulin secretion and production 
 
In the previous chapter we demonstrated that glucolipotoxicity reduces insulin 
production and secretion, impairing β-cell function. At the same time, glucolipotoxicity 
Transfection reagent Scrambled 
CD40 siRNA 
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increases the expression of CD40, revealing a role for this receptor in the β-cell. Here 
we wanted to determine if the increase in CD40 expression could be partly responsible 
for the reduction of insulin in glucolipotoxicity, and therefore if CD40 is able to 
influence insulin secretion and production. 
In order to address this aim, we investigated the effect of CD40 downregulation on 
insulin mRNA levels, insulin content and secretion. 
 
4.4.1 Effect of CD40 downregulation on insulin mRNA levels 
 
In order to determine if CD40 downregulation can influence insulin mRNA expression, 
INS-1 cells were transfected with a “scrambled” and a siRNA specific for CD40. After 
72h, cells were lysed, RNA extracted and RT-qPCR performed using primers specific 
for the insulin gene.  
Figure 4.11A shows that the siRNA used as control (scrambled siRNA) did not affect 
insulin mRNA levels in our experimental system. 
Importantly, downregulation of CD40 induced a 1.7 fold increase (p<0.05) in insulin 
mRNA (Figure 4.11B). This result suggests a potential new role for CD40 in the 
regulation of β-cell function. 
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Figure 4.11 Effect of CD40 downregulation on insulin mRNA levels. INS-1 cells were 
transfected with transfection reagent alone, a scrambled and a siRNA specific for CD40. Cells 
were lysed after 72h, RNA extracted and RT-qPCR performed using primers specific for insulin 
gene. A) Data represent ∆∆Ct values expressed as a fold change compared to cells transfected 
with transfection reagent only. Data are expressed as means + SD of 2 independent experiments. 
B) Data represent ∆∆Ct values expressed as a fold change compared to cells transfected with a 
scrambled siRNA. Data are expressed as means + SD of 4 independent experiments (*p<0.05). 
 
4.4.2 Effect of CD40 downregulation on insulin content 
 
Insulin biosynthesis at RNA level may not be indicative of the amount of insulin protein 
inside the cell. In order to assess if CD40 downregulation is able to influence the total 
insulin content, INS-1 cells were transfected with a “scrambled” and a siRNA specific 
for CD40. After 72h cells were lysed using acid-ethanol extraction and total insulin 
content measured using Mercodia ELISA kit (Uppsala, Sweden). As shown in Figure 
4.12 CD40 downregulation induced a 1.3 fold increase in the total insulin content. 
164 
 
Taken together, these results indicate that the downregulation of CD40 increases both 
insulin mRNA and insulin content. 
 
 
 
Figure 4.12 CD40 downregulation and insulin content. INS-1 cells were transfected with a 
scrambled and a siRNA specific for CD40. Cells were lysed after 72h using acid-ethanol 
extraction and total insulin content measured using Mercodia ELISA kit. Data represent ng of 
insulin secreted per μg of total protein. Data are means + SD from 3 independent experiments. 
 
4.4.3 Effect of CD40 downregulation on insulin secretion 
 
We then decided to investigate the effect of CD40 downregulation on insulin secretion. 
To this end, INS-1 cells were transfected with a “scrambled” and a siRNA specific for 
CD40. After 72h, cells were treated with a secretagogue cocktail to stimulate insulin 
secretion and the amount of secreted insulin measured using Mercodia ELISA kit 
(Uppsala, Sweden).  
Figure 4.13 shows the effect of CD40 downregulation on insulin secretion. A 1.5 fold 
increase (p<0.05) in insulin secretion was detected in cells lacking CD40, indicating that 
CD40 also regulates insulin secretion. 
 
165 
 
 
 
Figure 4.13 Effect of CD40 downregulation on insulin secretion. INS-1 cells were transfected 
with a scrambled and a siRNA specific for CD40. After 72h, cells were treated with a cocktail to 
stimulate insulin secretion and the amount of insulin secreted measured with Mercodia ELISA 
kit. Data represent ng of insulin secreted per μg of protein. Data are means + SD from 3 
independent experiments (*p<0.05). 
 
4.4.4 CD40 downregulation in glucolipotoxicity 
 
Previously we showed that insulin mRNA levels decrease and CD40 expression 
increases when INS-1 cells are exposed to glucolipotoxic conditions. In addition, when 
CD40 is downregulated, in normal RPMI (11 mM glucose) conditions, insulin mRNA 
levels increase.  
We then decided to investigate if the downregulation of CD40 in glucolipotoxicity is 
able to restore the impaired insulin expression. In order to assess this, INS-1 cells were 
transfected with a “scrambled” and a siRNA specific for CD40 gene. The following day 
cells were incubated in RPMI-1640 media supplemented with 27 mM glucose, 200 μM 
oleic acid, 200 μM palmitic acid for 72h. After the incubation time, cells were lysed, 
RNA extracted and RT-qPCR performed using primers specific for CD40 and insulin 
gene.  
Figure 4.14 shows the effect of CD40 knock-down on CD40 and insulin mRNA levels 
in control and in glucolipotoxic conditions. Figure 4.14A shows the expression of 
CD40: glucolipotoxicity induced an increase in CD40 expression also in presence of 
CD40 siRNA. These RNA levels almost equated the level in scrambled cells in control 
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conditions. Figure 4.14B shows the expression of insulin: a 1.5 fold increase in insulin 
mRNA could be detected with CD40 knock-down also in glucolipotoxic conditions, 
indicating that the downregulation of CD40 was able to partly restore the impaired 
insulin expression in glucolipotoxicity. However, in these experimental conditions, 
CD40 mRNA levels were higher in glucolipotoxicity than in control conditions, also 
when cells were transfected with CD40 siRNA. Therefore, CD40 mRNA levels were not 
reduced enough to see a complete recovery of insulin expression in glucolipotoxicity. 
 
 
 
Figure 4.14 Effect of CD40 downregulation on insulin in glucolipotoxicity. INS-1 cells were 
transfected with a scrambled and a siRNA specific for CD40. The following day, the transfected 
cells were treated with RPMI-1640 supplemented with 27 mM glucose, 200 μM oleic acid, 200 
μM palmitic acid. After 72h, cells were lysed, RNA extracted and RT-qPCR performed using 
primers specific for CD40 (A) and for insulin gene (B). Data represent ∆∆Ct values expressed as 
a fold change compared to cells transfected with a scrambled siRNA in control conditions 
(normal RPMI). Data are expressed as means + SD of 3 independent experiments (*p<0.05). 
 
4.4.5 Effect of CD40 downregulation on insulin transcription factors 
 
We showed above that downregulation of CD40 is able to increase insulin biosynthesis, 
both in control than in glucolipotoxic conditions.  
It is known that insulin promoter is regulated by different transcription factors, and high 
concentrations of glucose and fatty acids can affect not only their binding activity but 
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also their expression. In particular, PDX-1 and MafA, the main insulin transcription 
factors, show a reduced mRNA expression in glucolipotoxicity [136]. 
To assess whether CD40 can influence insulin transcription by affecting the expression 
of one or more of its transcription factors, INS-1 cells were transfected with a 
“scrambled” and a siRNA specific for CD40. RT-qPCR was performed using primers 
specific for PDX-1, TFAM, HNF1, MafA as before. Figure 4.15 shows the results of the 
qPCR performed on the insulin transcription factors. Data indicate that downregulation 
of CD40 did not affect the expression of any of the transcription factors analysed.  
These results suggest that CD40 influences insulin transcription through a mechanism 
that is independent from the expression of its transcription factors. 
 
 
 
Figure 4.15 Effect of CD40 downregulation on the mRNA levels of insulin transcription 
factors. INS-1 cells were transfected with a scrambled and a siRNA specific for CD40. After 
72h cells were lysed, RNA extracted and qPCR performed using primers specific for PDX-1, 
TFAM, HNF1, Maf A. Data represent ∆∆Ct values expressed as a fold change compared to cells 
transfected with a scrambled siRNA. Data are expressed as means + SD of 3 independent 
experiments.  
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4.4.6 Presence of NF-κB binding sites on insulin promoter 
 
In the previous paragraph we showed that CD40 downregulation does not affect the 
expression of the insulin transcription factors, indicating that the increase of insulin 
secretion and production observed upon CD40 downregulation is not due to a 
mechanism involving the expression of conventional insulin transcription factors. 
We therefore hypothesized that CD40 could either: 
- influence the binding of insulin transcription factors or 
- activate NF-κB, which, in turn, could influence insulin transcription. 
Our previous data indicated that CD40 is able to activate NF-κB, therefore, to determine 
if NF-κB can regulate insulin, we checked if there are some NF-κB consensus binding 
sites ahead of the insulin gene. NF-κB consensus sequence is known to be 
5'GGGACTTTCC-3', but we did not find this nucleotide sequence in the insulin 
promoter area. However, NF-κB is able to bind also to the generic sequence 
5’GGGRNNYYCC-3’, where R is a purine and Y a pyrimidine. We subsequently used 
the online program TF search (http://www.cbrc.jp/research/db/TFSEARCH.html), 
which allows the identification of the potential transcription factors binding sites in a 
given sequence. This program identified a possible p65 binding site, laying 1600 bp 
ahead of the insulin gene.  
This finding opens the possibility that CD40 could regulate insulin transcription through 
NF-κB. Further investigations are necessary to establish if NF-κB is able to effectively 
bind insulin promoter and if CD40 downregulation could modify NF-κB binding. 
 
4.5 Effect of CD40 downregulation on downstream signalling 
 
In the previous paragraphs we demonstrated that downregulation of CD40 does not 
influence cell viability but is able to affect insulin biosynthesis and secretion. In order to 
determine if CD40 downregulation affects other β-cell functions, as the expression of 
other genes of the TNFR pathway, we checked the expression of these genes in 
scrambled and in knock-down cells. In particular, because of the potential link with the 
NF-κB pathway, we focused on TRAF proteins, adaptor molecules downstream of 
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CD40 signalling, analysing their expression with CD40 downregulation and their role in 
glucolipotoxicity.  
 
4.5.1 Role of CD40 on TRAFs expression levels 
 
To determine if CD40 signalling is able to influence the expression of other members of 
the TNFR pathway, we determined the effect of its downregulation. RT-qPCR was 
performed as before using primers specific for TRAF1, TRAF2, TRAF3 and TRAF6. 
Figure 4.16 shows the expression of TRAFs proteins upon CD40 downregulation. These 
data indicate a trend for a decrease in TRAF1 (25%), TRAF2 (25%) and TRAF6 (30%) 
expressions upon CD40 knock-down; TRAF3 expression, on the other hand, was not 
affected.  
These results suggest the possibility of a link between CD40 and the downstream TRAF 
proteins, in particular TRAF1, TRAF2 and TRAF6. Interestingly, it has ben shown that 
TRAF1, TRAF2 and TRAF6 are able to activate NF-κB [176, 180]. The fact that CD40 
downregulation could be able to modulate TRAFs expression suggests that CD40 
blockade may possibly inhibit NF-κB activation and the consequent inflammatory 
process. These data open the possibility of development of novel therapeutic strategies, 
blocking CD40 and its downstream signalling. 
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Figure 4.16 Effect of CD40 downregulation on TRAF proteins.  INS-1 cells were transfected 
with a scrambled and a siRNA specific for CD40. Cells were lysed after 72h, RNA extracted 
and qPCR performed with primers specific for TRAF1, TRAF2, TRAF3 and TRAF6. Data 
represent ∆∆Ct values expressed as a fold change compared to cells transfected with a 
scrambled siRNA. Data are expressed as means + SD of 3 independent experiments.  
 
4.5.2 TRAFs mRNA levels in glucolipotoxicity 
 
As TRAF1, TRAF2 and TRAF6 mRNA levels decrease when CD40 expression 
decreases, we decided to assess their levels in glucolipotoxicity, when CD40 is 
overexpressed. To investigate this, INS-1 cells were cultured for 72h in RPMI-1640 
supplemented with 27 mM glucose, 200 μM oleic acid, 200 μM palmitic acid in 
different combinations. After the incubation time, cells were lysed, RNA extracted and 
qPCR performed using primers specific for TRAF1, TRAF2, TRAF3 and TRAF6.  
Figure 4.17 shows that all TRAFs mRNA levels were similar in control conditions. 
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Figure 4.17 TRAFs expression level. INS-1 cells were cultured for 72h in RPMI-1640, cells 
were lysed, RNA extracted and qPCR performed using primers specific for TRAF1, TRAF2, 
TRAF3 and TRAF6. Data represent amplification plots of the respective TRAFs in control 
conditions. 
 
Figure 4.18 shows TRAFs mRNA levels in glucolipotoxicity. There was a significant 
increase in TRAF2 expression, especially with incubation of both glucose and fatty 
acids (1.7 fold, p<0.05). There was a trend towards the increase of TRAF1 and TRAF6 
mRNA levels (2.5 and a 2.2 fold respectively), with combination of glucose and fatty 
acids, whereas TRAF3 showed a trend towards decreased levels in glucolipotoxicity.  
These results suggest that TRAF1, TRAF2 and TRAF6 mRNA levels could be linked to 
CD40 expression, as they show the same pattern of overexpression in glucolipotoxicity. 
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Figure 4.18 Effect of glucolipotoxicity on TRAFs expression.   INS-1 cells were cultured for 
72h in RPMI-1640 supplemented with 27 mM glucose, 200 μM oleic acid and 200 μM palmitic 
acid in different combinations. After the incubation time, cells were lysed, RNA extracted and 
qPCR performed using primers specific for TRAF1, TRAF2, TRAF3 and TRAF6. Data 
represent ∆∆Ct values expressed as a fold change compared to cells grown in normal RPMI 
(control). Data are expressed as means + SD of 3 independent experiments (*p<0.05). 
 
4.5.3 TRAFs protein expression in glucolipotoxicity 
 
To determine whether the changes in mRNA levels correspond to differences at the 
protein level, INS-1 cells were cultured as before. After the incubation time, cells were 
lysed with TritonX-100 buffer and protein separated on a 12.5% SDS PAGE gel. The 
gel was then transferred on a membrane and then immunoblotted with anti-TRAF1, 
TRAF2, TRAF3 and TRAF6 polyclonal antibodies. Figure 4.19 shows that the 
expression of TRAF1, TRAF2 and TRAF6 increased in glucolipotoxicity, while TRAF3 
expression was unaffected. In particular, TRAF1 increased with incubations of high 
glucose or high fat alone, and its overexpression was more evident in the presence of 
both high glucose and high fat. TRAF2 expression increased especially with high 
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glucose and high fat. TRAF6 appeared to increase in all the conditions compared to 
control, but it is barely detectable in these experimental conditions. Further optimisation 
of the blotting technique is necessary to obtain clearer results. 
These results confirm the data observed at the RNA level and suggest a potential role of 
TRAF2 and TRAF6 in glucolipotoxicity. However, these experiments need to be 
repeated in order to reach statistical significance. 
 
A 
 
 
B 
 
Figure 4.19 TRAFs protein expression in glucolipotoxicity. INS-1 cells were cultured for 72h 
in RPMI-1640 supplemented in 27 mM glucose, 200 μM oleic acid, 200 μM palmitic acid in 
different combinations. After the incubation time, cells were lysed with TritonX-100 buffer and 
protein separated on a 12.5% SDS PAGE gel. The gel was then transferred on a membrane and 
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then immunoblotted with anti TRAF1, TRAF2, TRAF3 and TRAF6 polyclonal antibodies. A) 
Western blots are representative of 3 independent experiments; B) Quantitation of the previous 
western blots using the program Image J. Bands are normalised using actin as a loading control 
and subsequently normalised to control conditions. 
 
4.5.4 TRAFs expression in vivo 
  
To determine whether upregulation of TRAF2 and TRAF6 also occurred in vivo, we 
performed RT-qPCR analysis using islets from C57BL/6 mice fed a high fat diet for 10 
weeks or control mice. Data indicate a significant increase in TRAF2 mRNA levels (2 
fold, p<0.05) in the high fat diet mice compared to lean control. TRAF6 did not show 
any significant change. The increase seemed to be specific for TRAF2 as TRAF6 
mRNA did not seem to be affected (Figure 4.20). 
 
 
 
Figure 4.20 TRAFs expression in vivo. C57BL/6 mice were fed a high fat diet for 10 weeks 
prior to sacrifice, pancreas removed and total RNA extracted from isolated islets. RT-qPCR was 
performed using specific primers for TRAF2 and TRAF6. Data represent ∆∆Ct values expressed 
as a fold change compared to the expression in islets of mice fed a control diet. Data are 
expressed as means + SD of 3 independent experiments (* p<0.05). 
 
4.6 Discussion 
 
CD40 is a member of the TNFR superfamily that plays a key role in the immune system 
and it is also associated with inflammatory responses in non-immune cells. A functional 
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CD40 is also expressed in mouse and human pancreatic β-cells and is able to induce 
inflammatory responses, upon activation of NF-κB [213, 242-244].  
We demonstrated in the previous chapter that CD40 is overexpressed in INS-1 cells 
incubated under chronic conditions of high glucose and fatty acids, suggesting that it 
may be involved in the inflammatory process of glucolipotoxicity induced inflammation 
during the progression to T2D. 
In this chapter, we characterised the role of CD40 in the β-cell, with particular focus on 
its potential role on β-cell function. We first demonstrated that CD40 activation by 
CD40L is able to induce NF-κB p65 translocation to the nucleus, and consequently NF-
κB activation (Figure 4.1 and 4.2). The combination of high level of CD40L in diabetes 
along with upregulated expression of functional receptor in β-cells suggests that CD40 
signalling may be responsible for much of the NF-κB-dependent islet inflammation. 
Since NF-κB activity is known to induce islet cell death [144], this lead to the 
hypothesis that a prolonged CD40 signalling through this pathway is likely to be a major 
contributor to islet cell death in the presence of chronically elevated levels of glucose 
and fatty acids. 
To establish the specific role of CD40 in the pancreatic β-cell, we then performed a 
targeted knock-down of the gene in INS-1 and we determined cell viability in control 
conditions. We demonstrated that CD40 downregulation did not affect cell number 
(Figure 4.8) and did not activate caspase 3 (Figure 4.9), indicating that CD40 silencing 
is not involved in regulation of survival/apoptosis, at least in normal conditions.  
In addition, we observed an increased number of cells in G1 phase upon CD40 
downregulation, indicating that the absence of CD40 could induce a slight increase 
metabolism in the β-cell. These data were also confirmed by the effect of CD40 
downregulation on insulin. We showed an increase in insulin gene transcription (Figure 
4.11), insulin content (Figure 4.12) and secretion (Figure 4.13) in INS-1 cells transfected 
with a siRNA specific for CD40. These results suggest a new role for CD40 in the 
pancreatic β-cell. CD40 is able to regulate the function of the β-cell, and its 
downregulation was able to partially improve the impaired insulin production in 
glucolipotoxicity (Figure 4.14). In literature, no direct correlation between CD40 and 
insulin metabolism has been reported so far, although Poggi et al demonstrated that 
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obese CD40L
-/-
 mice have preserved insulin sensitivity and low plasma insulin levels 
compared to obese CD40L
+/+
 mice [247]. Our study is the first to suggest a direct 
correlation between CD40 and β-cell function.  
The increase in insulin production observed in CD40 knock-down cells is independent 
to changes in the expression of insulin transcription factors (Figure 4.15), suggesting 
that downregulation of CD40 could either affect the binding activity of these 
transcription factors or act through NF-κB. We showed before that CD40 can activate 
NF-κB and we found a predicted NF-κB binding site 1600 bp ahead of the insulin 
promoter. The absence of CD40 would reduce the negative effect of NF-κB on insulin 
promoter, inducing insulin transcription. 
Like the other members of TNFR superfamily, CD40 signalling is mediated principally 
through TRAFs, linking CD40 to downstream signalling pathways, among which 
activation of NF-κB. In this chapter, we showed that there was a trend towards a 
reduction in the expressions of TRAF1, TRAF2 and TRAF6 upon CD40 
downregulation (Figure 4.16), suggesting a potential direct connection between CD40 
and its downstream effectors. In addition, TRAF1, 2 and 6 expressions resulted 
upregulated in glucolipotoxicity (Figure 4.18, 4.19, 4.20), when also CD40 expression 
increases, showing that TRAFs expression perfectly reflects CD40 expression. 
Interestingly, CD40 results to be able to influence the expression of the downstream 
effectors, and this discovery can open the way to new therapeutic approaches, blocking 
the pathways activated by CD40. TRAF5 was not considered in the present analysis 
because it is the least studied TRAF in CD40 signalling. Future studies could include 
investigations on its role in glucolipotoxicity and in relation to CD40. 
Taken together these results suggest a potential link between CD40 and insulin, as 
represented in Figure 4.21. In glucolipotoxic conditions, CD40 expression increases, 
leading to an increase of TRAFs expression, which can then activate NF-κB. NF-κB in 
turn binds to the insulin promoter and blocks the transcription of the gene. Given these 
results, an interesting therapeutic approach would be the blockage of the CD40 pathway. 
Upon CD40 downregulation, also TRAFs expression decreases, with subsequent 
reduction in the activation of NF-κB and subsequent increase in the transcription of the 
insulin gene. 
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Figure 4.21 Hypothetic mechanism linking CD40 to insulin. A) In glucolipotoxic conditions; 
B) with CD40 downregulation. 
 
The results of this chapter suggest the possibility that it would be possible to enhance 
islet function in glucolipotoxicity through targeted disruption of CD40 signalling 
pathways. A similar approach has been employed as a general immunosuppressant 
strategy following transplantation, and also to treat people suffering from lupus and 
different types of cancer. Intervention has not always been successful however, as there 
are a number of reports where anti-CD40L monoclonal antibodies have been shown to 
trigger thromboembolic events [332-333]. Importantly, these dangerous side effects 
have not been observed when the receptor, rather than the ligand, is targeted. Indeed 
there are now numerous promising clinical trials taking place involving a number of 
different anti-CD40 monoclonal antibodies [334-335], which may be worth 
consideration for use as an adjunct therapy for people with a history of poorly controlled 
T2D. Lucatumumab in particular would appear a strong initial candidate for this role. It 
is a human monoclonal antibody against CD40 and not only it is reported to be well 
tolerated [336], at least in moderate and intermediate strength doses [337], but it has also 
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previously been shown to prevent induction of NF-κB activity in multiple myeloma 
cells [338]. 
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Chapter 5 
 
 
Transcriptome profiling of the 
 
β-cell in glucolipotoxicity 
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5.1 Introduction 
 
The transcriptome is the entire repertoire of transcripts in a species and represents a key 
link between the information encoded in the DNA and the phenotype. Discovering and 
interpreting the complexity of the transcriptome represents a crucial method of 
understanding the functional elements of the genome. This analysis can lead to a more 
complete understanding of many biological issues such as the onset of disease and 
progression. 
The main goal of the whole transcriptome analysis is to identify, characterise and 
catalogue all the transcripts differentially expressed within a specific cell/tissue, at a 
particular stage. It has the potential to determine the correct splicing patterns and the 
structures of the genes, and to quantify the differential expression of transcripts in both 
physiological and pathological conditions [257]. Evolution of high-throughput 
techniques has allowed transcriptome profiling of model of diseases both in vitro and in 
vivo in an unbiased and highly sensitive manner, without previous knowledge of the 
genes involved in a particular disease. Next generation sequencing technology also 
tolerates de novo assembly of the reads, with access to transcriptional variations across 
the whole genome and not restricted only to sequences on certain particular probes. 
Moreover, with adaptations of next generation techniques, it is now possible to identify 
differentially expressed small RNAs, in particular miRNAs. MiRNAs are endogenous 
~22 nucleotides long RNAs that play important regulatory roles in animals and plants by 
targeting mRNAs for cleavage or translational repression [281]. They can regulate both 
physiological and pathological processes such as development, metabolism, cancer and, 
relevant to this thesis, insulin resistance and diabetes.   
 
The aim of this part of the thesis was to explore the molecular mechanisms activated in 
the β-cell under chronic exposure to high concentrations of glucose and fatty acids, 
using RNA sequencing. As reported in chapter 3, previous experiments in our lab 
identified several genes that are differentially expressed in glucolipotoxic conditions 
using Affymetrix microarrays. However, microarray analyses have several limitations 
because they need to rely on existing knowledge about the genome sequence, they have 
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high backgrounds levels due to cross-hybridisation, and a limited dynamic range of 
detection due to both background and saturation of signals [266]. RNAseq experiments 
allowed to expand the information gained through the microarray analysis, allowing the 
identification of expression changes at all the genome level, and the potential to discover 
novel transcripts, corresponding to molecules which structure and functions had not 
been elucidated so far.  
Specifically we were interested in the investigation of novel molecules differentially 
expressed in conditions of glucolipotoxicity, which could be potential new targets for 
therapeutic strategies. These targets could be further studied to determine if they could 
have a role in regulating β-cell function. 
 
5.2 Experiment set-up 
 
We chose to perform RNA sequencing experiments to identify novel molecules 
involved in β-cell function impairment in glucolipotoxicity. The information gained 
from this study represented a broader view of the expression changes during 
glucolipotoxicity compared to the previous Affymetrix microarray data (Chapter 3). We 
chose to use INS-1 cells as they are a reliable model to study changes in gene expression 
and insulin secretion.  
 
5.2.1 Experimental conditions 
 
In order to discover novel mechanisms involved in the process of glucolipotoxicity, 
INS-1 cells were incubated in four experimental conditions, as those used for all the 
previous experiments of this thesis: 
1- Control (RPMI-1640 containing 11 mM glucose) (C) 
2- High glucose (RPMI-1640 containing 27 mM glucose) (HG) 
3- High fat (RPMI-1640 containing 200 μM oleic acid, 200 μM palmitic acid) (HF) 
4- High glucose high fat (RPMI-1640 containing 27 mM glucose, 200 μM oleic 
acid, 200 μM palmitic acid) (HGHF). 
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We used the same conditions adopted for the Affymetrix study, in order to compare 
some of the results obtained. In addition, differently from the Affymetrix experiment 
where only the combination of high glucose and high fat was used, in this RNAseq 
experiment we also evaluated the effects of glucose and fatty acids alone. 
INS-1 cells were cultured for 72h in the 4 experimental conditions, subsequently lysed 
and RNA extracted (see Chapter 2, section 2.10.1). The experiment was performed in 
triplicate, in order to minimise experimental errors, for a total of 12 samples. 
 
5.2.2 Extraction and quality control of RNA 
 
The quality of the 12 RNA samples was confirmed using the Agilent Bioanalyser, using 
the protocol described in the Material and Methods section (Chapter 2, section 2.10.3). 
A RIN number (a tool that estimates the integrity of the RNA sample) between 8 and 10 
was assigned to all samples, indicating that they consisted of high quality RNA. A 
representative electropherogram is shown in picture 5.1.  
 
 
 
Figure 5.1 Agilent Bioanalyser analysis of RNA samples. The 12 samples of RNA extracted 
from INS-1 cells were run on an Agilent Bioanalyser system, in order to assess quality of the 
RNA. All the samples were assigned a RIN number between 8 and 10, indicative of high quality 
RNA. 
 
The electropherograms for all the samples and the correspondent RIN numbers are 
presented in Appendix B. 
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5.2.3 Obtaining expression data 
 
High quality RNA was then sent to Dr. Sarah Lamble laboratory in Oxford for the 
subsequent stages of library preparation and sequencing, performed over one lane of a 
flow cell on an Illumina-HiSeq 2000 instrument. The statistics of the RNAseq 
experiment are presented in Appendix C. 
Raw RNAseq data were then analysed by Dr. Rob Lowe (Blizard Institute). In the 
sequencing process, the Illumina instrument produced quality-scored base calls during 
the run. The sequencing output files (compressed FASTQ files) were then used for the 
secondary analysis.  
 
Reads were aligned to an annotated reference genome using Top Hat v 2.0.9: 
http://tophat.cbcb.umd.edu. Reads aligned to exons, genes and splice junctions were 
counted using the reference genome “rn4”, extracted from UCSC 
(http://genome.ucsc.edu/goldenPath/credits.html#rat_credits).  
Data visualisation and interpretation, calculating gene as well as transcript expression, 
then reporting differential expression, was done using the HTseq-count program: 
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html).  
Normalisation process, which correct for in-sample distributional differences within the 
read counts, such as differences in total counts (sequencing depths), and within sample 
gene-specific effects, such as gene length or GC-content effects, was performed using 
the program DEseq: 
(http://www.bioconductor.org/packages/devel/bioc/html/DESeq.html) 
The statistical significance of fold changes was calculated by comparing the 
experimental read values to the control samples and the p values were subsequently 
adjusted at genome wide level using Bonferroni formula. 
 
5.3 Multivariance analysis to identify sample clusters 
 
After data were analysed, we performed the following comparisons: 
- HG vs C 
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- HF vs C 
- HGHF vs C 
- HG vs HF 
- HG vs HGHF 
- HF vs HGHF. 
For the subsequent analysis we focussed on the genes differentially expressed in the 3 
experimental conditions compared to control conditions (HG vs C, HF vs C, HGHF vs 
C). 
Genes were considered to be differentially expressed if  reads changed more than 2 fold 
up/down compared to control  with the adjusted p value of p<0.05. 
The following numbers of genes resulted differentially expressed with an adjusted p-
value of p<0.05: 
- HG: 2701 differentially expressed genes, 588 upregulated and 2113 
downregulated; 
- HF: 2561 differentially expressed genes, 5 upregulated and 2556 downregulated; 
- HGHF: 7994 differentially expressed genes, 1724 upregulated and 6270 
downregulated. 
 
Venn diagrams using the program Gene Venn (http://genevenn.sourceforge.net/) were 
used to identify differentially expressed genes common to more than one condition, 
hence to identify logical relations between our sets of data. Venn diagrams are 
representations useful to identify relationships between groups of objects. 
Figure 5.2 represents the Venn diagrams of the number of genes differentially expressed 
in the 3 different conditions compared to control, with a p value of p<0.05. This analysis 
shows that most of the genes that were differentially expressed in high glucose 
compared to control (red diagram) were also differentially expressed in condition of 
high glucose/high fat (green diagram) (2568 genes). Similar results were obtained for 
genes differentially expressed in high fat compared to control (yellow diagram) (2463 
genes). 4377 genes were differentially expressed only in high glucose/high fat, whereas 
1415 genes were differentially expressed in all the three conditions. These results 
indicate that, in most of the cases, high glucose alone or high fat alone did not affect 
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gene expression significantly but the combination of high glucose and high fat 
cooperated in altering gene expression. In very few cases (8) high glucose alone and 
high fat alone had opposite effects on gene expression, leading to a null effect when 
glucose and high fat were used together. 
 
 
Figure 5.2 Venn diagrams showing the correlation between differentially expressed genes 
in the 3 conditions compared to control with p<0.05. The red diagram represents the genes 
differentially expressed in HG vs C, the yellow diagram the genes in HF vs C and the green 
diagram the genes in HGHF vs C. The numbers corresponds to the differentially expressed 
genes with a p value p<0.05. 
 
The distribution of genes expressions in in the different conditions compared to control 
conditions was then investigated using scatter plots. Figure 5.3 shows the scatter plot of 
statistical significant genes (p<0.05) in each of the three experimental conditions 
compared to control. Each graph represents the comparison between the expressions of a 
gene in an experimental condition to its expression in control conditions. The red line 
corresponds to control conditions and each blue dot represents a gene: dots above the 
red line are genes overexpressed; dots below the red line are downregulated. 
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High glucose (Figure 5.3 A) triggered both upregulation and downregulation of genes, 
but expression values were not very different from control conditions. High fat 
treatment (Figure 5.3 B) induced in general downregulation of gene expressions but 
values were very similar to control conditions. Finally, in conditions of high 
glucose/high fat (Figure 5.3 C), genes were both upregulated and downregulated and 
expression values were more different and spread from control conditions.  
 
These results are in line with our previous experiments showing that the combination of 
high glucose and high fat is able to affect more β-cell function than each condition 
alone. Examples of this cooperation can be seen in the impairment of insulin secretion 
and expression and in the increase of CD40 and TRAFs expression in glucolipotoxicity.  
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Figure 5.3 Scatter plots of differentially expressed genes in comparison to control. A) High 
glucose vs control; B) High fat vs control; C) High glucose/high fat vs control. Each graph 
represents the comparison between the expression of a gene in each condition and the expression 
in control conditions. The red line corresponds to control conditions. Each dot represents a gene: 
dots above the red line are genes overexpressed, dots below the red line are downregulated. 
Values below 10 are considered as baseline and not represented. Only genes with a significant p 
value of p<0.05 are represented. 
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5.3.1 Hierarchical clustering 
 
In order to determine how these different conditions relate to each other, according to 
gene expression, hierarchical clustering was performed. Hierarchical clustering is a 
method to visualise correlation between different samples and conditions. The program 
regroups genes with a similar pattern of expression, which will be represented close to 
each other. The bigger is the distance between two genes or conditions, the bigger is the 
difference among them. 
Figure 5.4 represents the cluster plots of the differentially expressed genes with an 
adjusted p value p<0.001 in high glucose vs control conditions (A), high fat vs control 
(B) and high glucose high fat vs control (C). The cluster analysis was performed by Dr. 
Rob Lowe (Blizard Institute). In Figure 5.4 the rectangles represent each gene and the 
colour indicates the level of its expression, ranging from blue (low expression) to red 
(high expression). The expression of each significant gene is considered in each of the 
12 experimental samples independently. 
In Figure 5.4A (HG vs C), the first rows represent genes overexpressed in high glucose 
and the lower part of the graph represents genes downregulated in high glucose. Control 
and high fat conditions clustered together, while high glucose and high glucose/high fat 
clustered together, indicating that most of the genes differentially expressed in high 
glucose were also differentially expressed in high glucose high fat. Not all these genes 
were differentially expressed also in high fat conditions. 
Among the genes differentially expressed in high fat vs control (Figure 5.4B) with 
p<0.001, nearly all the genes were downregulated. In this case, high glucose, high fat 
and high glucose/high fat clustered together, indicating that, when genes were 
differentially expressed in high fat, with high probability they were also differentially 
expressed in the other conditions compared to control. 
Figure 5.4C represents the cluster plot of the genes differentially expressed in high 
glucose/high fat. The first rows represent genes that were upregulated with a p value 
p<0.001. This analysis shows that high fat conditions presented a pattern of colour 
similar to controls. High glucose conditions started to differentiate from control, while 
high glucose/high fat conditions contained the most varied expression levels compared 
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to controls. The rows in the second part of the diagram represent genes that were 
downregulated in glucolipotoxicity. Downregulation was similar for conditions of high 
glucose and high fat, while high glucose/high fat conditions together showed the most 
effective downregulation. 
 
       A 
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Figure 5.4 Hierarchical clustering of differentially expressed genes with p value p<0.001. 
The rectangles represent each gene (rows) and the colour indicates the level of its expression, 
ranging from blue (low expression) to red (high expression). The expression of each significant 
gene is considered in each of the 12 experimental samples. A) High glucose vs control B) High 
fat vs control C) High glucose high fat vs control. (C=control, G=high glucose, F=high fat, 
GF=high glucose high fat). 
 
In conclusion, the hierarchical clustering shows that high glucose and high fat alone are 
able to change genes expression, but the combination of these conditions has additional 
effect. 
These results are in line with the cluster plots shown previously, confirming that most of 
the genes are downregulated by the treatments and that the combination of high 
glucose/high fat leads to a stronger effect than each condition alone. 
It is also worth noticing that this downregulation is not caused by a toxic effect or by β-
cell death, as MTT assays and caspase 3 activity assays (Chapter 3, Figure 3.2 and 3.4) 
revealed no activation of apoptosis in these experimental conditions. Only the function 
of the β-cell resulted affected at the time point considered.  
Clustering showed us that expression profiles of high fat samples are similar to control, 
while the combination of high glucose/high fat gives the highest difference in expression 
changes. 
Considering that most of genes differentially expressed in high glucose alone and high 
fat alone are also differentially expressed in the combination of the two conditions, in all 
further analyses we focussed on the comparison between high glucose/high fat and 
control conditions. 
 
5.4 Pathway analysis 
 
Once the list of genes differentially expressed in our experimental conditions was 
obtained, we decided to determine which pathways are mainly affected by 
glucolipotoxic conditions. To assess this, we used the programs Panther 
(http://www.pantherdb.org/) and Metacore (http://thomsonreuters.com/metacore/) to 
identify enriched pathways, enriched functions and associated diseases. 
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5.4.1 Identification of enriched pathways 
 
The program Panther allows the identification of enriched pathways, molecular 
functions, biological processes, cellular components and protein classes among a given 
list of genes. In this case, the list of genes differentially expressed in conditions of high 
glucose/high fat in comparison to control with a statistical significance of p<0.05 was 
uploaded to the program. The program calculates the number of genes that are enriched 
with a specific pathway and gives also the statistical significance of any enrichment. 
Enrichment is considered statistical significant when there are more genes in the list 
associated with a particular pathway than it would be expected by chance based on the 
total number of genes associated with that pathway. Table 5.1 lists the significantly 
enriched pathway (p value p<0.05). In the table, the number of genes for each pathway 
that would be expected by chance are also indicated (“expected”), compared to the 
number of genes of that pathway that are differentially expressed in our experiment. The 
list includes pathways involved in glucose metabolism (glycolysis), inflammation 
mediated by chemokine and cytokine signalling pathways, and vesicle trafficking.  
 
PATHWAYS EXPECTED 
HGHF 
P<0.05 
P VALUE 
Glycolysis 44.23 12 3.78 E-10 
Blood coagulation 15.91 35 9.17 E-09 
Heterotrimeric G protein signaling 
pathway-Gi alpha and Gs alpha 
mediated pathway 
42.95 68 2.34 E-05 
Huntington disease 73.81 46 2.42 E-04 
Cadherin signalling pathway 48.68 74 3.27 E-04 
Heterotrimeric G protein signalling 
pathway-Gq alpha and Go alpha 
mediated pathway 
35.63 57 4.18 E-04 
Nicotinic acetylcholine receptor 
signalling pathway 
23.86 40 5.72 E-04 
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Inflammation mediated by chemokine 
and cytokine signalling pathway 
76.68 100 1.54 E-03 
Synaptic vesicle trafficking 8.91 17 5.81 E-03 
Endothelin signalling pathway 26.09 39 1.01 E-02 
Ionotropic glutamate receptor pathway 14.95 25 1.07 E-02 
Thyrotropin-releasing hormone 
receptor signalling pathway 
13.68 23 1.07 E-02 
Phenylethylamine degradation 1.91 6 1.31 E-02 
Dopamine receptor mediated 
signalling pathway 
18.77 29 1.35 E-02 
Plasminogen activating cascade 5.41 11 1.69 E-02 
Alzheimer-disease-presenilin pathway 38.18 51 2.27 E-02 
Wnt signalling pathway 92.90 112 2.68 E-02 
Integrin signalling pathway 58.22 73 2.88 E-02 
Muscarinic acetylcholine receptor 1 
and 3 signalling pathway 
14.32 22 3.36 E-02 
5HT2 type receptor mediated 
signalling pathway 
15.27 23 3.52 E-02 
Nicotine pharmacodynamics pathway 11.45 18 3.85 E-02 
 
Table 5.1 List of enriched pathways in HGHF vs C p<0.05. 
 
As expected, most of the identified pathways were associated to diabetes or its 
molecular complications: 
 Glycolysis is the metabolic pathway that converts glucose to pyruvate, so this 
process is strictly connected to the amount of glucose in the blood. In addition, 
insulin either directly or indirectly increases the rate of glycolysis [339], and in 
β-cells it has been observed that chemical glycolytic oscillations are consistent 
with insulin oscillations at both high and low initial concentrations of glucose 
[340]. 
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 Cadherin signalling pathway, inflammation mediated by cytokines and 
chemokines and endothelin signalling pathway are all involved in the 
inflammatory process induced by chronic exposure of the β-cell to high 
concentrations of glucose and fatty acids. A detailed explanation of the role of 
inflammation in T2D is described in chapter 1.4.  
 Nicotinic acetylcholine receptors are known to interact with anti-inflammatory 
pathways and have been implicated in the control of appetite and body weight, as 
well as lipid and energy metabolism [341]. It has been shown that acetylcholine 
can bind its receptor in the β-cells, triggering intracellular pathways which 
culminate in the rise of intracellular calcium and insulin secretion [342].  
 Vesicle trafficking is also involved in the development of T2D, especially in 
relation to insulin exocytosis. Disruption of the microtubule network responsible 
of vesicle trafficking impairs granule movement and the exocytotic response [9]. 
 Altered glutamatergic transmission may contribute to the impaired insulin 
secretory response in the β-cell, as it has been shown that glutamate pathways 
are involved in insulin secretion [343].  
 Dopamine receptor signalling is implicated in glucolipotoxicity. The number of 
dopaminergic receptors as well as central dopaminergic transmission are 
increased in diabetes [344]. It has been shown that dopamine D2-like receptors 
are expressed in the pancreatic β-cell and mediate inhibition of insulin secretion 
[345]. 
 Alzheimer’s disease pathway can be connected to T2D and glucolipotoxicity 
could influence the expression of molecules involved in this pathway in the β-
cell. This can be explained by the fact that the pancreas is a highly innervated 
organ that shares a number of molecular similarities with brain at the level of 
transcriptome and proteome. Diabetes could increase the likehood of 
Alzheimer’s disease, due to the impact of insulin abnormalities, insulin 
resistance and advanced glycation end products on the development of amyloid 
plaques and neurofibrillary tangles. T2D and Alzheimer’s disease are both 
characterised by localised amyloid deposits that progress during the course of the 
disease [346].  
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 Wnt signalling pathway plays an important role in intestinal tumorigenesis but it 
has also been associated to T2D. Wnt can increase cellular sensitivity to insulin, 
regulating the transcription of IRS-1 [347], therefore the disruption of this 
pathway could be involved in the development of diabetes. In addition GLP-1 
stimulates Wnt signalling in pancreatic β-cell, enhancing cell proliferation; thus 
positive feedback between GLP-1 and Wnt signalling may result in increased 
proliferation, and inhibition of apoptosis in pancreatic β-cells [348]. Wnt 
signalling is also a strong activator of mitochondrial biogenesis, which leads to 
increased production of ROS known to cause DNA and cellular damage [347]. 
 5HT2 type receptor signalling pathway has been reported to have lipolytic action 
on adipocytes, increasing plasma level of free fatty acids. It has also been shown 
that 5HT2 receptors are expressed in pancreatic β-cells and they have a role in 
the inhibition of insulin secretion [349]. 
 Signalling pathways associated to protein G, receptors and metabolism result to 
be implicated in glucolipotoxicity. This is explained by the fact that β-cell 
function and insulin production and release are related to many signalling and 
metabolic pathways (glucose metabolism, IGF pathways, PI3K pathway), which 
involve signalling through protein G and receptors. As a consequence, disruption 
of these pathways leads to a condition of impairment of insulin production and 
secretion. 
 Thyrotropin-releasing hormone receptor signalling pathway will be further 
investigated in chapter 6 of this thesis, as a future topic of study. 
 
In summary, this pathway analysis revealed that glucolipotoxicity is able to change the 
expression of molecules involved in pathways related to inflammation and signalling in 
T2D. This confirms the fact that our experimental conditions resemble the detrimental 
conditions of T2D and its molecular complications. 
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5.4.2 Identification of enriched molecular functions 
 
Figure 5.5 shows the enriched molecular functions between our list of differentially 
expressed genes in high glucose/high fat compared to controls and with a p value 
p<0.05. This analysis indicates that among our significantly differentially expressed 
genes there were more genes associated with the molecular functions represented in the 
pie chart than it would have been expected by chance. 
The functions affected in glucolipotoxicity were mainly involved in catalytic activity, 
receptor activity and protein binding transcription factor activity. This is in line with the 
fact that many molecules implicated in the impairment of insulin secretion and 
production are involved in signalling pathways, and consequently receptor activity and 
catalytic activity are obviously impaired. Moreover, a differential expression of 
transcription factors and proteins that regulate their binding are required to induce gene 
expression changes. 
 
 
Figure 5.5 Enriched molecular functions in HGHF vs C with p<0.05. The pie chart 
represents the enriched molecular functions among the differentially expressed genes in high 
glucose/high fat compared to control with a p value p<0.05. 
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5.4.3 Identification of enriched biological processes 
 
Figure 5.6 shows the enriched biological processes involved in conditions of 
glucolipotoxicity. This analysis indicates that among our significant differentially 
expressed genes there were more genes associated with the biological processes 
represented in the pie chart than it would have been expected by chance. 
The pie chart reveals that the biological processes mostly affected were apoptotic 
processes, cellular processes, metabolic processes, showing that there was an 
enrichment of processes involved in metabolism and cellular activity. This can be 
explained by the impairment of the β-cell function, activity and insulin metabolism in 
glucolipotoxicity. In addition, the detrimental effects of glucolipotoxicity start leading to 
the activation of apoptotic pathways, culminating with β-cell death. Our results showed 
no activation of apoptosis in the experimental conditions tested, although we cannot rule 
out the activation of early stages of the apoptotic pathway, which has yet to have an 
impact on cell viability during the time period considered. 
 
 
Figure 5.6 Enriched biological processes in HGHF vs C with p<0.05. The pie chart 
represents the enriched biological processes among the differentially expressed genes in high 
glucose high fat in comparison to control with a p value p<0.05. 
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5.4.4 Identification of enriched cellular components 
 
Figure 5.7 shows the enriched cellular components among the genes differentially 
expressed in our conditions. This analysis indicates that among our significant 
differentially expressed genes there were more genes located in the cellular components 
represented in the pie chart than it would have been expected by chance. 
Most of the molecules differentially expressed were located in organelles or on the 
membrane. This is in line with the finding that many of the molecules involved in 
glucolipotoxicity are signalling molecules or receptors, so they can be located in the 
membrane. Moreover, considering that glucolipotoxicity has also effect on ROS 
production and energy, it can affect the expression of mitochondrial molecules. 
Transcription factors and molecules involved in regulating their binding are located in 
the nucleus. 
 
 
Figure 5.7 Enriched cellular components in HGHF vs C with p<0.05. The pie chart 
represents the enriched cellular components among the differentially expressed genes in high 
glucose/high fat in comparison to control with a p value p<0.05. 
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5.4.5 Identification of enriched protein classes 
 
Table 5.2 shows the classes of the molecules involved in glucolipotoxicity. This analysis 
indicates that among our significant differentially expressed genes there were more 
genes associated with the protein classes listed in the table than it would have been 
expected by chance. Proteins differentially expressed in high glucose/high fat compared 
to control were mainly receptors, nucleic acid binding molecules, signalling molecules 
and transporters. This is consistent with the fact that the molecules involved in 
glucolipotoxicity are implicated in signalling pathways, in regulating transcription 
factors binding and in molecular transport.  
 
PROTEIN CLASS P VALUE 
Receptor 1.88 E-38 
G-protein coupled receptor 1.67 E-24 
RNA binding protein 3.54 E-20 
Ribosomal protein 1.54 E-18 
Signalling molecule 1.28 E-17 
Nucleic acid binding 2.91 E-17 
Transporter 8.91 E-16 
Immunoglobulin 1.13 E-13 
Ion channel 2.72 E-13 
Cell adhesion molecule 4.58 E-11 
 
Table 5.2 Enriched protein classes in HGHF vs C with p<0.05 
 
5.4.6 Identification of associated diseases  
 
Interestingly, the molecules resulted differentially expressed in our experiment were 
also found to be important in other diseases, therefore they are indicative of the presence 
of a pathologic condition. The predicted associated diseases to our experimental 
conditions of glucolipotoxicity were identified using the program Metacore. Table 5.3 
lists the first 50 diseases associated with the list of differentially expressed molecules in 
200 
 
HGHF vs C with a p value p<0.05. The table indicates also the enrichment, expressed as 
the ratio of the number of genes that would be associated to each disease by chance 
compared to the number of the differentially expressed genes in our list associated with 
the disease.  
The table indicates the presence of diseases associated with inflammation, obesity, T2D 
and insulin resistance, which confirms that our experimental conditions influenced the 
expression of molecules implicated in diabetes and insulin resistance. In addition, the 
list includes other diseases associated with diabetes, which may have a common 
aetiology, for example, cardiovascular diseases and hypertension. These are generated 
mainly by the inflammatory process and oxidative stress characteristic of T2D. 
In addition, Table 5.3 lists many forms of neoplasm associated with our conditions of 
glucolipotoxicity. Chronic exposure of the β-cell to high concentrations of glucose and 
fatty acids can alter the expression of molecules involved in the aetiology of cancer and 
epidemiologic evidence suggests that people with diabetes are at significantly higher 
risk for many forms of cancer [350]. Several studies indicate an association between 
diabetes and the risk of liver, pancreas, endometrium, colon/rectum, breast and bladder 
cancer. Mortality is also moderately increased in subject with diabetes. Common risk 
factors such as age, obesity, physical inactivity and smoking may contribute to increased 
cancer risk in diabetic patients. In addition, hyperinsulinemia most likely favours cancer 
in diabetic patients as insulin is a growth factor with metabolic and mitogenic effects, 
and its action in malignant cells is favoured by mechanisms acting at both the receptor 
and post-receptor level [351]. 
As explained before, also Alzheimer’s disease is connected with diabetes, for the 
similarity of the β-cells to neurons, which could justify the common aetiology of the two 
diseases. 
Moreover, some autoimmune and inflammatory diseases are listed, including 
Rheumatoid Arthritis, Systemic Lupus Erythematosus and Multiple Sclerosis, 
confirming that conditions of glucolipotoxicity generate the activation of an 
inflammatory status. 
In conclusion, our experimental system supports many of the known molecular changes 
evolving or associated with T2D. 
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ASSOCIATED DISEASES RATIO P VALUE 
Lung Neoplasms  5326/16891 1.23 E-71 
Neoplasms 1520/20277 3.38 E-36 
Arthritis, Rheumatoid  629/1592 2.81 E-35 
Wounds and Injuries  400/980 6.81 E-34 
Stomach Neoplasms  1459/3803 9.20 E-34 
Breast Neoplasms  2995/8967 6.52 E-32 
Inflammation 392/898 8.36 E-31 
Prostatic Neoplasms  3287/9711 1.90 E-30 
Rectal Neoplasms  2329/6608 3.68 E-30 
Colorectal Neoplasms  1526/9302 9.89 E-30 
Multiple Sclerosis 830/2278 1.01 E-28 
Hypertension  304/606 1.76 E-25 
Lupus Erythematosus, Systemic  411/928 2.11 E-23 
Skin Neoplasms 1612/4478 2.62 E-22 
Carcinoma, Non-Small-Cell Lung  1139/3021 4.34 E-22 
Asthma 647/1608 8.66 E-22 
Arthritis 239/1798 1.52 E-21 
Sjogren's Syndrome  286/584 5.43 E-21 
Depressive Disorder, Major  428/966 1.14 E-20 
Endometrial Neoplasms  3350/10214 1.35 E-20 
Fibrosis 226/498 6.61 E-20 
Pulmonary Disease, Chronic 
Obstructive  
468/1103 2.58 E-19 
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Laryngeal Neoplasms  876/2278 3.23 E-19 
Melanoma  1278/3867 5.09 E-19 
Cardiovascular Diseases  191/3605 3.87 E-18 
Coronary Artery Disease  248/508 5.19 E-18 
Myocardial Infarction  247/508 1.15 E-17 
Infection  416/1186 2.66 E-17 
Melanoma, Cutaneous Malignant  405/938 2.96 E-17 
Kidney Neoplasms  2892/9603 3.14 E-17 
Obesity 438/1069 4.00 E-17 
Colonic Neoplasms  645/1659 3.12 E-16 
Neoplasm Metastasis  312/704 5.46 E-16 
Bipolar Disorder  316/706 5.46 E-16 
Idiopathic Pulmonary Fibrosis  136/243 7.97 E-16 
Migraine Disorders  75/111 1.14 E-15 
Arteriosclerosis 195/709 1.49 E-15 
Ovarian Neoplasms  1214/3403 2.21 E-15 
Diabetes Mellitus, Type 2  601/1529 2.50 E-15 
Carcinoma  660/5784 4.50 E-15 
Glioblastoma 994/2714 6.01 E-15 
Carcinoma, Ductal, Breast  578/1470 1.70 E-14 
Coronary Disease  181/658 5.03 E-14 
Stroke 176/406 6.32 E-14 
Mouth Neoplasms 1303/4289 6.32 E-14 
Infarction 139/261 7.17 E-14 
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Alzheimer Disease  415/1257 1.37 E-13 
Glioma 256/5175 2.03 E-13 
Insulin Resistance  217/775 1.59 E-12 
Bronchitis, Chronic  48/63 1.60 E-12 
 
Table 5.3 Associated diseases in HGHF vs C p<0.05. 
 
5.5 Comparison with QTL and GWAS data  
 
QTLs (Quantitative Trait Loci) are stretches of DNA containing or linked to genes that 
are believed to make a significant contribution to the expression of a particular 
phenotype. QTLs are usually associated with more than one gene and with the 
environment, and include several medically significant traits (e.g. blood pressure, 
obesity). 
In human, association of complex common diseases to a particular chromosomal region 
uses the differential frequency of single nucleotide polymorphisms (SNPs) between 
patients compared to controls. The study of such SNP variations genome wide, known 
as GWAS (Genome Wide Association Study), has allowed researchers to identify genes 
as well as chromosomal regions associated with complex diseases like diabetes. 
In order to investigate if the differentially expressed genes in glucolipotoxicity are 
associated with known diabetic genes or regions, we studied their connection to known 
data of QTL regions or GWAS studies. 
 
In order to understand if the differentially expressed genes are located in the rat diabetic 
QTLs regions, which are regions of the genome that have been associated to diabetes, 
we used the database RGD (Rat Genome Database: http://rgd.mcw.edu/) to localise 
diabetic QTLs on the rat chromosomes. Figure 5.8A represents the localisation of 110 
QTLs associated with diabetes (blue bars). Figure 5.8B represents the localisation of the 
first 500 statistical significant differentially expressed genes of our list (red bars). First, 
it must be noticed that these significant genes were spread all over the 21 rat 
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chromosomes, therefore there was not a particular chromosome enrichment. In addition, 
they mainly overlapped with the rat diabetic QTLs, therefore they were located in 
regions of the genome known to be associated with diabetes.  
 
 
 
Figure 5.8 Association of differentially expressed genes in HGHF vs C to Rat diabetic 
QTLs. A) Localisation of 110 QTLs associated with diabetes (blue bars); B) Localisation of the 
top 500 differentially expressed genes in high glucose high fat in comparison to control (red 
bars). 
 
Permutation statistical test showed a small but significant enrichment (1.06, p<0.001) of 
our differentially expressed genes in the QTLs, indicating that these QTLs regions 
include more of our glucolipotoxicity induced genes than it would be observed by 
chance.  
 
Similarly, we investigated if known GWAS genes were present in our list of 
differentially expressed genes in glucolipotoxicity. In particular, we checked for the 
presence of genes associated with T2D in the NHGRI GWAS catalog 
(www.genome.gov/gwastudies), with a p value <10-8. Out of 61 genes present in the 
catalog, 26 were differentially expressed in our experiment with statistical significance. 
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Considering that in our experiment we obtained 7994 differentially expressed genes in 
glucolipotoxicity out of 24000 rat genes (1/3), the same proportion would be expected 
by chance in the GWAS list (20 genes). With this calculation, there was an enrichment 
of our glucolipotoxicity induced genes in the GWAS list. However, the analysis with a 
permutation test did not give a significant enrichment.  
Table 5.4 shows the list of GWAS genes differentially expressed in our experimental 
conditions, with the corresponding fold change and p value in conditions of high 
glucose/high fat compared to controls. Many of the important GWAS genes associated 
with diabetes are listed in this table and are differentially expressed in conditions of 
glucolipotoxicity with high fold change and highly significant p value. This result 
suggests the involvement of the specific genes identified through GWAS studies in the 
development of T2D. 
 
GWAS GENE 
FOLD 
CHANGE 
P VALUE 
MADD 
(MAP-Kinase Activating Death Domain) 
1.37 0.02 
TCF7L2 
(Transcription factor 7-like 2) 
0.46 0.05 
KCNQ1 
(Potassium Voltage-Gated Channel, KQT-Like 
Subfamily, Member 1) 
0.70 0.02 
PCSK1 
(Proprotein Convertase Subtilisin/Kexin Type 1) 
1.51 0.00557 
IGF2BP2 
(Insulin-Like Growth Factor 2 MRNA Binding 
Protein 2) 
0.018 4.90 E-08  
HHEX 
(Hematopoietically Expressed Homeobox) 
0.12 0.000213 
MTNR1B 
(Melatonin Receptor 1B) 
0.01 2.17 E-05 
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PDE8B 
(Phosphodiesterase 8B) 
0.31  1.35 E-08 
AP3S2 
(Adaptor-Related Protein Complex 3, Sigma 2 
Subunit) 
1.48 0.03 
CAMK1D 
(Calcium/Calmodulin-Dependent Protein Kinase 1D) 
Inf 1.65 E-06 
KLF14 
(Krupper-like Factor 14) 
0.006 1.51 E-06 
LARP6 
(La Ribonucleoprotein Domain Family, Member 6) 
Inf 3.19 E-05 
PRC1 
(Protein Regulator Of Cytokinesis 1) 
1.52 0.017 
HNF4A 
(Hepatocyte Nuclear Factor 4, Alpha) 
2.09 0.0022 
DUSP9 
(Dual Specificity Phosphatase 9) 
0.016 0.001148 
LGR5 
(Leucine-Rich Repeat Containing G Protein-Coupled 
Receptor 5) 
0.13 8.74 E-05 
FAH 
(Fumarylacetoacetate Hydrolase) 
0.33 0.000213 
RND3 
(Rho Family GTPase 3) 
1.85 0.002 
ADAMTS9 
(A Disintegrin And Metalloproteinase with 
Thrombospondin Motif 9) 
0.19 0.0026 
WFS1 
(Wolfram Syndrome 1) 
0.58 0.001454 
ANK1 0.43 7.95 E-07 
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(Ankyrin 1) 
KCNK16 
(Potassium Channel, Subfamily K, Member 16) 
2.93 1.08 E-14 
NOTCH2 
[Notch (Drosophila) Homolog 2] 
0.42 2.13 E-06 
RBMS1 
(RNA Binding Motif, Single Stranded Interacting 
Protein 1) 
0.49 0.000636 
RPL9P23 
(Ribosomal Protein L9 Pseudogene 23) 
1.47 0.006 
APOB 
(Apolipoprotein B) 
0.15 0.000449 
 
Table 5.4 Association to known GWAS genes. 
 
The presence of TCF7L2, IGF2BP2, NOTCH2, WFS1, HHEX, ADAMTS9 is of high 
importance, as specified below. 
 TCF7L2 is a transcription factor involved in the Wnt signalling pathway and it is 
implicated in blood glucose homeostasis. Potential mechanisms by which 
TCF7L2 variants influence T2D include its role in adipogenesis, myogenesis and 
pancreatic islet development, as well as in β-cell survival and insulin secretory 
granules function [352]. It is also involved in the transcriptional regulation of the 
genes encoding for proglucagon and glucagone like peptides GLP-1 and GLP-2, 
which play a role in postprandial insulin secretion. 
 IGF2BP2 encodes a member of the IGF-II mRNA binding protein (IMP) family. 
It binds to the 5’ UTR of the IGF-II mRNA and regulates IGF-II translation. In 
β-cells, it is important for the regulation of their function [353]. 
 NOTCH2 is generally involved in development and cell fate decision, but there 
is increasing evidence that NOTCH2 signalling is important also for immune 
functions. In particular, NOTCH2 signalling pathway has been shown to 
suppress the TLR-induced IL-6 and TNF-α expression in macrophages. 
NOTCH2 genetic variants can increase the inflammatory response in T2D [354]. 
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It has shown to be expressed in pancreatic β-cells, where it regulates pancreas 
development [355]. 
 WFS1 is a transmembrane protein that participates in the regulation of calcium 
homeostasis, by modulating the filling state of the endoplasmic reticulum Ca
2+
 
stores. Genetic variants of WFS1 can alter calcium dynamics involved in insulin 
granules secretion. In β-cells, it has been shown to be implicated in the 
regulation of insulin secretion [356]. 
 HHEX encodes a member of the homeobox family of transcription factors 
involved in hematopoietic differentiation. It is also expressed in the embryonic 
ventral-lateral foregut that gives rise to the ventral pancreas and the liver.  This 
part of the pancreas is the major site of pancreatic polypeptide production. 
Therefore, it is possible that SNPs in this gene affect hormone’s production 
during embryogenesis and adulthood, inducing the effects on insulin release. It 
has been shown that HHEX is associated with decreased β-cell sensitivity to 
glucose [357]. 
 ADAMTS9 is a disintegrin and metalloproteinase with trombospondin motifs. It 
is implicated in the cleavage of proteoglycans, the control of organs shape during 
development and the inhibition of angiogenesis. It has also a protease-
indipendent function in promoting the transport from the endoplasmic reticulum 
to the Golgi apparatus of a variety of secretory cargos [358]. 
The expression level of these genes is represented in Figure 5.9. 
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Figure 5.9 Expression level of GWAS genes. RNAseq was performed on the RNA of INS-1 
cells treated with the 4 experimental conditions. Values are mean + SD of number of reads 
associated with a particular condition. 
 
5.6 Identification of the top hits 
 
We then focussed on the characterisation of the top hits genes, which are the genes 
differentially expressed in high glucose/high fat compared to control with the highest 
adjusted p value. Table 5.5 lists the top 10 hits in our list obtained from comparison 
between high glucose/high fat and control conditions. 
 
GENES 
FOLD 
CHANGE 
P VALUE 
SLC38A4 
(Solute Carrier Family 38, Member 4) 
4.9 4.67E-30 
SEPP1 
(Selenoprotein P, Plasma 1) 
6.6 1.06E-28 
PDE2A 
(Phosphodiesterase 2A, CGMP-
Stimulated) 
4.7 2.90E-27 
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SLC16A6 
(Solute Carrier Family 16, Member 6) 
0.2 7.77E-22 
GPR119 
(G-protein Coupled Receptor 119) 
7.1 2.05E-21 
ABCA4 
(ATP-Binding Cassette, Sub-Family A 
(ABC1), Member 4) 
Inf 2.63E-20 
DNAJC22 
(DnaJ (Hsp40) Homolog, Subfamily C, 
Member 22) 
3,7 2.63E-20 
VOM2R62 
(vomeronasal 2 receptor, 62) 
Inf 2.63E-20 
HRSP12 
(Heat-Responsive Protein 12) 
3.5 1.73E-18 
COL15A1 
(Collagen, Type XV, Alpha 1) 
Inf 3.25E-18 
 
Table 5.5 Top hit genes in the comparison HGHF vs C p<0.05. 
 
Most of these genes are known to be associated directly or indirectly with diabetic 
conditions. 
 SLC38A4 is a sodium dependent amino acids transporter. It is found 
predominantly in the liver. A SNP in this gene is associated with hyperglycemia 
[359]. 
 SEPP1 is a selenoprotein responsible for some of the extracellular anti-oxidant 
defense properties of selenium or it might be involved in the transport of 
selenium. It has been shown that hepatic SEPP1 mRNA levels correlated with 
insulin resistance in humans and genetic variants of this gene are associated with 
fasting insulin [360]. In β-cells, its expression is modulated by high glucose and 
it is associated with the anti-oxidant protection of the β-cells [361]. 
 PDE2A is a cyclic nucleotide phosphodiesterase with a dual-specificity for the 
second messangers cAMP and cGMP, key regulators of many important 
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physiological processes. It has also a potential role in regulating calcium channel 
activity [362], and it may be involved in the calcium dynamics regulating insulin 
exocytosis in the β-cell. 
 SLC16A6 is a proton-linked monocarboxylate transporter, which catalyses the 
rapid transport across the plasma membrane of many monocarboxylates such as 
lactate and pyruvate.  
 GPR119 is a G-protein coupled receptor highly expressed in the pancreatic islets. 
The activation of GPR119 is associated to glucose-dependent insulin secretion in 
pancreatic β-cells, along with glucose-dependent insulinotropic peptide (GIP) 
and GLP-1 release in intestinal K cells and L cells respectively [363]. 
 ABCA4 is an ATP binding cassette mainly expressed in the retina; its expression 
in the β-cell could be explained by the similarity in the proteome of β-cells and 
neurons. 
 DNAJC22 is a membrane protein associated with a rat T2D QTL. 
 VOM2R62 encodes for a vomeronasal receptor, involved in G protein coupled 
receptor signalling pathway. It is associated to a QTL for insulin level and 
diabetes. 
 HRSP12 is an endoribonuclease responsible for the inhibition of the translation 
by cleaving mRNA. It is associated with diabetic QTLs. 
 COL15A1 encodes the alpha chain of type XV collagen, which is mainly 
expressed in basement membrane zones. It may function in the adhesion of 
basement membranes to underlying connective tissue stroma. 
The differential expression of the genes listed is represented in Figure 5.10. 
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Figure 5.10 Expression level of top hit genes. RNAseq was performed on the RNA of INS-1 
cells treated with the 4 experimental conditions. Values are mean + SD of number of reads 
associated with a particular condition. 
 
5.7 Discussion 
 
The study of the transcriptome allowed a deep understanding of the molecular changes 
implicated in the onset of many pathologic conditions and the combination with high-
throughput techniques helped gaining a more complete view of all the transcriptome 
changes in a single experiment. 
In this thesis, RNAseq technology was used to characterise the molecular changes in the 
β-cell after exposure to high concentrations of glucose and fatty acids. In particular, the 
main aim was to discover new molecules that could be involved in the impairment of β-
cell function. We initially focussed our attention on the general characterisation of the 
experimental results, performing clustering and pathway analysis, in order to identify 
the principal mechanisms affected by glucolipotoxicity. 
INS-1 cells were used as an experimental system and they were incubated for 72 h in 
four different conditions: control, high glucose (27 mM glucose), high fat (200 µM oleic 
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acid, 200 µM palmitic acid), high glucose/high fat (27 mM glucose, 200 µM oleic acid, 
200 µM palmitic acid). 
2701 genes resulted differentially expressed in high glucose, 2561 in high fat and 7994 
in high glucose high fat, with an adjusted p value of p<0.05. Most of the genes were 
downregulated, suggesting that conditions of glucolipotoxicity block the expressions of 
numerous genes, including insulin. In addition, more than 95% of the genes 
differentially expressed in high glucose alone, or high fat alone, were also differentially 
expressed in high glucose/high fat (Figure 5.2). For this reason, the subsequent pathway 
analysis was performed using the combination of the two treatments. The high 
glucose/high fat vs control comparison contained the highest number of differentially 
expressed genes and this was the condition that clustered more differently from control 
(Figure 5.4). This result is consistent with the fact that glucose and fatty acids act 
together to impair β-cell function. This is consistent with our previous results on insulin 
secretion and content, on CD40 and TRAFs upregulation, which showed that 
impairment of these processes was potentiated by the combined incubation of glucose 
and fatty acids. Furthermore, this is also consistent with previous studies showing the 
synergism between fatty acids and glucose [107]. 
The fact that the experimental conditions used are representative of the molecular 
changes that affect the β-cell during the progression to diabetes was confirmed by 
pathways analysis (Table 5.1). Pathways involved in glucose metabolism (glycolysis), in 
inflammation mediated by chemokines and cytokines signalling pathways and vesicle 
trafficking were significantly affected by the treatments. These are all mechanisms 
directly involved in T2D progression, as they are connected to glucose or insulin 
trafficking, or to the inflammatory process generated in the β-cell under glucolipotoxic 
conditions [144, 154]. In addition, pathways that are indirectly involved in diabetes also 
resulted significantly affected. Examples of these pathways are glutamatergic 
neurotransmission, which may contribute to the impaired insulin secretory response in 
T2D and Wnt signalling pathway which is involved in cell sensitivity to insulin and in 
β-cell proliferation. Interestingly, another pathway that resulted affected by 
glucolipotoxicity involves molecules implicated in Alzheimer’s disease. The pancreas is 
a highly innervated organ that shares a number of molecular similarities with brain at the 
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level of transcriptome and proteome. T2D and Alzheimer’s disease are both 
characterised by localised amyloid deposits that progress during the course of the 
disease. In addition diabetes could increase the likehood of Alzheimer’s disease, due to 
the impact of insulin abnormalities, insulin resistance and advanced glycation end 
products on the development of neural amyloid plaques and neurofibrillary tangles. This 
functional connection between pancreas and brain could be the explanation also of the 
presence, in the β-cell, of other molecular pathways (thyroid pathway) specific of the 
brain (Chapter 6).  
These results are in line with the pathway analysis performed for the previous 
Affymetrix experiment (Chapter 3, Figure 3.9) and with microarrays studies performed 
by other research groups. Specifically, it has been shown differential expression of islets 
hormones and genes involved in metabolism, ER stress, oxidative stress, apoptosis and 
signalling, when rat islets and MIN6 cells were incubated to high concentrations of 
glucose [264-265]. Similar findings were also obtained by Cnop and coworkers, who 
investigated the effect of incubation of human pancreatic islets to high concentrations of 
palmitate [272]. However, these projects relied only on microarrays results or they only 
considered the effects of high glucose and fatty acids alone. Our study is novel as we 
used RNA sequencing, which can give more detailed information about all the 
transcriptome profiling, and we investigated also the effects of the combinations of high 
glucose and fatty acids. 
Accordingly to our pathway analysis (Table 5.3), the genes that are differentially 
expressed under condition of glucolipotoxicity were found to be associated with several 
diseases including inflammation, obesity, T2D and insulin resistance, confirming that 
our experimental conditions influence the expression of molecules implicated in 
diabetes and insulin resistance. In addition, the list includes other diseases associated 
with diabetes, for example, cardiovascular disease and hypertension. These are 
generated mainly by the inflammatory process and oxidative stress characteristic of 
T2D. 
As a further confirmation of the fact that the experimental conditions used are 
representative of T2D conditions, these differentially expressed genes were located in 
known rat diabetic QTLs loci (Figure 5.8), and contained several known GWAS genes 
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(Table 5.4). In particular, the top hits of the list showed the presence of TCF7L2, 
IGF2BP2, NOTCH2, WFS1, HHEX, ADAMTS9, whose association to diabetes has 
been demonstrated (Figure 5.9). 
In addition, the 10 top hits of the list (the genes differentially expressed in HGHF vs C 
with the highest p value) were genes that are directly or indirectly connected to diabetes 
or its associated diseases (Table 5.5). 
In conclusion, all these information confirmed that INS-1 cells respond to 
glucolipotoxicity in a manner similar to what is observed in vivo during the progression 
to T2D. 
 
In conclusion, these results show all molecular changes induced by the exposure of β-
cells to conditions of glucolipotoxicity. However, most of the information derived from 
the pathway analysis has been already studied in relation to diabetes [272, 364]. A more 
detailed and accurate research on the RNAseq data results is now required to discover 
novel mechanisms of glucolipotoxicity in T2D. 
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Identification of novel  
 
mechanisms of glucolipotoxicity 
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6.1 Introduction 
 
As discussed in Chapter 5, using RNAseq procedures we identified several 
glucolipotoxicity induced differentially expressed genes, in order to discover novel 
mechanisms that could affect the β-cell after exposure to high concentrations of glucose 
and fatty acids. 
Several of these differentially expressed genes and their correspondent pathways 
analysed so far are already known to be associated with diabetes. They overlap with, or 
are situated close, to rat diabetic QTLs chromosomal regions. In addition SNPs close to 
or within several of these genes have been reported to be associated with diabetes in 
many GWAS studies. Functional pathways associated with our differentially expressed 
genes are known to interact with insulin.  
Nevertheless, after a detailed observation and analysis of our data and associated 
pathways, we have indentified some potential new research areas. 
Consistent with our previous studies on CD40 and its role in the β-cell, we expanded the 
analysis to other molecules involved in the TNFR pathway, including some receptors 
that have not been studied previously. The TNFR pathway resulted to be highly affected 
by glucolipotoxicity and these findings could be useful to understand in more details the 
network of CD40 in glucolipotoxicity. 
Supporting previous observations but highlighting a less studied pathway was the 
potential role of the Hypothalamic-Pituitary-Thyroid (HPT) genes in islet cells [365-
368]. The thyroid is a gland located in the neck that controls the body metabolism 
through the hormones T3 and T4, which regulate the growth and function of other 
systems in the body. The connection between thyroid and β-cells is quite interesting as, 
not only we demonstrated that some thyroid specific molecules are expressed in the β-
cell, but their expression can be also influenced by exposure to a glucolipotoxic 
environment. 
We also identified some miRNAs, which could be interesting targets for future analysis. 
MiRNAs are regulatory RNAs and known to be involved in the pathogenesis and 
evolution of different diseases. Some of them have been associated to the pathogenesis 
of T2D, influencing insulin secretion through different mechanisms [295, 302-304].  
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Finally, with the RNAseq technology, we also identified several potentially interesting 
novel genes or ESTs (expressed sequence tags), encoding for proteins whose structure 
and functions have not been elucidated so far. Preliminary protein structural/functional 
bioinformatics analyses suggest that some of these novel genes could be involved in 
pathways regulating β-cell function. 
 
6.2 The TNFR pathway 
 
In previous experiments (Chapters 3 and 4), we focussed our attention on CD40, a 
member of TNFR superfamily, and its role in glucolipotoxicity. We also analysed the 
effects of glucolipotoxicity on other molecules involved in the TNFR pathway, in 
particular on TRAF proteins.  
In this part of the project we investigated the expression changes of other molecules 
involved in the TNFR pathway in conditions of glucolipotoxicity. 
To this end, we used the program Metacore, and we drew a pathway scheme 
highlighting the molecules that changed their expression in glucolipotoxicity. Figure 6.1 
shows the results of the analysis. The bar on the right of the gene indicates that the gene 
was differentially expressed in some of the experimental conditions (1 corresponds to 
high glucose, 2 to high fat and 3 to high glucose/high fat). This pathway analysis shows 
that the TNFR pathway was highly affected by conditions of glucolipotoxicity. 
Figure 6.1 shows changes in the expression of receptors (TNFRSF1B, TNFRSF11A, 
TNFRSF17), of ligands (TNF-α, TNFSF4, CD40L, TNFSF11, TNFSF12, TNFSF13B, 
TNFSF13) and of TNF inducible proteins (IRAK1/2, TRAF2, TRAF3, MAP3K14, CAT, 
NF-κB2, NF-κBiB, BCL2A1). 
 
219 
 
 
 
Figure 6.1 Analysis of the TNFR pathway. Representation of the TNFR pathways molecules differentially expressed in HGHF vs C with a p 
value p<0.05. The red bar at the right of the gene indicates the level of differential expression and it can indicate either upregulation or 
downregulation. 
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Figure 6.2 represents the mRNA expression changes of members of the TNFR pathway. 
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Figure 6.2 Expression levels of TNFR pathway genes. RNAseq was performed on the RNA of 
INS-1 cells treated with the 4 experimental conditions. Values are means + SD of number of 
reads associated with a particular condition. 
 
This analysis showed that expression values for most of the receptors decreased in 
glucolipotoxicity (Figure 6.2), which was in contrast to the effect seen on CD40 receptor 
(Chapter 3), indicating that glucolipotoxicity induced specific responses on each 
particular TNFR. Consistent with this, TNFR1B expression decreased in 
glucolipotoxicity, while TNFR1A expression remained unchanged. TNFR21 and 
TNFR26 were considered because their expression was affected also in the previous 
Affymetrix experiment. TNFR21 encodes Death Receptor 6, a protein that activates NF-
κB and c-Jun, inducing cell apoptosis. TNFR26 is a novel member of the TNFR family 
which has not been characterised so far. 
Figure 6.2 shows that ligands expression decreased in glucolipotoxicity, including 
expression of CD40L.  
These data also confirmed the increase in TRAF2 expression, and the involvement of 
NF-κB in glucolipotoxicity. Interestingly, data showed a reduced expression of NFKB2 
in glucolipotoxicity, which would seem in contrast with our previous results showing an 
increased activation of NF-κB under chronic exposure to glucose and fatty acids. 
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However, NF-κB expression changes do not always correspond to its activation, which 
is determined by p65 translocation in the nucleus.  
In addition, a reduced expression of IRAK2, a serine-threonine kinase associated with 
activated IL-1R, was also observed. IRAK is reported to be involved in the IL-1-induced 
upregulation of NF-kB. This can further explain why there was a decrease in the NF-κB 
genes expression in our experimental system. 
 
6.2.1 TNFR pathway validation  
 
In order to validate some of the results, we used quantitative PCR with specific primers 
for the genes of interest. INS-1 cells were cultured for 72h in the 4 experimental 
conditions, RNA was extracted, reverse transcribed and qPCR performed. Figure 6.3 
shows the validation of some of the receptors. 
TNFR1A did not change its expression in glucolipotoxicity, confirming the RNAseq 
data. TNFR21 showed a significant decrease (42%, p<0.05) especially in the presence of 
both high glucose and high fat. TNFR26 is of particular interest, as it showed a 90% 
decrease with high glucose or high fat alone, and a nearly 100% decrease with the 
combination of the conditions (p<0.001). Considering that TNFR26 has not been studied 
so far, it could be a novel and interesting subject for future studies aimed to confirm its 
role in glucolipotoxicity. 
In addition, CD40 was validated and the RT-qPCR confirmed the results shown 
previously (Chapter 3). CD40 did not show statistical significant differential expression 
in glucolipotoxicity from the RNAseq reads count, but its expression was very low 
(average 30 reads for the gene), which led to difficult detection of the expression 
changes and consequently reduced statistical significance. 
These data shows also the importance of a validation by RT-qPCR of the results 
obtained by RNAseq analysis, in order to confirm the differential expression. 
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Figure 6.3 Validation of TNF receptors by RT-qPCR. INS-1 cells were cultured for 72h in 
the 4 experimental conditions, RNA was extracted, reverse transcribed and RT-qPCR performed 
using specific primers. Data represent ∆∆Ct values expressed as a fold change compared to cells 
grown in RPMI (control). Data are expressed as means + SD of 3 independent experiments 
(*p<0.05; **p<0.01; ****p<0.001). 
 
Figure 6.4 shows the validation by RT-qPCR of some of the ligands and TNF inducible 
proteins involved in the TNFR pathway. 
TNF resulted to be downregulated in glucolipotoxicity (55% decrease, p<0.05), 
confirming the RNAseq data. 
However, NF-κBib, NF-κB2 and IRAK did not show statistical significant differential 
expression in glucolipotoxicity. NF-κBib, which is NF-κB inhibitor, showed a trend 
towards an increased expression, while NF-κB2 had a trend towards a decreased 
expression in glucolipotoxicity, as shown by the RNAseq data. No change in expression 
was detected for IRAK by RT-qPCR. 
These discrepancies between RNAseq and RT-qPCR can be explained by the fact that 
the fold change of some of the genes studied (NF-κBib, NF-κB2, IRAK) was not very 
high in the RNAseq data and the p value was at the borderline of significance. RT-qPCR 
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detected the variability between the samples and, as a consequence, even if data showed 
the same trend as the RNAseq experiment, they did not reach statistical significance. 
 
 
 
Figure 6.4 Validation of TNF ligands and inducible proteins by RT-qPCR. INS-1 cells were 
cultured for 72h in the 4 experimental conditions, RNA was extracted, reverse transcribed and 
RT-qPCR performed using specific primers. Data represent ∆∆Ct values expressed as a fold 
change compared to cells grown in RPMI (control). Data are expressed as means + SD of 3 
independent experiments (*p<0.05). 
 
6.3 Thyroid pathway 
 
The pathway analysis of our differentially expressed genes in glucolipotoxicity (Table 
5.1) revealed changes in the Hypothalamic-Pituitary-Thyroid (HPT) pathway. 
The thyroid is a gland located in the neck, which controls metabolism, how the body 
makes protein and it is responsive to other hormones. It produces the hormones 
triiodothyronine (T3) and thyroxine (T4), which regulate the growth and function of 
other systems in the body. The hormonal output from the thyroid is regulated by the 
thyroid stimulating hormone (TSH) produced by the anterior pituitary gland, which 
225 
 
itself is regulated by the thyrotropin stimulating hormone (TRH) produced by the 
hypothalamus. The hormones T3 and T4 are synthesised by follicular cells where the 
enzyme thyroid peroxidase (TPO) catalyses the addition of iodine to a protein called 
thyroglobulin (Tg). Upon stimulation by TSH, the follicular cells reabsorb Tg and 
cleave the iodinated tyrosines from Tg in lysosomes, forming T3 and T4 and releasing 
them in the blood.  
There is a feedback loop regulating the release of the thyroid hormones (Figure 6.5). 
TRH and TSH production and secretion are suppressed when T4 levels are high. TSH 
production is also inhibited by somatostatin (SRIH). 
 
 
 
Figure 6.5 Feedback loop regulating the release of thyroid hormones. TRH and TSH 
productions are suppressed when the T4 levels are high. Figure adapted from “Harrison’s 
principles of internal medicine”. 
 
As shown in Figure 6.6, several genes involved in the thyroid pathway were 
differentially expressed in glucolipotoxicity in our experimental system, including 
hormones (TRH), receptors (Trhr, Tshr, Sstr), enzymes (Tpo, Dio1), solute carriers 
(Slc5ac) and thyroid specific transcription factors (Nkx2-1, Nkx2-2). 
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Figure 6.6 Expression levels of thyroid genes. RNAseq was performed on the RNA of INS-1 
cells treated with the 4 experimental conditions. Values are mean + SD of number of reads 
associated with a particular condition. 
 
Glucolipotoxicity mainly downregulates the expression of these genes, therefore we 
hypothesise that some of them may have a positive role in stimulating insulin secretion. 
For instance, it has been shown previously that TRH can promote insulin release in adult 
pancreatic islets and its expression can be involved in the regulation of the β-cell 
function [369]. The blockage of these gene expressions in glucolipotoxicity could be 
responsible of the impairment of β-cell function in T2D [366-367]. 
 
6.4 miRNAs 
 
Some miRNAs have been already shown to be involved in the regulation of the 
pancreatic β-cell function, in particular in the development of the pancreas, as well as in 
the impairment of insulin secretion, or in the generation of an inflammatory status [297, 
301, 303].  
From our total RNAseq data, we discovered 4 miRNAs that were differentially 
expressed with statistical significance: Mir-3547, Mir-1949, Mir-205 and Mir-375 
(Figure 6.7).  
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Figure 6.7 Expression levels of miRNAs. RNAseq was performed on the RNA of INS-1 cells 
treated with the 4 experimental conditions. Values are mean + SD of number of reads associated 
with a particular condition. 
 
While Mir-1949 has not been extensively studied, it has been suggested to be associated 
to the progression of a leukemia [370] or to be involved in foetal lung development 
[371]. It is upregulated 2 times with high glucose and 5 times with high glucose/high fat 
(p value adjusted <0.001). 
Mir-205 is a miRNA that has been associated with various cancers in several studies. It 
has reported to be silenced in breast cancer, prostate, bladder and lung cancer [372]. It 
plays also a role in regulating stem cell fate, probably regulating the expression of the 
tumour suppressor PTEN. Its expression is also associated with obesity [301]. While 
Mir-205 was downregulated by glucolipotoxicity in our experiment, its role in insulin 
secretion and development of T2D remains to be determined. 
Mir-375 is a miRNA known to be associated to diabetes. It has a key role in β-cell 
development and function and it is essential for insulin secretion [295]. It has also been 
proposed as a biomarker for β-cell cell death [373]. Overexpression of this miRNA 
impairs exocytosis of insulin-containing intracellular vesicles due to aberrant regulation 
of its target myotropin [295]. Consistent with this, Mir-375 is upregulated 3 times with 
high glucose and 8 times with high glucose high fat (p value adjusted 0.0025). 
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The detection of these small RNAs from the RNAsequencing experiment, which should 
filter short transcripts, can be explained by the fact that miRNAs are transcribed as 
longer RNA molecules that are then processed to produce the mature miRNAs. 
Therefore the RNAseq system can detect the longer RNA molecule. 
The presence of miRNAs associated with diabetes and obesity is a further confirmation 
that our experimental system is a reliable representation of the conditions of T2D. 
 
6.4.1 Mir-3547 is overexpressed in glucolipotoxicity 
 
Very little is known about Mir-3547. As mentioned above, our data showed that it was 
upregulated 3 times in conditions of high glucose, 2 times with high fat and 7 times with 
combination of high glucose/high fat (adjusted p value 3.10 E-11). We hyphothesised 
that Mir-3547 could be a novel biomarker for diabetes, and, for this reason, we decided 
to investigate this miRNA. 
First we validated the results by quantitative RT-qPCR. INS-1 cells were cultured for 
72h in RPMI-1640 supplemented with 27 mM glucose, 200 μM oleic acid, 200 μM 
palmitic acid. Cells were lysed, RNA extracted and miRNAs separated using mirVana 
miRNA isolation kit (Life Technologies, UK), following manufacturer’s instructions. 
Small RNAs were retro-transcribed to cDNA using TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Life Technologies, UK) with the specific assay 
for Mir-3547. Taqman microRNA assay kit (Applied Biosystems, Life Technologies, 
UK) was used to perform a RT-qPCR on the cDNA retro-transcribed from the small 
RNA.  
Data confirmed that glucolipotoxicity increased Mir-3547 expression by more than 2 
fold (Figure 6.8) confirming the RNAseq data. 
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Figure 6.8 Mir-3547 expression in glucolipotoxicity. INS-1 cells were cultured for 72h in 
RPMI-1640 supplemented with 27 mM glucose, 200 μM oleic acid, 200 μM palmitic acid. Cells 
were lysed, RNA extracted and miRNAs separated using mirVana miRNA isolation kit. Small 
RNAs were retro-transcribed to cDNA using TaqMan® MicroRNA Reverse Transcription Kit 
with the specific assay for Mir-3547. Taqman microRNA assay kit was used to perform a qPCR 
on the cDNA retro-transcribed from the small RNA. Data represent ∆Ct values expressed as a 
fold change compared to cells grown in RPMI (control). Data are values from 1 experiment. 
 
6.4.2 Mir-3547 co-localises with Baiap3 locus 
 
Mir-3547 is situated on rat chromosome 10 in the intron between exons 24/25 of another 
gene, Baiap3, on the rat genome (Figure 6.9). This is the same as in mouse, where the 
miRNA locates between exons 25/26 of Baiap3 on chromosome 17. In humans Baiap3 
is located on chromosome 16, with no annotated intronic miRNA.  
Baiap3 is a p53 target gene that encodes for a brain-specific angiogenesis inhibitor. The 
protein is a seven span transmembrane protein and a member of the secretin receptor 
family. It interacts with the cytoplasmic region of brain-specific angiogenesis inhibitor 1 
[374]. This protein also contains two C2 domains, which are often found in proteins 
involved in signal transduction or membrane trafficking. Its expression pattern and 
similarity to other proteins suggest that it may be involved in synaptic functions and it is 
a member of the Munc13 protein family, which have a role in the priming step of vesicle 
exocytosis. It has been shown to regulate exocytosis, in particular of autocrine or 
paracrine growth factors by tumour cells [375].  
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Figure 6.9 Chromosomal localisation of Mir-3547. 
 
As Mir-3547 is located in the introns of a gene, it is one of those intronic miRNAs that 
can be classified as mirtrons. Mir-3547 would be co-expressed as pre-miRNA within the 
intron region of the host transcript using its Pol-II promoter. The intronic pre miRNA is 
eventually released by the host transcript after splicing machinery. However, this is not 
the only possible mechanism, as Mir-3547 could also be transcribed independently from 
Baiap3 gene using a yet unidentified promoter and following the classic miRNAs 
maturation processes.  
In order to determine the most likely mechanism for the generation of Mir-3547, it is 
necessary to evaluate the rate of transcription of Baiap3, in conditions of 
glucolipotoxicity, as Mir-3547 is overexpressed under exposure to high concentrations 
of glucose and fatty acids. The RNAseq data indicated that Baiap3 is also overexpressed 
in glucolipotoxicity (Figure 6.10). In particular, it is overexpressed 2.5 times with high 
glucose and till 5/6 times with high glucose/high fat. 
This suggests an important link between Baiap3 and Mir-3547, as their expressions are 
both affected by glucolipotoxicity. In addition, Baiap3 has been reported to be involved 
in secretion [375], therefore it could be implicated in the impairment of insulin secretion 
in glucolipotoxicity. This will need to be further explored. 
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Figure 6.10 Expression level of Baiap3. RNAseq was performed on the RNA of INS-1 cells 
treated with the 4 experimental conditions. Values are mean + SD of number of reads associated 
with a particular condition. 
 
The fact that Mir-3547 and Baiap3 are both overexpressed in glucolipotoxicity suggests 
that the two mRNA could be transcribed together. Preliminary experiments using 
quantitative RT-qPCR with primers annealing to different region of Baiap3 (as shown in 
Figure 6.11) could support this hypothesis. The first set of primers overlap with the 
junctions of exons 24 and exon 25 covering the miRNA region, the second set amplifies 
between exons 3 and 4, so externally to the miRNA region. These primers were used to 
amplify cDNA from INS-1 cells cultured for 72h in the 4 different conditions of 
glucolipotoxicity. In control conditions, the miRNA region shows a lower CT (more 
copies) in comparison to the non miRNA region. This suggests that there are more 
transcripts containing exon 24/25 (the region of Mir-3547) than using primers that 
amplify exon 3/4 region of Baiap3.  
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Figure 6.11 Amplification plot of Baiap3 in control conditions using different primers. The 
first couple of primers anneal between exon 4/5, external to the miRNA region; the second 
couple of primers anneals between exon 24/25, so overlapping the Mir-3547 region. 
 
These results indicate a differential rate of transcription between Baiap3 and Mir-3547 
and this could be due to the fact that: 
- the different primers could have different efficiency of amplification; 
- Mir-3547 could be transcribed together with Baiap3, using its promoter, and 
subsequently be spliced off; the differential rate of transcription could be due to 
alternative splicing events; 
- Mir-3547 could use its own promoter, independently from Baiap3 gene; 
- a combination of the above conditions. 
The study of Baiap3 expression in conditions of glucolipotoxicity could help clarifying 
this. 
 
6.4.3 Baiap3 is overexpressed in glucolipotoxicity 
 
As shown in Figure 6.12 Baiap3 was overexpressed in conditions of high glucose/high 
fat, but the level of its overexpression changed according to the type of primers used. 
When primers in the miRNA region were used, we observed a nearly 3 fold increase in 
Baiap3 expression. Interestingly, when external primers were used we obtained a 5 fold 
overexpression. This result can be explained considering that the miRNA region showed 
a higher expression in comparison to the non miRNA region. Since we obtained more 
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copies of the miRNA region, we noticed a lower increase in glucolipotoxicity, because 
the amount was already high. 
Future experiments are needed to clarify the reason of this differential expression. 
 
 
Figure 6.12 Baiap3 is differentially overexpressed in glucolipotoxicity. INS-1 cells were 
cultured for 72h in the 4 experimental conditions, RNA was extracted, reverse transcribed and 
RT-qPCR performed using 2 different couples of primers for Baiap3. The first couple of primers 
anneal between exon 4/5, external to the miRNA region; the second couple of primers anneals 
between exon 24/25, so overlapping the Mir3547 region. Data represent ∆∆Ct values expressed 
as a fold change compared to cells grown in RPMI (control). Data are expressed as means + SD 
of 3 independent experiments. 
 
6.4.4 RNAseq shows a new exon for rat Baiap3 
 
Despite sequences for mouse and human Baiap3 genes are known and annotated, the 
sequence for rat Baiap3 is not annotated in November 2004 rat (Rattus norvegicus) 
genome assembly version 3.4, or in NCBI assembly/382928 (RGSC Rnor_5.0). 
However in Ensemble database rat BAIAP3 is annotated under 
ENSRNOG00000017893. Based on this sequence, Baiap3 gene is composed of 33 
exons, while mouse and human Baiap3 are composed of 34 exons. Specifically, the 
missing exon should be exon 1, localised 4 kbases upstream of exon 2 (Figure 6.13A).  
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The alignment of the reads from our RNAseq data to the Baiap3 region shows a 
concentration of reads in a region that may correspond to the missing exon (Figure 
6.13B). Nucleotide sequence blast suggests that this region of rat chromosome 10 
(derived from our reads) is highly homologous (>80%) to exon 1 of the mouse Baiap3 
on chromosome 17 (Figure 6.13C). 
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Figure 6.13 Rat Baiap3 sequence. A) Comparison of Baiap3 sequence among different 
species; B) RNAseq reads mapping on rat Baiap3 region C) Blast of sequence of hypothetic rat 
exon 1 from RNAseq to mouse exon 1. 
 
6.4.5 Analysis of Human Baiap3 gene 
 
No significant similarity was found between the RNAseq region studied above and exon 
1 region of human Baiap3 gene on chromosome 16. In addition, there is not annotated 
intronic Mir-3547, but there are some shorter variants of the gene.  
Analysis of the human Baiap3 genomic sequence from available methylation studies 
suggested that there are potentially 2 hypomethylated regions (Figure 6.14A), one 
upstream of exon 1 close to the start codon, which may regulate Baiap3 transcription, 
and the other internal between exon 10 and 15. We hypothesise that this internal 
hypomethylated region may be an enhancer site or a promoter for shorter proteins 
derived from alternative splicing of Baiap3 gene (Figure 6.14B). 
Furthermore we noticed that various studies have identified two active promoters 
(purple regions in Figure 6.14C), one upstream of exon 1 and one internal to the gene in 
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different cell lines. These regions overlap with the hypomethylated sites showed in 
Figure 6.14A.  This second active site could be regulating the variant BAIAP3-015 
expression in human.  
However, in rat and mouse, our data led us to propose that Mir-3547 could have its own 
promoter, located internally to the Baiap3 gene, which can be used for transcription 
independently from Baiap3 transcription. There is the possibility that the internal 
promoter could regulate the transcription of the miRNA but further investigations are 
required to understand gene regulations in this locus. 
 
A 
 
 
 
B 
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Figure 6.14 Promoter’s regions near human Baiap3 genes. A) The graph represents the 
methylation pattern of the human Baiap3 area. A low value is indicative of hypomethylation. B) 
Different splice variants of human Baiap3 gene. C) The image represents the active promoters 
regions on human Baiap3 genes (indicated in purple). Each row corresponds to a different cell 
line. 
 
6.5 Novel genes 
 
As mentioned before, RNAseq technology can also detect novel genes or expressed 
sequence tag (ESTs) whose function and role in the cell is still unknown. In general, 
their name is a number indicating the chromosomal position proceeded by LOC (locus) 
or RGD (rat genome database). 
Several of these genes are differentially expressed in condition of glucolipotoxicity, 
some of which are listed in Figure 6.15. 
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Figure 6.15 Expression levels of novel genes. RNAseq was performed on the RNA of INS-1 
cells treated with the 4 experimental conditions. Values are means + SD of number of reads 
associated with a particular condition. 
 
To elucidate the function of some selected novel genes we subjected them to structural 
analysis, using the on-line platform for protein structure and function predictions I-
TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) as well as the 
Protein Sequence Analysis Workbench (PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/)) 
The following genes are of particular interest: LOC691995, RGD1564664, 
RGD1304931, RGD621098, RGD1309676. The predicted structure of these genes is 
represented in Figure 6.16.  
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Figure 6.16 Predicted structures of novel genes. The figure shows the nuclear localization 
signal (NLS) in red, the nuclear export signal (NES) in yellow and the transmembrane domain 
(TM) in green. 
 
LOC691995 is a predicted transporter protein containing both nuclear localisation signal 
(NLS), nuclear export signal (NES) and one or more transmembrane domains. It could 
be a shuttling protein involved in nuclear/cytoplasm transport. 
RGD1564664 is also a putative transporter and it is mainly localised in the 
mitochondria, with a small percentage of the protein in the nucleus. 
RGD1304931 is another predicted transporter, containing a NLS and a NES. 
RGD621098 is a soluble cytoplasmatic protein, and no transmembrane domain was 
detected. 
RGD1309676 is mainly extracellular with endoplasmic reticulum presence. 
These listed clones are interesting as they are mainly transporter proteins and they 
contain nuclear localisation signals. This indicates that they could be possible 
transcription factors and be involved in the regulation of expression of genes implicated 
in insulin secretion. Future studies are necessary to define their role in the β-cell and if 
they can be implicated in the regulation of insulin secretion. 
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6.6 Discussion 
 
As the incidence of T2D is increasing at an alarming rate worldwide, there is an urgent 
need to find new therapeutic strategies, especially therapies able to reverse the impaired 
β-cell function. In particular, it would be useful to identify novel strategies to restore 
insulin secretion during the progression of diabetes, but most of the mechanisms 
involved in β-cell dysfunction are still not known. The aim of this part of the study was 
to determine in more details the effect of glucolipotoxicity on the β-cell and the different 
molecules affected by exposure to high concentrations of glucose and fatty acids. The 
identification of novel targets can open the way to future studies aimed at the 
development of therapeutic strategies able to restore the β-cell function. This will allow 
the treatment of the disease at an early stage, when only impairment of function but not 
β-cell death occurs. The transcriptome profiling using RNAseq described in chapter 5 
has identified some interesting pathways that could be further investigated to assess their 
role in the β-cell function. 
 
Considering our previous studies on CD40 (Chapter 3 and 4) and its role in the β-cell 
function, particular attention was paid to the study of the TNFR pathway in its complex 
and its validation by RT-qPCR. Many of the genes involved in this pathway were  
differentially expressed under the experimental conditions, among which receptors 
(TNFRSF1B, TNFRSF11A, TNFRSF17), ligands (TNF-α, TNFSF4, CD40L, TNFSF11, 
TNFSF12, TNFSF13B, TNFSF13) and TNF inducible proteins (IRAK1/2, TRAF2, 
TRAF3, MAP3K14, CAT, NF-κB2, NF-κBiB, BCL2A1) (Figure 6.1). 
There was a specific effect of the exposure of cells to high concentrations of glucose and 
fatty acids on this pathway, as some of the receptors resulted in downregulation in 
glucolipotoxicity, while others, as CD40 (studied in chapter 3 and 4) resulted 
upregulated. On the other hand, the expression of the ligands was generally 
downregulated, but their differential expression has proven to be difficult to validate by 
RT-qPCR because of their low expression levels. In addition, glucolipotoxicity changed 
the expression of genes involved in the NF-κB pathways, confirming the activation of 
inflammatory and apoptotic pathways generated by the involvement of TNF receptors. 
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Another interesting pathway identified by this RNAseq experiment is the thyroid 
pathway. Many genes involved in thyroid metabolism were differentially expressed in 
glucolipotoxicity in INS-1 cells, both hormones, receptors, enzymes and transcription 
factors (Figure 6.6), the expression of which are normally associated with the thryoid 
gland and the hypothalamus. Interestingly these genes were expressed in the β-cell and 
their expression was affected by glucolipotoxicity. Previous studies have reported the 
expression of TRH and its receptor in the pancreas and its colocalisation with insulin 
secretory granules, suggesting a potential involvement in insulin secretion [376]. In 
addition, Kulkarni et al demonstrated that TRH can promote insulin release in the adult 
pancreatic islet and its expression can be involved in the regulation of the β-cell function 
[369]. Expression of TRH has also been demonstrated in INS-1 cells, where it is able to 
increase insulin production in cells extracts [365]. Moreover, it has been shown that 
blockage of TRH synthesis can influence insulin secretion [366], which suggests that 
TRH is implicated in regulation of insulin secretion in β-cells. The down-regulation of 
this gene in condition of glucolipotoxicity could have a role in the reduction of insulin 
secretion and production observed in these experimental conditions. In addition, other 
studies showed that thyroid hormone (TH) receptor is expressed in rat β-cells and TH 
can regulate MAFA expression, affecting insulin secretion [367]. TH has also been 
positively associated to insulin secretion in people with pre-diabetes [368]. The fact that 
most of the thyroid genes are expressed in the β-cell and that their expression is affected 
by conditions of glucolipotoxicity can be due to the fact that the pancreas or pancreatic 
cell lines show similarities in the developmental process or gene expression to neurons, 
and possess variable derivative peptides and hormones. This is another mechanism that 
underlies the connection between brain and pancreas, suggesting the possibility of a 
similar regulation and control. A functional action of the thyroid hormones in the 
pancreas could be to oppose the effects of somatostatin (which reduces insulin and 
glucagon secretion) to balance the regulation of islets cell function. In addition, there 
could be an autocrine or paracrine effect of TRH in the pancreas, which can activate the 
transcription of the other genes. Future studies are necessary to define the role of this 
pathway in insulin secretion or production and the way it could be used to develop novel 
therapies to preserve insulin secretion. 
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Four differentially expressed miRNAs were identified in the list from the 
RNAsequencing (Figure 6.7). In particular, Mir-205 and Mir-375 are known to be 
associated with diabetes or obesity [295, 301]. Of interest is Mir-3547, which resulted 
overexpressed with high statistical significance in glucolipotoxicity, as also confirmed 
by an independent qPCR (Figure 6.8).  Interestingly, Mir-3547 localises within a gene, 
Baiap3, on chromosome 10 (Figure 6.9). In particular, it locates in the intron between 
exons 24/25 of Baiap3 on the rat genome. Baiap3 is a p53 target gene that encodes for a 
brain-specific angiogenesis inhibitor. This protein also contains two C2 domains, which 
are often found in proteins involved in signal transduction or membrane trafficking. It is 
a member of the Munc13 protein family and it can regulate exocytosis [375], and, for 
this reason, it is an interesting object of study because it could be involved in insulin 
secretion. Baiap3 was overexpressed in glucolipotoxicity as well (Figure 6.10), but our 
results showed a different level of expression changes accordingly to the primers used: 
primers overlapping with the miRNA region generated more transcript than primers 
annealing externally to the miRNA region (Figure 6.11). This may suggest that 
alternative splicing occurs or that Mir-3547 uses an independent internal promoter to 
regulate its own transcription. These data are also complemented by the study of 
hypomethylation sites or active promoter regions on human Baiap3 region (Figure 6.14). 
Together with the promoter of Baiap3 gene, another region, internal to the gene, resulted 
active and hypomethylated. This could be an enhancer of the Baiap3 gene, a promoter of 
shorter transcripts of Baiap3 gene or, more interestingly, a Mir-3547 promoter. Future 
studies are required to define the transcriptional regulation of these genes in rodents and 
humans. Dysregulation of either Baiap3 or Mir-3547 has not previously reported to be 
implicated in β-cell function in response to glucolipotoxicity. Baiap3 is likely to be 
involved in vesicle exocytosis and therefore could have a role in insulin secretion. 
Future studies to characterise Baiap3 in the β-cell, its overexpression in human and to 
understand the genetic architecture in rodent and man are required to further evaluate a 
role in insulin secretion. 
 
Finally, the RNAseq experiment identified some novel genes, in which the structure and 
function are still unknown (Figure 6.15). In particular, LOC691995, RGD1564664, 
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RGD1304931 are of particular interest because their predicted structure contains both a 
Nuclear Localization Signal and a Nuclear Export Signal (Figure 6.16). This structure 
suggests that they could be shuttling protein involved in nuclear/cytoplasm transport or 
transcription factors, regulating genes involved in insulin secretion. At the moment, 
experiments are ongoing in order to characterise the biological function of these 
molecules and their potential role in regulating insulin and β-cell function. 
 
The four pathways analysed are only starting point for future analysis that could identify 
novel pathways involved in glucolipotoxicity. The fact that these molecules are 
differentially expressed in glucolipotoxicity is the first result but further validation is 
necessary, in particular to investigate a potential involvement in the regulation of insulin 
secretion. 
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Chapter 7 
 
 
General discussion and conclusions 
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7.1 General discussion 
 
Over the past three decades, the number of people with diabetes mellitus has more than 
doubled globally, making it one of the most important public health challenges to all 
nations. The World Health Organization states that 347 million people worldwide were 
suffering from diabetes in 2008, which equates to 9.5% of the adult population [63]. 
T2D and pre-diabetes are increasingly observed among children, adolescents and young 
adults and they make up 90% of the diabetes cases. The causes of the epidemic of T2D 
are embedded in a very complex group of genetic and epigenetic systems interacting 
within an equally complex framework that determines behaviour and environmental 
influences. 
In the UK, the cost of diabetes to the NHS is over £1.5 million an hour or 10% of the 
NHS budget for England and Wales. In total, an estimated £14 billion per year is spent 
to treat diabetes and its complications, with the treatment of complications representing 
the much higher cost [377]. 
As diabetes is triggered by many genetic and environmental factors, different for each 
individual, treatments should also vary individually and specifically, the so called 
“personalised medicine”. Regular and successful treatments can also decrease the risk of 
developing diabetes complications. The main therapeutic approaches are the following: 
- healthy lifestyle: corrections in diet, with assumptions of high fibre, low fat 
foods (low carbs fruits, vegetables, whole grains) and regular aerobic physical 
exercise can help to ameliorate glucose levels without the need of other 
medications. 
- medications: drugs are used to reduce hyperglycemia and increase insulin 
secretion or action or to reduce the inflammatory process. For example, 
metformin decreases hyperglycemia primarly by reducing glucose production by 
the liver, activating AMP kinase and stimulating insulin sensitivity (acting on 
GLUT4 to enhance peripheral glucose uptake). Sulfonylureas stimulate insulin 
secretion by binding to an ATP sensitive K
+
 channel, leading to membrane 
depolarisation. Thiazolidinediones act by activating peroxisome proliferator-
activated receptors (PPARs), which bind to DNA and increase the transcription 
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of genes implicated in glucose and fatty acids metabolism and they reduce the 
level of inflammatory cytokines. GLP-1 receptor agonists activate GLP-1 
receptor, stimulating adenylyl cyclase pathways, which result in increased 
insulin release. The sodium-glucose transporter-2 (SGL2) inhibitors act by 
blocking the re-absorption of glucose by the kidney thereby increasing glucose 
secretion. 
- insulin therapy: treatment of diabetes by administration of exogenous insulin; 
- cell based therapies: treatment of diabetes by pancreas or islet transplantation. 
Healthy lifestyle and medications are usually sufficient for the treatment of T2D, 
whereas patients with T1D need daily injections of insulin and, in the worst cases, islets 
transplantation. 
With a greater understanding of the mechanisms of glucolipotoxicity on the β-cell new 
therapeutic approaches will be identified. A specific therapy at an early stage of the 
disease could restore the impaired β-cell function and avoid the development of diabetes 
complications, decreasing the severity and cost of the treatments. 
 
In this thesis we aimed to identify novel molecules involved in the impairment of the β-
cell function and to discover novel potential targets for therapeutic strategies. We 
simulated the glucolipotoxic conditions of T2D by incubating INS-1 cells in media 
containing 27 mM glucose, 200 μM oleic acid and 200 μM palmitic acid for 72 hours. 
Oleic and palmitic acid are the most abundant fatty acids in human diet, therefore these 
conditions are representative of the real physiology of β-cells in diabetes. In addition, 
the conditions of glucolipotoxicity used affected insulin secretion and production but not 
cell viability, therefore cells were at an early stage when cellular function is impaired 
but cells are still viable. In this way it was possible to investigate mechanisms 
implicated in the early stages of glucolipotoxicity, with the aim to develop therapeutic 
strategies at the onset of diabetes. 
Combining transcriptome profiling using Affymetrix microarrays and RNA sequencing, 
we aimed to identify novel molecules differentially expressed in glucolipotoxicity. We 
first focussed our attention on the inflammatory process of T2D and here we showed for 
the first time an important role for CD40 in glucolipotoxicity-induced β-cell 
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dysfunction. We showed that CD40 is upregulated at the RNA and protein levels in 
INS-1 cells exposed to glucolipotoxic conditions. Similar data were obtained in islets of 
mice fed a high fat diet and in human islets exposed to fatty acids. In addition, targeted 
downregulation of CD40 in INS-1 cells leads to an increase in insulin secretion and 
production, elucidating a new direct role of this receptor in regulating β-cell function. 
As CD40 is able to activate NF-κB, we hypothesised that the connection between CD40 
and insulin could lie in this transcription factor. We showed that there is a hypothetical 
NF-κB binding site upstream of the insulin promoter, which may be responsible of the 
effect of CD40 on insulin transcription. In addition we showed a trend of TRAF proteins 
(adaptor molecules that bind to the intracellular domain of CD40 and are responsible for 
the transduction of the signal) in mirroring CD40 expression: in conditions of CD40 
downregulation we showed a trend towards decreased mRNA levels of TRAF2 and 
TRAF6, while in glucolipotoxicity (when CD40 is overexpressed) expression of both 
TRAF2 and TRAF6 increased. Increased TRAF2 mRNA levels were also observed in 
islets of mice fed a high fat diet. However, these results require further validation, in 
order to determine whether CD40 affects insulin expression through NF-κB.  
In general, these experiments showed for the first time the importance of CD40 in 
glucolipotoxicity and the possibility of blocking its pathway as a way to improve β-cell 
function. In this context, the use of anti-CD40 monoclonal antibodies [334-335] may be 
worth of consideration for use as an adjunct therapy for people with T2D. Lucatumumab 
in particular would appear a strong initial candidate for this role, as not only it is 
reported to be well tolerated [336], at least at moderate and intermediate doses [337], but 
it has also previously been shown to prevent induction of NF-κB activity in multiple 
myeloma cells [338]. In addition, this therapy has also been used as a general 
immunosuppressant strategy following transplantation, so it could be used as a 
combined approach at a later stage of the disease to restore the function of the impaired 
β-cells and to favour the activity and vitality of the new transplanted cells. However, 
this strategy would need to be modified for the treatment of diabetes, as immune cell 
interactions with the Fc region of cell-bound Lucatumumab could potentially lead to 
either opsonisation of β-cells or antibody-dependent cell cytotoxicity. An alternative 
solution could be the use of phage display technology, with the generation of antibody 
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fragments containing heavy and light chain antigen recognition sites, whilst lacking the 
Fc region. This is an area that clearly warrants future research. 
In order to expand the results obtained with the microarray experiment and to gain more 
information about the glucolipotoxicity process, we then performed a RNA sequencing 
experiment on INS-1 cells exposed to glucolipotoxicity. Clustering and pathway 
analysis confirmed the fact that the conditions used are really representative of the 
pathological changes observed in T2D. Most of the pathways and molecules 
differentially expressed in this system are already known in their association to diabetes 
and insulin resistance. However, a more detailed analysis allowed us to identify some 
new pathways that could be the objective of future studies to investigate their ability to 
influence β-cell function. 
We identified other members of the tumour necrosis factor family (TNFRSF21 and 
TNFRSF26), which were downregulated in response to glucolipotoxicity. These 
molecules have not been studied so far, therefore they could be an interesting subject to 
study in relation also to CD40. 
Another important pathway identified in this study is the thyroid pathway. Many genes 
involved in the thyroid metabolism resulted differentially expressed in glucolipotoxicity 
in INS-1 cells, both hormones, receptors, enzymes and transcription factors. The 
expression of some of these genes in the β-cell and their effects on insulin secretion has 
already been shown previously [365, 376]. However, here we showed for the first time 
that the expression of these genes can be regulated by glucolipotoxity, therefore they can 
be possibly involved in the impairment of insulin secretion in diabetes. A clinical 
correlation between thyroid dysfunction and diabetes has already been elucidated, and 
patients with diabetes have a higher prevalence of thyroid disorders compared to the 
normal population [378-380]. Future studies are necessary to determine whether 
downregulation or overexpression of these thyroid genes in INS-1 cells could affect 
insulin secretion or production. 
We also showed for the first time that Mir-3547, a novel miRNA which has not been 
studied so far, is upregulated in glucolipotoxicity and co-localises with a gene, Baiap3, 
encoding for a protein that could be involved in exocytosis. MiRNA deficiencies or 
excesses have been correlated with a number of clinically important diseases, and some 
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therapeutic applications aim to restore normal levels and functions of these dyregulated 
miRNA. A detailed study of rodent Mir-3547 in relation to insulin secretion and β-cell 
function, and the identification of the equivalent miRNA in humans, may reveal a 
potential novel mechanism by which glucolipotoxicity affects -cells and it may define 
a novel target for the development of therapeutic strategies that could reduce the levels 
of this miRNA.  
As the involvement of miRNAs in diseases is a relatively novel area of investigation and 
most of these miRNAs have still unknown roles, we aimed also to identify differentially 
expressed miRNAs in glucolipotoxicity using small RNA sequencing. The analysis of 
these results is still ongoing. 
Finally, we showed also the involvement of some novel genes in glucolipotoxicity, 
whose structure and function is still unknown. In particular, LOC691995, RGD1564664, 
RGD1304931 are of particular interest because their predicted structure contains both a 
Nuclear Localization Signal and a Nuclear Export Signal and they could be shuttling 
protein involved in nuclear/cytoplasm transport or transcription factors, regulating genes 
involved in insulin secretion.  
Additional studies are now required to investigate these novel pathways of 
glucolipotoxicity, in order to determine whether they are involved in the impairment of 
insulin secretion in diabetes and, as a consequence, if they can be appropriate targets for 
novel therapeutic strategies. 
In general, this thesis can be considered as a starting point for numerous and interesting 
investigations, aiming to validate and further analyse potential therapeutic targets at an 
early stage of the disease. 
 
It must however be noted that the experimental system used has some limitations. 
 
One general limitation of the system used is the fact that all the initial experiments were 
performed in vitro on INS-1 cells. INS-1 cells are good and reliable model to study 
expression changes on a large scale but they are not representative of the real human 
physiology. First of all they are rat cells and, despite rat and human genomes share high 
similarity, some of the molecules and pathways identified could have relevance in rat 
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but not in humans, an example in this thesis being Mir-3547. There are some species 
related differences: for example it has been shown that 24h exposure of human islets to 
elevated glucose and palmitate is sufficient to induce apoptosis [107], whereas we and 
others have not observed cell death in INS-1 cells under the same conditions for 72h 
[381]. Moreover, the concentration of fatty acids used in vitro varies among different 
studies. The key determinant is the fraction that is bound to the BSA, which is the part 
that can be effectively introduced in the cell. 
In addition, INS-1 cells are isolated cells and therefore they do not provide information 
about integrative physiology and connections in the context of the human pancreas.  
On the other hand, in vitro studies are quicker to perform and at a lower cost and they 
allow a strict control of the environmental conditions. This facilitates the study of 
conditions, like diabetes, in which there is a strong environmental counterpart. In 
addition, experiments using cell lines can be easier for the functional characterisation of 
the different targets. The use of cell lines is also preferable in whole genome sequencing 
experiments, as they allow reproducibility of the results and the use of set and controlled 
conditions. 
In general, a good approach would be to perform the general screening on cell lines, like 
in this thesis, and then to validate the results of the interesting targets in vivo, in mouse 
or human islets, as in our characterisation of CD40 and TRAFs expressions.  
 
Another limitation of this system is that the expression changes were only investigated 
after 72h of incubation. We demonstrated that the decrease in insulin expression is a 
gradual process, starting already after 24h of incubation. The choice of only 72h as a 
timepoint could miss the detection of some important mechanisms involved in the very 
early stages of β-cell dysfunction. However, a more detailed time-course can be 
investigated once the interesting targets are identified at the 72h timepoint. 
 
7.2 Conclusions 
 
This thesis elucidates some novel mechanisms involved in the glucolipotoxicity process 
associated with T2D. We identified molecular changes in the expression of molecules 
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involved in an early stage of glucolipotoxicity, when the function but not the viability of 
the β-cell is impaired. This will allow the identification of targets that can be studied to 
possibly define novel therapeutic approaches aiming to treat diabetes at its onset. 
 
7.3 Future research 
 
 CD40 experiments: 
 
Confirmation of the direct role of CD40 in regulating insulin: 
Since we hypothesised that CD40 can regulate insulin through NF-κB, we plan to verify, 
through gel shift, that NF-κB binds insulin promoter. Once verified this, we plan to 
investigate if there is a lower NF-κB binding in presence of CD40 downregulation. 
 
Confirmation of decreased TRAFs expression with CD40 downregulation: 
We showed a trend towards reduced expression of TRAF2 and TRAF6 upon CD40 
downregulation. This needs to be confirmed. 
 
Effect of upregulation of CD40: 
The effects of CD40 on insulin and TRAFs expression could be verified by 
overexpressing CD40 using an expression vector. In this way we could simulate the 
effect of CD40 overexpression in glucolipotoxicity and confirm its direct role on insulin. 
 
Functional analysis of other unstudied members of the TNFR pathway: 
We showed that other TNF receptors (TNFRSF21 and TNFRSF26) are differentially 
expressed in glucolipotoxicity. It could be interesting to investigate if these genes are 
involved in the regulation of the β-cell function.  
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 Novel pathways (Mir-3547, thyroid genes and novel genes): 
 
Validation of the differential expression: 
We showed that Mir3547, genes of the thyroid pathways and different novel genes are 
differentially expressed in glucolipotoxicity. Their differential expression has to be 
confirmed by qPCR and Western blot (where required). 
 
Confirmation in other systems: 
Most of the data in this thesis were obtained using INS-1 cells. Results need to be 
validated in other systems (mouse and human islets). 
 
Functional analysis: 
In order to verify the function of these genes and pathways in the β-cells, we could 
downregulate or overexpress these genes and investigate the effects on cell viability and 
cell function. 
 
 Others: 
 
Identification of novel molecules involved in glucolipotoxicity from the RNAseq 
experiment: 
The same validation and functional study described before can be applied to other 
molecules and pathways not mentioned in this thesis but differentially expressed in 
glucolipotoxicity. 
 
Identification of novel miRNAs involved in glucolipotoxicity from the small RNAseq 
experiment: 
The analysis of the data from the small RNA sequencing experiment is still ongoing. 
Once miRNAs significantly modulated are identified, they should be validated and 
analysed as before, to understand their role in the β-cell. 
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Appendix A: List of Primers 
 
GENE PRIMER FORWARD PRIMER REVERSE 
18S 
TCTTCCACAGGAGGCCT
ACACG 
GCCCCACACCCTTAATGG
CAGT 
INSULIN 
CCCTAAGTGACCAGCTA
CAATCA 
CCACAAAGGTGCTGTTTG
AC 
CD40 
GTCGGATTCTTCTCCAAT
G 
ACAGAGGGTATCAGTCTG
AC 
CD40 
(mouse) 
TGGTCATTCCTGTCGTGA
TG 
GGCTCTGTCTTGGCTCATC
T 
PDX1 
GAAATCCACCAAAGCTC
ACG 
AGGCCGGGAGATGTATTT
GT 
MAF A 
CCCGACTTCTTTCTGTGA
GC 
GCGGTAAGTACCTGGAGC
TG 
TRAF1 
GAAGGTTCTCCCTGATGT
GG 
ACTCCTTTAGGACCCCCA
GA 
TRAF2 
AGCCGTCTGTCCCAATG
ATG 
CTTTACACGCAGGGCACT
CAGTC 
TRAF3 
CCTCATAAGTGCAGCGT
TCA 
TGCAGCAAGGAAACCTTC
TT 
TRAF6 
AAAGCTGTCCTCTGGCA
AATATC 
GTGATTCCTCTGCATCTTT
TCGT 
TRAF2 
(mouse) 
CAGCTGTCTGTCCCAATG
ATG 
AGGCCTTTACATGCAGGA
CACT 
TRAF6 
(mouse) 
TCCTCATCAGAGAACAG
ATGCCTA 
GGTATTCTCTTGCAAGTGT
CGTG 
TNFR1A 
GAGAAACAGAACACCGT
GTG 
TAGGCACAGCTTCATACA
TTC 
TNFR21 ATTGACATCCTGAAGCTT TGGCGTTGCAAAGAAACT
276 
 
GTA GAT 
TNFR26 
CAAGAAGAAGTGTCCGA
GTG 
CTCCAAACAGTTTTCAGA
ATC 
TNF 
GCTCCCTCTCATCAGTTC
CA 
ACCACCAGTTGGTTGTCTT
TG 
NFkBiB 
CCCTTAGTCTTTGGCTAC
GTCACT 
GTCGTTCTGCAAGTCCAG
GTACTC 
NFkB2 
ATTTTGAATTCAGCCCCT
CCAT 
TTCACAGCCATATCGAAA
TCTGAA 
IRAK 
TCCTGTGTCACCTGGAAC
TC 
AAGGAGCATGGTTTCACA
GG 
BAIAP3 
TAGACGACGAGGAGGTC
TTGCTA 
CAGAGACTTTCAGGGCAT
AGGTG 
BAIAP3 
micro 
GCCCTGGATGAAGACCT
TCTG 
AGTCCGGAGACAGACTGA
TGTG 
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Appendix B: Agilent Bioanalyser samples analysis 
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Appendix C: RNAseq statistics 
 
Sequence Library 
Total number of 
sequences 
Concordant 
pair 
alignment 
Mapping 
Efficency 
(%) 
WTCHG_75162_241_1 13944504 10689061 76.7 
WTCHG_75162_242_1 16013074 11900359 74.3 
WTCHG_75162_243_1 15600005 11769452 75.4 
WTCHG_75162_244_1 14252227 10791261 75.7 
WTCHG_75162_289_1 17552825 13171860 75 
WTCHG_75162_290_1 14546058 10824393 74.4 
WTCHG_75162_291_1 16289889 12239908 75.1 
WTCHG_75162_292_1 14613077 10697618 73.2 
WTCHG_75162_293_1 15576574 11465344 73.6 
WTCHG_75162_294_1 15182369 11722206 77.2 
WTCHG_75162_295_1 14329846 11241417 78.4 
WTCHG_75162_296_1 16283355 12541262 77 
WTCHG_77933_241_1 14342859 11072772 77.2 
WTCHG_77933_242_1 17097497 12792476 74.8 
WTCHG_77933_243_1 13776218 10471905 76 
WTCHG_77933_244_1 14979777 11377874 76 
WTCHG_77933_289_1 15597258 11748738 75.3 
WTCHG_77933_290_1 15392441 11547018 75 
WTCHG_77933_291_1 17142410 12944205 75.5 
WTCHG_77933_292_1 15435444 11383543 73.7 
WTCHG_77933_293_1 16069304 11862672 73.8 
WTCHG_77933_294_1 15661737 12228236 78.1 
WTCHG_77933_295_1 14409691 11409584 79.2 
WTCHG_77933_296_1 17285441 13360033 77.3 
WTCHG_77934_241_1 14425087 11157688 77.3 
WTCHG_77934_242_1 17180209 12886738 75 
WTCHG_77934_243_1 13785418 10502805 76.2 
WTCHG_77934_244_1 15030267 11442243 76.1 
WTCHG_77934_289_1 15654339 11817744 75.5 
WTCHG_77934_290_1 15382257 11566632 75.2 
WTCHG_77934_291_1 17151179 12987439 75.7 
WTCHG_77934_292_1 15484674 11446560 73.9 
WTCHG_77934_293_1 16117244 11916366 73.9 
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WTCHG_77934_294_1 15727561 12324882 78.4 
WTCHG_77934_295_1 14342245 11397557 79.5 
WTCHG_77934_296_1 17326810 13429144 77.5 
WTCHG_77935_241_1 14545807 11293450 77.6 
WTCHG_77935_242_1 17405016 13101915 75.3 
WTCHG_77935_243_1 13854689 10597867 76.5 
WTCHG_77935_244_1 15286750 11692435 76.5 
WTCHG_77935_289_1 15762445 11941010 75.8 
WTCHG_77935_290_1 15694464 11852530 75.5 
WTCHG_77935_291_1 17465250 13287170 76.1 
WTCHG_77935_292_1 15797844 11729239 74.2 
WTCHG_77935_293_1 16393651 12164830 74.2 
WTCHG_77935_294_1 15946883 12547687 78.7 
WTCHG_77935_295_1 14772818 11780727 79.7 
WTCHG_77935_296_1 17648078 13738852 77.8 
WTCHG_77936_241_1 14503410 11199468 77.2 
WTCHG_77936_242_1 17383619 13006095 74.8 
WTCHG_77936_243_1 13738928 10444723 76 
WTCHG_77936_244_1 15217015 11556476 75.9 
WTCHG_77936_289_1 15496067 11678805 75.4 
WTCHG_77936_290_1 15717523 11795334 75 
WTCHG_77936_291_1 17480462 13212245 75.6 
WTCHG_77936_292_1 15782125 11640670 73.8 
WTCHG_77936_293_1 16370522 12082381 73.8 
WTCHG_77936_294_1 15851026 12394702 78.2 
WTCHG_77936_295_1 14759613 11701161 79.3 
WTCHG_77936_296_1 17624904 13622488 77.3 
WTCHG_77937_241_1 14373087 11152438 77.6 
WTCHG_77937_242_1 17225161 12957733 75.2 
WTCHG_77937_243_1 13704178 10479698 76.5 
WTCHG_77937_244_1 15070776 11524984 76.5 
WTCHG_77937_289_1 15478860 11725487 75.8 
WTCHG_77937_290_1 15589026 11770001 75.5 
WTCHG_77937_291_1 17340328 13186893 76 
WTCHG_77937_292_1 15626789 11602000 74.2 
WTCHG_77937_293_1 16246554 12054223 74.2 
WTCHG_77937_294_1 15740739 12376164 78.6 
WTCHG_77937_295_1 14635521 11671636 79.7 
WTCHG_77937_296_1 17496235 13616899 77.8 
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